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Foreword
In the past 5 years, a growing concern over the use of illicit drugs in the
workplace has led to an interest in urinalysis as a way to detect and deter
drug use. Drug testing by urinalysis has been suggested and in many cases
implemented for prospective and current employees in industry; for personnel
of the armed forces; for parolees and bail seekers in civilian court systems;
for workers in the transportation industry; and for individuals who serve as
role models, such as nationally known athletes. Two factors have led to the
widespread use of urinalysis for drugs: technical developments in testing
methods and the growing demand for drug testing. Society is becoming
increasingly aware of the impact of drug use on public safety and of the
financial impact on industry of lost time and productivity. The annual loss of
productivity of employees has been estimated at $100 billion for alcohol and
drug abuse, a third of which is due to drug abuse alone.
Drug and alcohol abuse in the workplace is amenable to carefully planned
prevention programs, however, and urine drug detection provides a powerful
tool for use in such programs. Preemployment urine screening is now
common among “Fortune 500” companies and in several Federal agencies.
As a consequence of drug screening programs, laboratories that were
established to perform urinalysis associated with methadone treatment have
had to greatly expand their capacities; many new laboratories have sprung up
to meet the demands for drug assays; and clinical laboratories associated
with medical centers, under economic pressures in recent years, have begun
to venture into drug testing. However, results from laboratories that are not
subject to any established guidelines for drug testing are sometimes
unreliable. At present few guidelines exist for private laboratories; the
Department of Defense has strict certification requirements for laboratories
testing military personnel, and the Federal Railroad Administration as well as
State agencies in California and New York have quality control standards in
place, the latter for laboratories associated with methadone treatment
programs. Until quality control programs are mandated on a broad scale,
however, employers wishing to establish a drug screening program must rely
on their own initiative to evaluate the reliability of a testing laboratory, so
that no individual will be falsely accused of drug use and at the same time
regular use on the part of any tested employee will not escape detection.
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The National Institute on Drug Abuse (NIDA) is in a unique position to provide
advice on many of the technical issues associated with the role of urinalysis
in the prevention of drug abuse. Since 1972, this Institute has supported
major research efforts to develop analytical methods for detecting and
measuring drugs in biological fluids, with special emphasis on methods for
cannabinoids and other abused drugs. NIDA has supported the development of
many of the major technologies beiug used today for urine drug screening and
confirmation. NIDA has also played a leading rote in the study of behavioral
and pharmacokinetic effects of drugs of abuse--two areas of knowledge that
are critical to the assessment and implementation of effective drug screening
programs.
The purpose of this monograph is to provide informatiou that will assist those
involved in the planning or implementation of drug testing programs in
making informed choices: information such as what urine screening can and
cannot do, how it fits into an overall drug program, and how it can be used
most reliably. It is our hope that this powerful technology which has grown
out of basic research programs will be used to advantage to assist in the
prevention of drug abuse in the United States.
Charles R. Schuster, Ph.D.
Director
National Institute on Drug Abuse
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Establishing a Urinalysis
Program-Prior Considerations
Richard L. Hawks, Ph.D.
Urinalysis for detection of drug use should be considered in the context of an
overall plan to reduce or prevent the negative impact of drug abuse on an
industry or organization. It would be inadvisable, however, to proceed
without a careful assessment of the group to be affected by testing. Certain
questions should be addressed: What personnel, if any, are affected by drug
use? Which drugs are the major problem? Can the organization shoulder the
economic burden for an appropriate urinalysis and counseling program, and
perhaps the legal and emotional costs associated with such a program?
In some cases, a problem is obviously present, based on incidents of known
drug use or drug dealing within the organization. Or it may be only
suspected, due to higher than normal rates of absenteeism, decreases in
productivity, or an increase accidents or thefts in the workplace. In the
absence of any indicators of drug use, managers might justifiably decide to
pursue the issue no further.
Assessment starts with education. Managers of a potential drug program
should first become knowledgeable themselves about drug abuse and its
indicators. Information is available from State drug and alcohol abuse
organizations, through the National Clearinghouse for Drug Abuse
Information at NIDA (P.O. Box 416, Kensington, MD 20795), through forensic
science centers associated with universities or medical examiners’ offices,
and from a number of expert private consultants.
The presence and extent of a drug problem could be assessed by means of a
survey based on anonymous questionnaires. This approach could include an
anonymous urine drug screen that would not only let the management know
what to expect if a regular urinalysis program were initiated; it would also
constitute a “dry run” with few legal ramifications, and would send a clear
message to employees about the seriousness of concern about the drug
problem and the resolve to remedy it. This could in itself have a deterrent
effect.
Any assessment should include clarification of which substances are
involved. Alcohol is the largest problem in most industries; an estimated 100
million Americans are current users of alcohol. The most recent NIDA
survey estimates that 18 million Americans are current users of marijuana
and 5.8 million are current users of cocaine (based on admitted use at least
once during the month prior to the survey). In some locations, including
Washington, DC, and Los Angeles, use of phencyclidine (PCP) is particularly
acute. These illicit drugs, along with opiates, amphetamines, or hallucin-
ogenic compounds, have a significant presence in our society.
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A more complicated group of drugs to assess are the prescription drugs;
tranquilizers, barbiturates (sleeping pills), and antidepressants are probably
even more prevalent in the workplace than illicit drugs and potentially are
just as likely to impair job performance or to create health problems if used
in excess of prescribed amounts or without adequate medical supervision.
When the “assessment” questions are resolved, establishing an appropriate
drug abuse deterrent program, including urinalysis, becomes feasible. The
care with which the plan is developed and implemented will determine the
success of the program and associated benefits. The plan should include
careful consideration of the organization’s policies, goals, and philosophy.
Finally, the plan should be well documented and available to all employees of
the organization.
The plan should be tailored to the extent of the problem. If no clear
indication of significant drug use at a worksite or in an organization is
apparent, a program beyond a preventive educational effort may not be
warranted. Evidence of heavy psychoactive drug use in job situations where
safety is a sensitive issue should be dealt with more aggressively. The plan
should give paramount consideration to the purpose of the program, the
essence of which is usually the health and safety of employees as well as
economic concerns. Another important element of the plan should be to
guarantee the personal privacy and dignity of the employees as much as
possible.
Various alternatives to a urine testing program may be considered. If the
problem does not warrant a major program, it may be sufficient to maintain
an awareness of drug abuse indicators, to define isolated problems regularly
through the use of personnel data and supervisor reports, and to deal with
them through an employee assistance program.
Most of the urine samples being analyzed in industry today are associated
with preemployment applications. While many of the rights usually accorded
an applicant are not necessarily the same as those of an employee, the same
rights of privacy and accuracy of analysis should be accorded these
individuals. A preemployment screening plan may preclude employment of
individuals with positive urines, but such a plan should include some kind of
counseling, not only to make the individual aware of why the job was denied
but also to offer advice and direction in dealing with the drug problem. A
more enlightened probationary policy might allow the hiring of such an
individual based on other merits, on the condition that counseling be obtained
and drug use cease.
Therapeutic drugs, while potentially problematic when abused, may in fact
improve or enhance workplace safety by decreasing health-related
impairment. Chronic disease states that would be problematic in the
workplace or on the highway without the benefit of drugs include epilepsy and
mental illness. Other conditions such as stress may also contribute to
impaired performance and therefore benefit by drug therapy. Urine drug
programs may identify those individuals who are legitimately taking drugs to
alleviate these disease states. Consideration should be given to the fact that
sufficient discrimination still exists in our society that individuals with these
particular conditions may have been actively hiding them from their
coworkers or employers. This further argues for confidentiality in the
handling of urinalysis results, in the same way an organization would handle
an individual’s medical records.
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Other drug-specific characteristics that might influence policy development
are whether some drugs, because of their particular pharmacological effects,
may be of more concern than others. Alcohol, marijuana, phencyclidine,
heroin, and LSD, for instance, are all drugs of abuse, but they differ in the
time course of their effects on performance and on the time their previous
use can be detected. Marijuana components in some circumstances can be
detected for weeks after the last use; indication of cocaine use can rarely be
detected in urine for more than a day or two. A cocaine-positive urine
therefore indicates recent and possibly dependent use, particularly if the
individual was aware of the pending analysis and still could not abstain. A
similar conclusion cannot be drawn from a single marijuana-positive urine.
Effective programs for the detection of drugs of abuse in human urine
specimens are best accomplished with sensitive testing procedures. Because
of the numerous legally sensitive features of drug detection programs, the
analytical results must be unquestionably reliable and able to withstand
considerable scrutiny. Therefore, the testing laboratory must be experienced
and capable in a number of important functions, including quality control,
documentation, chain of custody, technical expertise, and demonstrated
proficiency over time in urinalysis testing. Most important, the laboratory
must produce data that are secure from false positives and defensible in a
forum where the data may be challenged (e.g., a legal hearing or subsequent
arbitration). A qualified expert should be available to testify as to the
laboratory procedures that were employed, as well as to the accuracy and
reliability of the testing result.
At the moment, private laboratories providing urine drug detection services
for private industry in the United States are generally not compelled to
comply with specific guidelines associated with accuracy of analysis.
Oversight of urinalysis laboratories is essential to ensure quality analyses and
to provide public credibility, either mandated by government regulation or
established within the private sector and coupled with motivation of the
laboratories to participate in such oversight programs. Government and
private industry appear to be interested in moving in this direction. Some
State legislatures are considering bil ls  to regulate drug urinalysis
laboratories, and some organizations and companies are preparing to provide
certification and proficiency-testing services to urinalysis laboratories.
Performance and qualification standards that will be the basis of a NIDA
registry of laboratories engaged in urine drug detection services are currently
under development. The success of such programs will depend on the
motivation of laboratories to participate in them--motivation that will
ultimately come from the laboratories’ clients who will demand the quality
and performance for which they are paying. NIDA officials hope this
monograph will provide sufficient background to enable both clients and
employees to ask the right questions and demand the appropriate quality of
analysis.
Many considerations are important to developing a sound drug program in an
organization. It cannot be overemphasized that the documentation of
well-thought-out policies, developed with input from all organizational
elements, is at the top of the list. An effective program to discourage drug
abuse in an organization must have clearly defined rationales, goals, and
rules. The consequences of a positive urinalysis result must be clearly stated
and not open to arbitrary responses by management. The rights and
sensitivities of the individual should be protected as much as possible.
Results of urine drug assays should be kept confidential. The individual
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should be accorded the benefit of trained counseling, with referral to
treatment programs if necessary. The program should be designed, in other
words, for prevention and rehabilitation rather than for law enforcement.
A technically effective program that generates negative results can be
considered successful, one that is serving to prevent drug use by employees
and simultaneously to provide management (or the public) with assurance that
alcohol and illicit drugs at least are not a factor in performance problems in
the organization. Positive results represent failures of the prevention
system. Nevertheless, as long as they are looked at as diagnostic of a
medical  condit ion or an att i tude that  is  susceptible to appropriate
intervention or treatment strategies, the system will foster hope for
improvement of the drug abuse situation in this country.
The chapters that follow will present examples of methods and procedures to
ensure the quality and accuracy of test results. They will concentrate on the
technical aspects of the methodology used for urinalysis, the means to ensure
accuracy in such analyses, and the background to help in the interpretation of
assay results. Descriptions of appropriately controlled and monitored
urinalysis programs currently in use will be presented, as well as specific
descriptions of what to look for in choosing a laboratory.
Although some parts of the text appear to be geared toward the scientist, the
monograph has been written to inform readers in all phases of program
operation. Some chapters discuss the practical aspects of conducting drug
testing programs, including laboratory selection and quality assurance and
examples of programs already underway. Others relate the technical
concepts and methods involved in employing urinalysis to detect drug use.
The final chapter summarizes testing approaches to selected drugs of abuse
and offers reference lists for further study.
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Drug Testing Programs
Robert E. Willette, Ph.D.
Many government agencies and private employers have initiated drug testing
programs. Although the vast majority have started since 1981, many have
been in place for several years. In order to appreciate the variety and scope
of different approaches to drug testing, several programs will be described.
It can be noted that most of the programs include drug testing under one or
more of the following conditions: (1) before employment or during a
probationary period; (2) under reasonable suspicion of alcohol or drug use,
such as following an accident or bizarre behavior; (3) as part of routine
physicals, often required by Federal regulations; (4) during random testing;
and (5) when monitoring employees during rehabilitation or counseling for
drug use.
MILITARY SERVICES
By far the most extensive programs of drug testing are conducted by the U.S.
military services. Of these, the U.S. Navy program is the most intensive and
successful. The Navy operates five drug testing laboratories, through which
approximately 1.8 million urine specimens are processed each year, each
being tested at the present time for cannabinoids, cocaine metabolite,
phencyclidine, amphetamines, opiates, and barbiturates. The Navy is
currently planning to include testing for LSD. The 1.8 million specimens are
collected, primarily on a truly random basis, at a rate of almost three times
per year per member of the Navy and Marine Corps. Since it is random, some
members may be required to provide specimens several times a year and
some none. This serves as a constant deterrent to drug use.
The Army and Air Force also collect random specimens but at a lower
frequency. AU of the services can collect specimens in the event of a
probable cause situation, usually Limited to cases of suspected drug use. It is
important to note that military standards for probable cause follow the
strictest legal standards and cannot be easily abused. Some amount of
testing is used for service members who have tested positive once and have
completed counseling and/or rehabilitation programs. They are usually
placed on a surveillance program for several weeks following their return to
active service.
All of the military services collect specimens under direct observation. This
is done to eliminate the possibility of specimen substitution or adulteration.
Nevertheless, laboratories occasionally receive specimens that have been
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adulterated. If it can be proven that the provider of the specimen did
adulterate the specimen, the individual will be subject to other charges.
Also, the observer can be disciplined for failing to perform his or her duty. In
this manner, it has been possible for the military to maintain a tight and
effective program.
The individual commanding officer can determine if the initial positive result
is sufficient grounds to discipline or discharge a service member for wrongful
ingestion of an illegal substance. In cases of a good service record and
significant promise for continued useful service, the member can he
retained. This is not very common following a second positive result.
The success of these programs can best be illustrated with the record of the
Navy. Starting in 1981 with an indicated use level of 48 percent for enlisted
personnel under the age of 25, the overall test results for any period after
1984 have been below the 5 percent screened-positive rate. Screening
figures are used, since not all specimens are confirmed due to the presence of
drug concentrations below the confirmation cutoffs. Admitted drug use in
this same population was about 10 percent, as indicated in a questionnaire
survey taken by the Department of Defense in 1985.
Standards for performance are monitored in the military program in several
ways. Testing methods and cutoff levels are established by the Office of the
Assistant Secretary of Defense for Health Affairs. That Office conducts an
annual inspection of each military and contract laboratory. In addition, each
service conducts regular inspections of its own laboratories. The Navy
laboratories are inspected quarterly by the Naval Medical Command, which is
responsible for the operation of the laboratories, and annually by a team of
operations and legal personnel and outside civilian experts. All of the
laboratories are also monitored by a proficiency testing and blind quality
control program, as described in the next chapter.
ADMINISTRATIVE OFFICE OF THE U.S. COURTS
The Administrative Office of the U.S. Courts is responsible for people who
are on probation or parole for Federal crimes. If this involved the use or
possession of drugs, they are provided counseling, if necessary, and are
monitored on a regular basis by means of urine testing. The Office contracts
with commercial laboratories for testing and monitors their performance by
submitting periodic blind quality control samples. Persons found positive for
drug use (usually more than once) have to appear before a Federal judge to
determine if probation or parole has been violated.
FEDERAL BUREAU OF PRISONS
In a manner similar to that of the U.S. Courts, the Federal Bureau of Prisons
maintains a contract laboratory to test specimens collected from Federal
prisoners. These are comprehensive drug screens that include a number of
prescription drugs as well as the more commonly used drugs of abuse. Since
drug administration is closely controlled, it is necessary to monitor for the
use of prescription drugs that are obtained illicitly. It usually requires
repeated offenses before prisoners have to appear before a judge to alter
their sentences or to have certain privileges removed.
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DEPARTMENT OF TRANSPORTATION
The U.S. Department of Transportation has regulatory authority over several
transportation industries, for which it has established certain drug-related
rules. In addition, the following DOT agencies have established drug testing
requirements for their own employees.
Coast Guard
The U.S. Coast Guard is a uniformed service and maintains a drug testing
program similar to that of the military services. Personnel are tested on a
random basis and following probable cause incidents. The Coast Guard uses a
contract laboratory to which specimens are sent under strict chain of
custody. The frequency of testing varies from region to region but is at the
rate of approximately once a year.
The Coast Guard has also issued proposed regulations for shipping fleets
covered under merchant marine laws.
Federal Aviation Administration
It has been announced that, during 1986, the Federal Aviation Administration
will initiate testing of all of its employees at the time of their required
periodic physical examinations. The program will be managed under a
contract that will conduct the testing as well as monitor collection of
specimens by approved air flight surgeons. Appropriate counseling and/or
treatment will be provided for any employee found to be using illegal drugs.
The FAA does not have any specific drug testing requirement for its
regula ted  indus t ry ,  commerc ia l  av ia t ion .  Regula t ions  do  lay  ou t
requirements for action following drug-related incidents, although the agency
has announced that no drug-related commercial airplane crash has ever
occurred. The physical examination requirements also preclude pilots who
are diagnosed as being addicted to alcohol or drugs. It is not known if any
airline tests its pilots for drugs, although many have announced that they
screen job applicants for drugs.
Federal Railroad Administration
In 1985, the Federal Railroad Administration (FRA) reissued regulations
governing railroad operations that included specific rules for drug testing.
This “Control of Alcohol and Drug Use in Railroad Operations” rule follows a
10-year history of 48 alcohol- and drug-related train accidents and incidents
that resulted in 37 fatalities, 80 injuries, and $34 million in damages. The
new regulations, which did not take effect until February 1986 following
several court actions, require preemployment drug testing and testing for
alcohol and drugs following certain accidents and in reasonable cause
situations. The regulations also spell out rather specific standards for the
testing, including publication of a field manual to assist the railroads in
developing their own programs.
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National Highway Traffic Safety Administration
Under the Motor Carrier Safety Regulations, the National Highway Traffic
Safety Administration has established physical qualification standards for
drivers engaged in interstate highway activities, i.e., trucks and buses. One
requirement has vacillated from “does not use amphetamine, narcotic, or any
habit forming drug” to “has no current diagnosis of drug addiction.” Although
the regulations do not specifically require drug testing, many regulated
companies have included drug testing as part of the DOT physicals, since this
is the only reliable means of detecting drug use. The regulations also permit
the discharge of a driver who has been found in possession of or “under the
influence” of a drug while on company property or on duty. No standards
have been established, although the regulations include all substances covered
under Schedule I of the Controlled Substances Act.
REGULATED TRANSPORTATION INDUSTRIES
Many companies in the air, rail, bus, and trucking industries have
implemented various drug testing programs, often to comply with the
mentioned regulations or on a voluntary basis.  Most common are
preemployment tests, which are the easiest to conduct from all legal
aspects. Only the Federal Railroad Administration has published standards
for testing.
In a rather provocative and forward move, the International Brotherhood of
Teamsters signed an agreement with the major trucking fiis that spells out
specific standards and conditions for drug testing. These include collection
procedures, test criteria, cutoffs for determining violations, and penalties.
The agreement requires that employees receive 30 days’ notice before they
have to provide a urine specimen as part of their physical examination. This
provides an opportunity for the employee to stop using drugs before being
tested. There are also provisions for testing employees under “probable
suspicion” situations, which would include accidents.
Several railroads implemented strict drug testing programs prior to the
effective date of the FRA regulations. One company, Southern Pacific, has
announced that human-factor accidents have gone down each year from 37
percent to 69 percent over the period of 1983 to the first 6 months of 1986
since implementing the testing program.
DEPARTMENT OF JUSTICE
During 1986, the Department of Justice authorized the implementation of
broad drug testing programs for its agencies. Although no indication of drug
use by its employees was seen, it was felt that the Department should set an
example for other government agencies and private employers. Several of its
agencies have tested employees in the past when there has been reasonable
suspicion that the employees were using illegal drugs.
Drug Enforcement Administration
The Drug Enforcement Administration (DEA) is entrusted with enforcing the
Nation’s drug laws and, as such, felt it was important to demonstrate that
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the agency was free of drug use. The program was initiated in 1986 in a
progressive manner. Testing began with trainees and will gradually include
all personnel, adding classes of employees in the more critical positions.
Testing will be done on a random basis, with collection and testing conducted
through a contract. The agency has an employee assistance program that is
available on a voluntary basis prior to detection of drug use. Employees
found to be using drugs will be subject to dismissal.
Federal Bureau of Investigation
The FBI initiated a drug testing program for its trainees in 1986. The
program will extend to special agents and other critical positions on an
incremental basis, similar to that for DEA. Collection and testing of
specimens is combined with that agency’s as well. The full policy for dealing
with employees found to be using drugs has not been announced at this time.
DEPARTMENT OF THE TREASURY
Several of the agencies within the Department of the Treasury are planning
to initiate drug testing within 1986. The first agency to do so was the
Customs Service, which has a direct involvement with the apprehension of
drug smugglers.
U.S. Customs Service
During the spring of 1986, the Customs Service initiated a drug testing
program with its senior staff being the first to be tested. The collection and
testing of specimens is being conducted under a contract. Personnel in
critical positions, such as agents and chemists, will be included in the
program on a random basis.
Secret Service Uniformed Division
Applicants and probationary officers of the Secret Service Uniformed
Division have been tested for a variety of drugs since 1984. The testing is
part of regular probationary physical examinations and is conducted by the
District of Columbia Police and Fire Clinic.
GOVERNMENT SERVICES ADMINISTRATION
The Federal Protection and Safety Division of GSA has recently established
policy and procedural guidelines for urine drug testing of all contract guards
hired by GSA to guard buildings in the Washington, DC, area. This program
includes preemployment, incident-related, and annual physical testing.
Consideration is being given to extending the program to include GSA’s
employees.
CENTRAL INTELLIGENCE AGENCY
Early in 1986, the CIA initiated a trial drug testing program for all applicants.
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NATIONAL AERONAUTICS AND SPACE ADMINISTRATION
NASA conducts drug tests on all astronaut applicant finalists at the Johnson
Space Center. The primary focus of the testing is to detect the chronic use
of several prescription drugs, as well as phencyclidine and amphetamines.
U.S. POSTAL SERVICE
Several offices of the Postal Service test job applicants for illegal drug use.
A general policy is in place to test for drugs in employees whose performance
deteriorates. Plans for testing under other circumstances are being reviewed
in light of protests from the postal workers union.
NUCLEAR REGULATORY COMMISSION--NUCLEAR POWER PLANTS
While the Nuclear Regulatory Commission (NRC) has no current policy
requiring drug testing, NRC licensees (nuclear power plant operators) have
been encouraged, on a voluntary basis, to have mandatory drug testing for all
personnel working in vital areas of the power plants. According to a recent
NRC report, 90 percent of all nuclear plants have some form of drug testing,
and the remaining ones are considering the implementation of programs in
the near future.
Because of the sensitive nature of the work involved in a nuclear power plant,
some operators have developed rather strict programs. All of those who
currently have programs include preemployment tests for drugs. Almost all
others test in probable cause situations. At least one company utilizes a
controversial, anonymous “hot line” for tips on drug dealers and users.
Accusations have been made that the hotline has been used to harass
employees, although it has uncovered many drug dealers. Being caught using
drugs usually results in termination. Many companies provide some level of
counseling or assistance, although this may apply only on a voluntary basis
prior to being detected.
PUBLIC UTILITIES--ELECTRIC AND GAS
Many nonnuclear power companies and gas companies have implemented drug
testing programs. These usually involve preemployment testing and testing
for probable cause. Evidence of growing concern about drug use among
employees is supported by the number of arbitrations conducted on behalf of
public utilities. Typically, a union will file a grievance on behalf of an
employee who has been fired for testing positive for drug use following some
incident. The argument usually questions whether the employee was
“intoxicated” on the job, as opposed to use of the drug off duty. Some
companies have resolved this issue by setting detection or confirmation levels
that serve as “per se” evidence of recent use or that denote a violation of the
rules.
LARGE INDUSTRIAL COMPANIES
A survey taken toward the end of 1984 suggested that nearly 30 percent of
the Fortune 500 companies were conducting preemployment drug testing.
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The number testing employees is unknown. It is known, however, that many
large companies have drug testing programs, some of which include all those
conditions discussed in the first chapter.
The most typical program would be similar to that described for public
utilities, except that many large companies have extensive employee
assistance programs (EAPs). Employees who have alcohol or drug problems
can avail themselves of professional help in the EAP, usually on a completely
confidential basis. They can be referred to the EAP by a supervisor, baaed on
well-defined criteria that would include deteriorating job performance,
repeated absenteeism, and injury. Sometimes the referral is made following
observed behavior, but a growing number of companies use drug testing as a
more objective measure of drug use. It is common for an employee who tests
positive to be given an opportunity to enroll in the EAP and be referred to an
appropriate counseling or treatment service. If employees refuse, they may
then be subject to termination. An employee who fails to satisfactorily
complete counseling or treatment or is detected using drugs a second time is
usually fired.
It is important to note that many companies are now including tests for
alcohol as part of their preemployment screens, in addition to the common
practice of testing for alcohol in accident and other probable cause
situations. Caution must be exercised in the interpretation of test results for
alcohol in urine, since there is significant variability between blood and urine
concentrations. It is strongly recommended that alcohol be included along
with drug tests on individuals in treatment, since multiple substance abuse is
not uncommon.
A few companies have implemented random testing similar to that in the
military. They argue that it is the fairest and most democratic form of drug
testing, because it applies equally to everybody. In order to be fair, the
random selection must be truly random and not a guise for focusing on
certain individuals or classes of employees. In at least one company division,
the employees have endorsed the random program over a probable cause
approach, because it eliminates the potential for supervisor harassment or
being “out to get” someone in particular. Also, a strong possibility exists of
“stigmatizing” individuals who are taken in for testing under a probable cause
condition. This does not happen in random testing because everyone goes.
Whether a company uses random testing usually depends on the nature of the
work and the nature of the drug problem. A program similar to that used by
the Navy offers a strong deterrent to drug use but will still detect the user
who will not stop using drugs. Many legal questions remain about random
testing, however. Although random testing is not specifically precluded by
Federal law, some courts and arbitrators have been holding private employers
to constitutional standards, which ordinarily apply only to government
actions. Therefore, it is very important to have any program, random or
otherwise, meet the constitutional tests for fairness, reasonableness, and due
process.
SMALL COMPANIES
Many small companies are initiating drug testing on preemployment as well
as other conditions. Although large companies can usually obtain volume
discounts for testing services, and thus lower per-specimen costs, the overall
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cost of drug testing has been lowered due to the increase in the volume of
testing. The small company can also obtain a more reasonable price for the
smaller number of specimens submitted to testing. A problem the small
company faces is its inability to maintain an EAP. Several available group
programs can be covered under insurance or benefit plans, but it is not
uncommon for such programs to be too expensive for a small company. For
many of them, firing is the only alternative for employee drug use.
THE PRESIDENT’S DIRECTIVE FOR FEDERAL GOVERNMENT EMPLOYEES
On September 15, 1986, President Reagen issued an Executive Order which
mandated efforts in all agencies to make the Federal workforce a model for
eliminating drug abuse in the national workplace. This includes the use of
urinalysis for drugs of abuse on selected employees of all agencies. The
means of implementing these directives are being rapidly developed and a
government-wide drug detection program is expected to be in place in 1987.
SUMMARY
Many Federal agencies and private companies are conducting drug tests on
job applicants and employees. Although the reasons for testing and the
circumstances under which testing is conducted vary considerably, the main
intent of these programs is to provide a drug-free environment for other
employees and a safe service to the public. The programs that have been
most successful usually include a clear communication to all employees and
applicants as to the nature of the drug program and the consequences of
detected drug use. Also, successful programs usually afford employees some
type of assistance and a second chance. Finally, it is essential for successful
programs to provide a reasonable and fair approach that includes procedures
for due process, that is, a line of review and appeal.
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Choosing a Laboratory
Robert E. Willette, Ph.D.
A number of important considerations need to be reviewed when selecting a
system for drug testing. The first major consideration is to decide if testing
will be done at the place of business (“onsite”) or by an outside laboratory.
Both systems have advantages. The second and more important consideration
is the choice of laboratory used for confirmatory testing and/or all drug
testing.
TESTING ONSITE
Methods available to companies for onsite drug testing provide an effective
and easy-to-use means of conducting urinalysis programs within the
organizational structure. Some of the advantages include simplified chain of
custody, control and a greater sense of confidentiality, and immediate results.
Chain of custody is a critical factor in a valid drug program. Confidence in
the program is derived from knowing that the specimen tested actually
belongs to the person who gave it. Onsite testing reduces the number of
people who handle a specimen, which reduces the potential for mistakes.
Control and a sense of confidentiality may be important factors in some
organizations. Testing at the place of business offers these advantages
although a working relationship with a professional laboratory will, in fact,
provide the same coverage.
Another advantage of onsite testing is that it provides immediate results of
the drug tests, which may be important if action must be taken involving a
member of the organization.
In most testing situations, it is essential that all specimens that give positive
results in the onsite tests be confirmed by an alternate method, i.e., one of
the  chromatograph ic  methods  such  as  gas  chromatography-mass
spectrometry. An outside laboratory should be used for this procedure. In
some situations, repeated testing of a sample from the original specimen,
coupled with adequate operator training, instrument calibration, and quality
control measures, may provide sufficient evidence of drug use when combined
with other evidence, such as observed behavior or counselor interviews or
admission in treatment programs. Some States have upheld onsite testing
under these rigorous standards for prison populations while others have not.
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One of the most frequently cited disadvantages of onsite testing is the
possibility for taking action on the presumptive positive result before a
confirmation is received. For example, the Department of Defense provides
for temporary removal of individuals in critical positions who test positive;
they must be reinstated with full privileges if the result is not confirmed.
However,  concern exists about the “tainting” of the person. I t  is
recommended that the onsite screening result be kept as confidential as
possible to minimize such exposure.
TESTING BY AN OUTSIDE LABORATORY
The most reliable method of testing depends on a confirmatory test of a
positive result using an alternative method of testing. An outside laboratory
should be used for this procedure.
Using an outside laboratory over onsite testing has advantages. Primarily,
these advantages center on the professional capabilities of a laboratory that
are not available to those who test only on the premises. Inherent in the
decision to use an outside laboratory is the need to ensure accuracy by
selecting a laboratory of the highest caliber.
If all specimens are sent to an outside laboratory, they are handled by a staff
of trained professionals who perform the tests. And an outside laboratory
can perform confirmatory tests immediately following a positive result using
an alternative method of testing, which avoids delays. Carrying out all
test ing in the same laboratory minimizes the possibility of sample
mishandling.
Additional benefits from using an outside laboratory often include laboratory
staff who can serve as expert witnesses in legal and labor action and who can
answer technical questions about the drug testing methods. The laboratory
can also use its expertise to help an organization establish sound specimen
collection and storage procedures.
CHOOSING THE BEST APPROACH
The advantages and disadvantages of onsite versus laboratory screening, as
described, suggest some of the factors that must be considered in choosing
the most appropriate arrangement for an organization. It is necessary to
have a technically oriented staff person available to operate the onsite
equipment. The testing area must be able to be secured from unauthorized
entry. It must have a refrigerator and adequate air conditioning in order to
maintain proper temperatures for storage and use of the reagents. The
operator must be reliable and trusted for his or her coufidentiality, although
it is possible to blind the operator from the identity of the specimen provider.
If these criteria can be met, the need for immediate or prompt results would
be a major factor in choosing to screen onsite. A careful evaluation of the
relative costs should be made. If the testing situation presents few positive
results, the onsite operation can be quite cost-effective, since extensive
specimen handling is eliminated. Only the positives need to be shipped to the
laboratory for confirmation.
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SELECTING A LABORATORY
Two major types of laboratories can be used. Large laboratories available
nationally or regionally offer testing for drugs of abuse through a toxicology
service, in addition to routine clinical testing for serum glucose levels,
hematology, and blood enzyme levels. Smaller laboratories often specialize
in drug testing and offer national service through the mail or courier services.
As yet, no official registry of approved or certified laboratories has been
compiled. The National Institute on Drug Abuse is currently developing
standards for proficiency testing and accreditation of laboratories engaged in
drug testing. The standards will be available sometime in 1987, along with a
registry of laboratories meeting them. In the meantime, it is essential to
understand what to look for in selecting the best laboratory available. The
following list of factors will help.
Factors to Consider
Information. Find out from Federal and State agencies if the laboratory has
been licensed in any government programs and how the laboratory
performed. Only California, New York, and Pennsylvania have proficiency
testing programs for drug testing laboratories. Get recommendations from
experts in the field of drug testing programs.
Inspection. Inspect the physical plant. Observe organization and procedures
for processing specimens.
Standard operating procedures. Review the laboratory’s manual for standard
operating procedures. The manual should include a detailed description of
every step for specimen handling and analytical methods. Each page should
be dated and signed to show that it is continually updated as the laboratory
modifies procedures. What is the laboratory doing to ensure that test results
are properly reviewed and recorded?
Chain of custody. Examine documentation on chain-of-custody procedures
from the time the specimens are collected until results are reported. Special
handling procedures should be in effect for employee drug testing specimens.
These specimens should be separated from routine clinical specimens before
sealed containers are opened.
Who has access to stored specimens and why? How are they stored? Positive
specimens should be stored frozen in a secure place, and there should be a
way to identify everyone who has had access to them. The laboratory should
also be able to track exactly where each specimen was from the time it
entered the laboratory until it was stored.
How are records and actual testing data stored? Who has access to them?
They should be filed in an easily retrievable manner.
Handling flawed specimens. An agreement needs to be made with a
laboratory about testing a specimen if there has been a flaw or an error in
the handling of the specimen. In most cases, it is best to obtain a new
specimen that cannot be faulted at a later date. Some laboratories will help
train personnel who collect specimens to avoid such errors.
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Specimen identification. After a container has been inspected, it should be
assigned a special identifying number or accession number. This is the
method for tracking the bottle, the request form, and the test result. Some
laboratories place several copies of the same preprinted number on the
specimen bottle. These extras are used to identify test tubes containing the
specimen or any other container. Bar-coded labels are now in use to further
ensure that accession numbers are not misread or entered incorrectly.
Specimen integrity. Integrity of the specimen is maintained by labeling
specimen and aliquot containers, as mentioned. To maintain chain of
custody, the original specimen container should never leave the secured or
limited-access part of the laboratory.
A completely new aliquot must be obtained from the original container when
doing a confirmatory test. Matching the numbers is essential in order to
avoid mixing up the specimens. Only one specimen container can be open at
a time.
Checking staff credentials. The staff of the laboratory must, at the very
least, meet State requirements. These vary from State to State. The
labaratory should have an internal certification program for each staff
position.
Minimum standards include the following:
The laboratory director or manager should generally have an
advanced degree in chemistry or toxicology, preferably in analytical
chemistry, forensic analysis or forensic toxicology. This person
should be certified or licensed by one of the appropriate boards or
societies.
The technical staff should have formal training as laboratory
technicians or technologists, chemists, or biochemists, or they should
have comparable on-the-job training and experience. Technicians
should be certified by the laboratory and appropriate outside bodies.
Laboratory certification covers each procedure the technician
performs and should include performance on quality control samples.
Find out how staff performance is monitored on a daily basis.
Examine the laboratory’s certification program and when each
technician was last certified.
Quality assurance program. This is a primary requirement for any
laboratory. It should be comprehensive in that it provides constant
surveillance of all aspects of laboratory operations.
QA programs measure accuracy of performance in specimen accessioning,
identification of aliquots,  and test  results,  availabili ty of current
maintenance records for instrument, records of calibration schedules and
general maintenance of good operating conditions; appropriate documentation
and handling of chain of custody procedures; proper level of technical
competence of the laboratory personnel; and generally attention to all
practices which assure accurate laboratory results.
Quality control. This is a significant part of the QA program. QC is intended
to ensure the accuracy of results by including samples with known
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concentrations with every batch of specimens that is analyzed. These
samples are “open,” or known to the operators, allowing them to evaluate the
performance of each batch. In addition, it is strongly recommended that the
laboratory include blind samples in its quality control program.
The laboratory should make these data available for inspection along with
evidence of its performance on proficiency test samples run on a "bind”
basis. These blind samples can be obtained from another laboratory or a
proficiency testing service. Review the quality control records. How are
these samples introduced? Are blind samples truly indistinguishable to the
technicians from regular specimens?
Review of Results. One of the most critical steps in an acceptable testing
process is the final review of all results and reports. The laboratory should
have a senior chemist or the laboratory director certify that the report being
sent to the client is  accurate,  whether the results  are transmitted
electronically, by phone or by mail.
Technical assistance and expert testimony. The laboratory should be able to
provide access to a well-informed staff capable of offering sound advice
about drug testing, selection of appropriate cutoff levels, and interpretation
of results.
In the event of legal or labor action, the laboratory must be able to defend a
drug test in a hearing or in court through expert testimony. An expert
witness who can defend testing methods and the scientific validity of results
usually has a doctoral degree or considerable experience in the field of drug
testing.
Supplies. An important consideration in laboratory selection pertains to the
materials the laboratory will supply. Most will provide all the specimen
containers, request forms, evidence tape or sealers for the bottles, packaging
materials (like plastic bags and boxes), and mailing or freight forms required
for specimen collection. Some laboratories also include overnight courier
service as part of the price.
Reporting results. It is important to understand and contract for specific
turnaround time in the laboratory. Many laboratories provide results within
48 to 72 hours after specimen pickup. If confidential hard copies are needed
immediately, some laboratories will set up an electronic means of
transmitting results, other than by telephone. Telephoned reports should be
avoided, since this method is least secure and most prone to mistakes. If
urgency is not a factor, a mailed envelope, clearly marked confidential and
addressed to the person authorized to receive the results, is adequate.
Equipment maintenance. Examine equipment thoroughly to determine
operation condition. Current maintenance records should be available for
each piece of equipment.
Proficiency testing. The laboratory should be participating in at least one
proficiency testing program. Determine what it is, and review the results.
Contact the agency providing proficiency testing and ask about the
laboratory’s accuracy in the program.
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LABORATORY EVALUATION CHECKLIST
A sample checklist for evaluating proposals from laboratories follows. The
scoring is arbitrary and optional, but its use does provide a simple means of
ranking various choices. An actual site visit should be made to the
top-scoring laboratories to determine if they perform the work as they claim
they do.
DRUG SCREENING--LABORATORY SELECTION
Laboratory Final Score
Quality Of Services (60 points)
Test methods (20 points)
(Consider sensitivity, established reliability)
Screening:
Confirmation:
Score
Internal chain of custody (10 points)
(Consider if description is adequate, methods of
identifying samples, recordkeeping)
Score
Quality assurance program (10 points)
(Consider use of standards, internal blind QC,
certification of standards
Score
Turnaround times, reporting of results (5 points)
(Consider how results are reported, timeliness)
Score
Specimen pickup, shipping (5 points) Score
Provision for frozen storage (5 points) Score
Supplies (5 points) Score
(Consider form design, labeling, security of bottles
and kits, instructions for use)
Services Total Score
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Personnel (30 points)
Laboratory director/manager (15 points)
(Consider who will provide expert testimony)
Management staff (10 points)
Technical staff (5 points)
Score
Score
Score
Personnel Total Score
Experience (10 points)
Current clients (5 points) Score
Court/arbitration experience (5 points) Score
Experience Total Score
General Comments
Reviewer Date
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Proficiency Testing
Control Programs
and Quality
Robert E. Willette, Ph.D.
In a 1985 article, Drs. Hansen, Caudill, and Boone* of the Centers for Disease
Control (CDC) proclaimed a “crisis in drug testing,” based on the results of
studies conducted by CDC on the reliability of drug testing laboratories
during the period of 1973 through 1981. Under funding from NIDA, CDC
conducted a nationwide proficiency testing program wherein 10 samples were
submitted to participating laboratories every 3 months. These “open PT”
samples were used as a measure of how well the laboratory could detect the
absence or presence of specific drugs when they knew they were being
tested. It is interesting to note that not all laboratories could maintain a
passing score, which was set at 80 percent. The “crisis” proclamation was
derived from the results obtained from a limited number of selected
laboratories to which the same samples were submitted on a douhle-blind
basis. Not all laboratories did as well when tested blind.
The article referred to studies conducted in the 1970s on laboratories
providing drug screening services to federally funded drug treatment
programs. Although most of these laboratories did not use the technology
currently available, the study dramatizes the need for adequate external
quality control over laboratory performance. Furthermore, it has focused
attention on the general lack of such programs.
This chapter will describe existing proficiency programs and present some
additional suggestions for monitoring laboratory performance.
DEPARTMENT OF DEFENSE
For more than 10 years, the U.S. Department of Defense has monitored the
performance of drug testing laboratories operated by the military services
and, more recently, laboratories providing drug testing to the military under
contract. The program is conducted by the Armed Forces Institute of
Pathology (AFIP)
At present, the program involves both open proficiency test samples and blind
proficiency testing samples. Twenty-four samples, spiked with varying
concentrations of the six drugs for which the military conducts urine tests,
are sent each month to the nine military laboratories and current contract
laboratories. These samples are analyzed and the quantitative results
*Hansen, H.J.; Caudill, S.P.; and Boone, J. Crisis in drug testing:
Results of CDC blind study. JAMA 253:2382-2387, 1985.
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reported to AFIP along with copies of the screening and confirmation test
records. The results must fall within two standard deviations of the group
mean in order for the laboratory to maintain satisfactory performance.
The blind program requires that AFIP send certified negative and spiked
samples to several field units that submit urine specimens on a regular basis.
Currently, 24 negative and 12 positive samples are submitted each week to
the laboratories. The submitting units must transfer the contents to their
normal bottles and submit the samples along with others using social security
numbers supplied by AFIP. Since these are sent blind to the laboratories,
copies of all results are sent to AFIP for decoding. If any discrepant results
are received, an investigation into the cause is conducted. Laboratories must
maintain a 90 percent score on positive samples and not generate any false
positives. If the latter occurs, the laboratory is not allowed to report out any
further results and must retest all positives that were obtained for a 2-week
period prior to and following the occurrence of the false positive.
Although this level of external proficiency testing seems intense, the military
drug testing laboratories process more than 200,000 specimens per month. In
the last 3 years, no false positive result has been reported out on a quality
control sample.
STATE PROGRAMS
The States of California, Pennsylvania, and New York conduct proficiency
testing programs on certain drug testing laboratories in their jurisdictions.
The California program is now limited to those laboratories conducting tests
for State-approved methadone treatment programs. It is a blind program
wherein several samples per month are submitted to the laboratories through
selected treatment facilities. Pennsylvania sends four open PT samples per
quarter to laboratories that perform drug testing on Pennsylvania urine
specimens, whether in or out of State. The New York program is also open,
with eight samples sent to every laboratory licensed to conduct such testing,
whether in or out of State. Laboratories are tested this way each quarter
unless their score is judged acceptable. Then, they are tested only twice a
year.
COLLEGE OF AMERICAN PATHOLOGISTS
Since the late 1940s, the College of American Pathologists (CAP) has
conducted interlaboratory comparisons designed to assess the state of the art
in clinical laboratory practice. The program includes laboratory inspection,
certification, and proficiency surveys. Starting in 1984, CAP initiated a
survey for urine screening for drugs of abuse. It consists of sending to
subscribing laboratories five urine samples containing five to six drugs each
quarter. The laboratories analyze the samples and report the qualitative and
quantitative (if they offer that service) results back to CAP for review. The
laboratories are provided with an evaluation report.
Laboratories that also conduct analyses of blood samples can subscribe to the
older toxicology surveys that include three or four samples of serum and one
or two samples of urine containing various drugs in toxic concentrations.
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AMERICAN ASSOCIATION OF BIOANALYSTS
The American Association of Bioanalysts has provided a variety of profi-
ciency testing programs since 1949. A urine toxicology program became
available in 1980. This survey provides subscribers with two urine samples
per quarter, each containing 10 of the more commonly abused drugs or their
metabolites.
DUO RESEARCH INC.
A consulting firm specializing in assessing drug testing programs, Duo
Research Inc. provides a blind proficiency testing service to government and
business. The service is similar to that described for the Department of
Defense, in that positive and negative samples are sent to sites that collect
and submit urine samples to a laboratory for drug testing. The number of
samples received by subscribers is tailored to the particular level of testing
being conducted. Monthly status and quarterly summary reports are
provided. An investigation is made in the event of an incorrect result.
INDIVIDUAL PROGRAMS
Some laboratories conduct their own external as well as the mandatory
internal quality control programs. Some laboratories with multiple locations
may submit samples to each laboratory director to insert in a blind fashion
into their routine testing. Others will provide customers with prepared
samples that they can submit back to the laboratory in a blind manner.
Although these are valuable adjuncts to other measures of performance, they
are not as secure as those programs that provide an independent source of
samples and interpretation.
AVAILABILITY OF REFERENCE MATERIALS
One of the difficulties in conducting quality control programs is the limited
availability of suitable reference materials. Experiments with urine
collected from individuals who are known to have taken a specific drug have
shown a significant variability in sample stability. It has thus been favored to
add known amounts of pure drugs and/or metabolites to a pool of drug-free
urine. Collecting sufficient quantities of the latter also presents its
difficulties. Some programs, such as that conducted by AFIP for the
military, use a combination of human urine and a synthetic matrix. This can
pose problems with assay interference and recognizability.
The most reliable proficiency testing and control samples are made from
drug-free human urine where drugs and/or their metabolites have been added
in concentrations consistent with normal detection ranges for the drugs in
question. Also, as is the case with morphine, a mixture of parent drug and its
conjugated metabolite must be added in order to simulate a real positive
specimen. Proper samples for methadone contain at least two of its meta-
bolites in order to be properly identified on thin-layer chromatographic
analysis.
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Few sources exist for some of the pure drug and metabolite standards. The
National Institute on Drug Abuse has maintained a program for preparing
such standards through a contract with the Research Triangle Institute (RTI),
but these materials are available only on a limited basis for research
purposes. Analytical quantities of pure drug standards can be obtained from
Alltech-Applied Science, State College, PA; Supelco Co., Bellefonte, PA; and
RTI, Research Triangle Park, NC. Larger quantities can be purchased
directly from RTI.
To ensure the highest standards of drug testing, every government agency or
private employer testing job applicants or employees must insist that the
laboratory being used participate in at least one, but preferably several, of
the proficiency testing programs described here.  This should be a
requirement written into the contract with the laboratory, and test results
should be submitted to the customer as soon as they are received. Open
proficiency tests can indicate the best that a laboratory can do when it knows
it is being tested, but a blind program is most effective in consistently
encouraging maximum laboratory performance.
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Specimen Collection and Handling
Joseph E. Manno, Ph.D.
The urine drug test can be useful and reliable for determining drug use
patterns only if it is performed and interpreted using appropriate procedures.
The validity of the result of a urine drug test requires that consideration be
given to the methods used for the collection, transportation, analysis, and
interpretation of the results.
RESPONSIBILITY
Three different groups are generally associated with the urine drug test
procedure. The collection site is responsible for collecting, labeling, boxing,
and shipping samples, ensuring that collection and storage procedures have
the proper documentation and security methods necessary. The collection
site also must provide all staff with sufficient training to understand the
collection process and the significance of laboratory results.
The courier is responsible for transporting samples to the laboratory and
maintaining appropriate chain-of-custody records for ensuring that samples
are not tampered with during transit. The laboratory is responsible for
receiving samples from the courier and further guaranteeing that the samples
were transported without tampering. The laboratory must also maintain
records to assure that the integrity of the samples is maintained in the
laboratory and that the results are correct. Although it is recognized that
each collection site must develop collection and shipping procedures that
meet its individual needs, the purpose of this discussion is to describe
procedures that will fulfill the necessary criteria in order to guarantee
optimum validity of drug screening results.
RANDOM SAMPLING
Random sampling is a process whereby urine samples are collected in a
manner that the subject cannot predict when the specimen will be requested.
Random sampling is most important when multiple samples will be collected
from the same person over a period of time. Random sampling principles
should also apply when single samples are collected for on-the-job drug
testing programs. For several reasons, random sampling procedures are
important to increase the overall “sensitivity” of the drug detection program.
The laboratory procedures for performing the urine drug screen have defined
sensitivity. Under most circumstances, intermittent drug use (i.e., taking
drugs on less than a daily basis) can be detected within a range of 6 hours to 2
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days or more after the drug was ingested. When individuals take drugs
chronically (on a regular basis, either daily or more than once a day), the
likelihood of detecting the drug in urine increases. However, it is possible for
individuals to tailor their drug use to conform to the pattern of urine
collection used. If they know a collection is forthcoming, they can
discontinue use of the drug long enough prior to the urinalysis so the drug use
will not be detected.
In substance abuse treatment centers, for example, if urines are collected
regularly at specific times, the subject can start using drugs immediately
after the collection and stop a day or two before the next scheduled
collection. With a 2- or 3-day drug-free period before collection, a good
possibility exists that the urine drug screen will be negative.
When urine drug tests are used as part of a preemployment program, if an
individual is told to report for a preemployment physical at a prearranged
tie, drug use could be discontinued prior to the appointment, thereby
increasing the chance for a negative screen. With the proliferation of
Laboratories, subjects may have enough time prior to a scheduled urine
collection to have their urine analyzed for the presence of drugs. If the urine
was found to be positive, they could then make an excuse for not keeping the
appointment. The most effective random sampling schedule for urine
collection is to contact subjects and require that they come immediately for
urine collection.
In substance abuse treatment facilities, random sampling increases the
effectiveness of the drug testing process, because it removes the regularity
needed for patients to schedule their drug use in order to adjust drug taking
so the screen is negative. Subjects are always in the position of not knowing
when the next screen will be taken; therefore, they can never safely take the
drug.
For preemployment drug testing, every attempt should be made to provide
only several hours’ notification before the subject must report for the test.
Ideally, prospective employees can be given a 1 or 2 week “time window”
during which they will report for the test. Then, notification can be given
several hours in advance of the test. As a matter of practice, however, this
may be very difficult to achieve in a preemployment situation.
Random sampling for on-the-job testing is more easily accomplished, since
the employees are readily available. The determination of testing days and
departments should be kept confidential. Employees who are absent on the
day of testing should be tested at a later, unscheduled date.
When a program of “probable cause” or “suspicion” is in force rather than
random sampling, samples are taken when a supervisor determines that the
behavior of the individual is cause for testing. Obviously, in such a case, the
specimen should be taken with as little forewarning as possible.
COLLECTION
The collection process is quite important, and several factors must be
considered in developing a suitable method. The validity of the results of a
urine drug test is dependent on the integrity of the specimen. The urine
container obviously must be clean, unbreakable, and leakproof. Since the
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analysis procedure used by laboratories has defined limitations, anythiug that
might cause the urine to be outside these limitations would produce an invalid
test. The way to achieve many of these limitations is common knowledge to
some individuals who undergo urinalysis. There are many ways for a urine
specimen to be invalidated if the individual has the opportunity.
Individuals have reportedly placed various chemical substances
under their fingernails and released them into the urine sample to
affect the subsequent analysis.
Placing a pinhole in the bottom of the urine container would
result in a leak that would not be detected at the collection site.
During shipping, however, most or all of the urine could leak out.
Ordinary table salt, detergent, or other commonly available
household chemicals can destroy the drugs or affect the assay in
such a manner as to generate a false negative analysis.
Frequently, soap dispensers or cleansers in toilet areas offer the
opportunity to add effective adulterants to the sample.
Use of a fluid-filled bulb placed under the arm, with a tube
leading to the genital area, is another method. The subject can
squeeze the bulb and release water or other substance that would
dilute or contaminate his/her own urine.
The subject can obtain urine from friends not using drugs or save
his/her own urine from drug-free periods. This urine can be
placed in the container during the collection period.
The subject can scoop water from the commode into the
collection container and dilute the urine.
It is important that specimen collection be directly witnessed if at all
possible by a reliable individual to prevent this sort of intentional
adulteration. While direct-observation collections provide the greatest
credibility to a drug deterrent program, the procedure can be embarrassing to
both parties. Where it is determined that privacy of the individual must take
precedent over other considerations (and such was the determination in
President Reagen’s recent Executive Order for urine drug testing in the
Federal workforce), there are means by which adulteration of samples can he
minimized. The temperature of the specimen should be close to body
temperature (37°C)* if the sample has not been diluted with water. This can
be checked by thermometer. Collection facilities can be set up with no soap
dispensers or cleaning agents available that can be used to adulterate the
sample. The water in the toilet can be dyed or the toilet itself can be a
chemical one, eliminating in both cases the availability of water for dilution.
Such a facility should be considered in circumstances where specimens can
not be witnessed as a matter of policy or where the possibility of the
subject’s bringing in something to contaminate or dilute the sample is
unlikely. A patient undergoing a physical, for instance, may not be dressed
and could not likely conceal anything to invalidate a sample by adulteration.
*Judson, B.A.; Himmelberger, D.U.; Goldstein, A. Measurement of
urine temperature as an alternative to observed urination in a narcotic
treatment program. Am J Drug Alcohol Abuse 6:197-205, 1979.
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In most cases, the laboratory is capable of detecting the adulteration of urine
specimens when water has been added by checking the specific gravity of the
urine. A colored water solution or a urine to which a large amount of water
had been added would have a lower than normal specific gravity. A pH check
would indicate an attempt to acidify or alkalinize the specimen to invalidate
screening assays. If adulteration is suspected, the laboratory should be
notified and requested to make such a determination. The laboratory can
also check on the validity of the sample by performing a creatinine analysis.
Creatinine is normally present in a urine sample and will be detected by the
test if the sample is urine. In addition, the concentration of creatinine can
be used to determine if the sample has been diluted (by adulteration or by
drinking excessive quantities of liquid).
Other means of influencing the outcome of a urinalysis that are more
difficult to detect involve the ingestion of large quantities of water before
providing a sample, which in effect dilutes the urine produced. Drinking
large volumes of water or other liquid several hours prior to the urine
collection could easily result in a tenfold dilution of urine. This dilution
could lower the concentration of drug sufficiently so that it could not be
detected by the laboratory analysis.
There is a widespread belief that drinking vinegar can produce negative
urinalysis results. While it is theoretically possible that sufficient vinegar
ingestion could alter urinary pH, it is highly unlikely that such a quantity
could be drunk without toxic consequences. Even if pH were altered slightly,
the effects on different drugs would be variable--the excretion rate of some
might be increased slightly and for others it might be decreased.
SECURITY
The security of samples as well as empty cups, laboratory invoices, cup
labels, and other packing or shipping material is critical. If subjects can
obtain empty cups or other laboratory material, it becomes quite easy to
substitute other urines for their own. Computer-printed labels should be
attached to the cup, rather than to the top, to make it more difficult for
subjects to switch samples.
The specimen donors should not generally be permitted to have any
involvement in the collection, labeling, boxing, packing, or transporting of
samples to the laboratory. It is important, however, that donors witness the
sealing of the bottle and sign or initial the seal. Access to collected urines or
any of the boxes, cups, tape, labels, or other laboratory materials should not
be allowed.
After collection, urine specimens should be stored under locked storage
conditions. If transport of the specimens is inordinately delayed, they should
be kept refrigerated (4°C) if possible.
-27-
DOCUMENTATION
Accurate and complete records of all individuals involved in the urine
collection, storage, and shipping procedures should be maintained. At least
two major documents will be utilized for documentation procedures. These
include a label attached to the urine specimen container and a separate
invoice or other listing of the samples transmitted to the laboratory.
Specimen Label
The specimen label should be affixed to the urine container and not to the
lid. This will prevent accidental or intentional switching of specimens and
identifying labels.
The label should contain the following information:
Name or other identification of the collection site or client
Date and time the sample was collected
Name or identification (social security numbers are frequently used)
of the subject (subjects should initial the label and thereby
acknowledge that the specimen is their urine)
Name or identification of the individual who witnessed the urine
collection (the witness’ initials should also be on the label)
Log number to link the specimen to the transmittal
invoice, although the subject ID number from the label along with
the site code number is generally sufficient for this purpose
Approximate volume of urine collected
If possible, certain information on the labels, such as the name of the
laboratory and/or the identification of the collection, should be preprinted.
This will reduce the chances of subjects’ switching labels or samples. AU
writing on the labels should be in ink that will not run if it becomes wet from
condensation of water or urine spillage. Clear plastic tape over the label
provides an excellent mechanism for preserving the integrity of the
information.
Invoice
A transmittal invoice that accompanies the urines will allow the laboratory
to check the individual urines against the invoice to confirm that all the
specimens collected actually reach the laboratory. The minimum
information the transmittal invoice should contain is:
Collection site or client name or identification number
Subject name or identification code
Accession number of the specimen (if used)
Specimen collection date
Desired tests to be run on the urine specimen (if are not preset)
Name or identification number of the witness and/or persons
responsible for collection, handling, storage, or packing of specimens
at the collection site
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PACKING AND SHIPPING
Sample identifications should be checked against the shipping invoice as they
are placed in the shipping box. The staff member should ensure that the
number of urines shipped and the tests desired correspond between the
invoice and the urine cups.
The shipping container should be sealed at all openings with tape that cannot
be removed. Additional security may be provided by the staff member’s
signing his or her name across the box and tape. In this manner, if the tape is
removed, it will not be possible to reseal the box without detection. The
laboratory should be supplied with a list of acceptable signatures.
Samples should be transported to the laboratory either by the courier or by a
reliable staff member. If a bonded courier transports the samples, a record is
kept which acts as proof of delivery for legal purposes. Courts have upheld
shipment of such samples by U.S. mail, however. If the samples are delivered
by a staff member, a receipt must be issued by the laboratory when the
samples are received. Specimen donors should never be permitted to
transport samples to the laboratory.
If the samples are delivered by courier, the invoice should be checked to
make snre that the invoice accurately states the number of boxes sent. If the
samples are delivered to the laboratory by a staff member, the staff member
should request a hand receipt stating the number of boxes delivered.
If fewer than the number of boxes or samples stated on the invoice are
received by the laboratory, or if a discrepancy is noted between the
information on the container label and the invoice, a report of the situation
discrepancy should be sent by the laboratory to the collection site.
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Analytical Methodology
Richard L. Hawks, Ph.D.
The specific methods chosen by a laboratory will depend on a number of
factors, including cost, workload (number of specimens), turnaround time,
sensitivity required, and reliability. In nearly all applications of urine drug
detection, a confirmation analysis is essential for all specimens screened
positive. A different type of analytical methodology should be used for the
confirmation analysis. Analytical methods used in most laboratories for the
detection of drugs in body fluids can be classified into two main categories--
immunoassays and chromatography--generally used respectively for
screening and confirmation.
Examples of these two types of methodologies are presented, including
sections describing how they are used for screening and confirmation
purposes. A brief discussion of new trends in urine drug detection methods
appears at the end of this chapter.
IMMUNOASSAYS
lmmunoassays are based on the principle of competition between labeled and
unlabeled antigen (drug) for binding sites on a specific antibody. Antibodies
are protein substances with sites on their surfaces to which specific drugs or
drug metabolites will bind. These antibodies are formed by inoculating
animals with appropriate immunogens. Two types of immunoassays are
usually employed in urinalysis at this time--the radioimmunoassay (RIA) and
the enzyme immunoassay (EIA). The difference between these types of
immunoassays is mainly in the indicator that is used. The EIA utilizes an
enzyme as an indicator in the assay (the label), while RIA uses a radioactive
indicator. Because antihodies often cross-react with related drugs, and
sometimes even with unrelated compounds, confirmation of positive
immunoassay results with an independent procedure is imperative for
definitive identification. The Abuscreen RIA manufactured by Roche
Diagnostics in Nutley, NJ, is the RIA system most frequently used for drugs
of abuse in this country (Abuscreen 1983). The EIA of most prevalent use in
the United States is the EMIT manufactured by Syva Company in Palo Alto,
CA.
Radioimmunoassay (RIA)
In radioimmunoassay testing (Chase et al. 1976; Ebert et al. 1981; Cook et al.
1982; Soares et al. 1982; Law et al. 1984; Cross et al. 1985). known amounts
of radioactive-labeled drug are added to a urine sample with knowu amounts
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of antibodies. The mixture is then allowed to incubate, during which time the
labeled drug and unlabeled drug compete for binding sites on the antibody.
After precipitation and centrifugation of antigen-antibody complexes, either
the supernatant fluid or the precipitated antibody is transferred to a gamma
counter (an instrument that determines the level of radioactivity of the
sample). The presence or absence of the drug is indicated by the amount of
radioactivity found, since this is proportional to the amount of antigen
(labeled drug) bound to the antibody. If the supernatant is counted, a positive
specimen is identified when the radioactive counts are equal to or greater
than those of a positive control prepared in the same manner as that of the
unknown urine. Conversely, when the precipitant (bound antigen) is counted,
a positive specimen is identified when the radioactive counts are equal to or
lower than those of a positive control prepared in the same manner as that of
the unknown urine.
RIA can detect very small concentrations of drug with sensitivity ranges on
the order of 1-5 nanograms per milliliter (ng/ml). The required sample
volume is small and sample preparation is minimal. The use of automated
pipetting and counting equipment allows for large-volume, multiple testing.
Some of the disadvantages of this technique are associated with the use of
radioactive substances and the high cost of reagents and instrumentation.
Turnaround time is long--from 1 to 5 hours.
Enzyme Immunoassay (EIA)
Unlike RIA, EIA is a homogeneous enzyme immunoassay technique. That is,
the antigen-antibody complex need not be separated by centrifugation. The
most frequently used EIA method in this country is the EMIT system (Rogers
et al. 1978; DeLaurentis et al. 1982; Law et al. 1982). In the EMIT assay, the
label on the antigen is an enzyme (protein) that produces a chemical reaction
for detection of drugs. This detection is based on the competition between
unlabeled drug or drug metabolite and labeled drug or drug metabolite for
binding sites on the antibody. Urine is mixed with a reagent containing
glucose-g-phosphate (G-6-P) and antibodies to the drug, as well as a second
reagent containing a drug derivative labeled with G-6-P dehydrogenase. The
enzyme-labeled drug when bound to an antibody site is incapable of
interacting with the substrate (G-6-P). If the enzyme-labeled drug does not
bind to the antibody, then it is free to react with the substrate. The drug in
the subject’s urine competes for the limited number of antibody binding sites
and thereby proportionally increases the total enzyme activity. The
enzymatic activity is therefore directly related to the concentration of the
drug present in the urine.
Some of the advantages of EMIT include (1) a short analysis time, (2) an
easily measured nonradioactive endpoint that is simply measured, and (3) no
necessary separation of bound and free fractions as in RIA. The EMIT,
however, is generally less sensitive than RlA but still has moderate to good
sensitivity and specificity (Allen and Stiles 1981). The enzyme/substrate
interaction is somewhat more sensitive to temperature variation and ionic
adulterants (such as salt). This procedure can be automated, allowing for
multiple sample testing and reduced costs. Two systems are currently
marketed--the EMIT-d.a.u. is designed for use in laboratories with large
sample throughput; the EMIT-st is a portable system which can be used
“on-site” and in situations where a small number of samples are analyzed in
any given period.
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CHROMATOGRAPHY METHODS
Chromatography is a method of analysis in which the various components in a
biological  specimen can be separated by a part i t ioning process.
Chromatographic separations to resolve mixtures of drugs and metabolites
require (1) a stationary (fixed) phase, which may be a solid or a liquid on an
inert support having a large surface area, and (2) a mobile (moving) phase of
liquid or gas. With a chromatographic method, substances are carried by the
mobile phase through a column or across a plate, where the stationary phase
interacts with the specimen to cause separation of the various components.
After separation, a detection method distinguishes the components for
identification and measurement.
Separation of the components of biological mixtures containing substances of
various molecular types is based on the time spent by each component in each
phase of the chromatographic system. Several different types of
chromatographic techniques are used in laboratories for urine drug analysis.
These various techniques offer different degrees of resolving power (the
ability to separate one component from another) and often utilized in
combina t ion ,  depending  on  the  d rugs  in  ques t ion .  Whi le  o ther
chromatographic techniques are available, thin-layer chromatography (TLC),
gas-liquid chromatography (GLC), and high-pressure liquid chromatography
(HPLC) are the most commonly used ones. The combination of GLC with
mass spectrometry (GC/MS) provides the most specific type of analytical tool
currently used in urinalysis.
Extraction of biological samples is necessary for all chromatographic
techniques for drugs other than alcohol. It is usually not required for the
immunologic methods. Liquid-liquid extraction is the most commonly used
method. This procedure involves the mixing of the sample in water with a
water-insoluble organic solvent. If the drug of interest is more soluble in the
organic phase, most of the drug is extracted from the water phase into the
solvent. The solvent is then evaporated to dryness, and the residue is
redissolved in a small amount of solvent and reserved for further testing.
This is called direct extraction.
Some selectivity can be achieved by an appropriate choice of solvents and pH
adjustment of the aqueous phase. Greater selectivity can also be obtained by
a technique called multiple extraction (or back extraction) when necessary.
Passing the drug back and forth from solvent to aqueous phase with pH
adjustment tends to isolate it from nondrug or other interfering substances.
Separation of classes of drugs can also be attained by this technique.
Liquid-solid extraction with resin or charcoal, and more recently other
solid-phase extraction techniques, provide the necessary isolation of drug or
drug metabolite from the biological sample and provide a relatively clean
sample for analysis by GLC, HPLC, TLC, or related procedures.
Thin-Layer Chromatography (TLC)
Of the chromatographic techniques, TLC is one of the oldest methods but is
still utilized as a practical technique for many large-scale multiple drug
screening programs (Michaud and Jones 1980).
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In TLC, an absorbent (stationary phase), such as silica gel, alumina, cellulose,
or ion exchange resin, is uniformly applied to a glass plate or plastic film.
Mixtures of known drug compounds (standards) or residues from an extraction
of drugs from urine are applied as spots to prepared plates, which are then
placed in a closed container with just enough solvent (mobiie phase) to wet
the bottom of the plate. The solvent is allowed to flow across the stationary
phase by capillary action, usually in an ascending fashion, allowing the
substances to separate. The separated substances can then be identified by
spraying the plate with reagents that produce characteristic color reactions.
Drugs visualized in this way are identified on the basis of (a) reference values
(ratio between the distance the mobile phase moves up the plate and the
distance the compound moves from the point of application), (b) metabolic
patterns (parent drug and characteristic metabolite), and (c) functional group
analysis (chemical characteristics as defined by the color reaction with the
spray reagent).
Advantages of using TLC are (1) low cost of equipment, (2) rapid analysis,
and (3) ability to detect more than one drug or metabolite per analysis.
Relatively small amounts of drugs can be detected, usually as low as of
0.5-1.0 micrograms per milliliter. The recent development of high-
performance thin-layer chromatography (HPTLC) plates has enhanced the
capability of thin-layer chromatography. In HPTLC, silica gel particle size
and the thickness of the layer on the plate are reduced, allowing for the
separation of drugs in much shorter distances. Increased sensitivity is also
gained because the applied spots are smaller than those for regular TLC. A
small spot in combination with the short migration distance results in high
drug concentration at the migrated spot. The net effects are increased
sensitivity for the detection of drugs and a shorter analysis time. References
to TLC methods for a variety of drugs can be found in the last chapter of this
monograph.
Some of the disadvantages of TLC are that it provides only fair specificity
and sensitivity and results that are highly dependent on the technician’s skill.
It does require practice to recognize patterns of drugs and/or their
metabolites by the visualized colored spots. These problems are minimized
by commercial systems that attempt to standardize the elements of
extraction, application, and visualization. One such system, manufactured by
Analytical Systems, Laguna Hills, CA, is called the Toxi-Lab system. TLC
also is a highly labor-intensive technique and sometimes requires extensive
sample preparation.
Gas-Liquid Chromatography (GLC)
Gas-liquid chromatography (interchangeably referred to as gas chromat-
ography or GC) is widely used in drug analysis as a confirmation method as
well as a primary screening method under some conditions (ElSohly et al.
1984; Woodworth et al. 1984). It utilizes an inert gas, such as nitrogen or
helium, as the moving phase to transport a vaporized sample of a drug
through a glass column containing a stationary liquid phase. The drug is
identified and quantified by a detector at the far end of the column.
The column’s capability to separate and identify drugs is optimized by
altering the types and amounts of a liquid (stationary phase) absorbed on
solid-phase substances such as silica compounds. Typically, columns used in
many GC methods are 3-6 feet in length and a few millimeters in diameter.
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There has been great technical development in capillary columns, which offer
an increase in separation power over the conventionally packed column.
Capillary columns (0.2-0.7 millimeters in diameter and 5-100 meters in
length) are made of fused silica and are available in several forms. With one
type, the Liquid phase (organic compound) is present as a thin film on the
capillary column walls. Bonded phases are widely used and offer several
advantages over nonbonded phases, notably (1) on-column injections and (2)
better stability and resistance to thermal shock. Capillary columns coupled
with GC provide superior resolution of compounds, give greater sensitivity,
and are generally recommended for applications in urine drug assays.
Either a conventional or a capillary column is placed inside an oven with
precise temperature control; the sample is injected into a heated port and is
carried through the column by the inert gas at a controlled flow rate. The
column material has the ability to absorb substances as they are being moved
from injector port to the detector. Different drug molecules tend to be
differentially adsorbed by the liquid phase and the gas vapor phase. The
equilibrium between these two phases as the drug passes through the column
creates the characteristic column retention time for that drug. This
retention time is the parameter of identification associated with GLC
procedures.
Several types of detectors are available to provide the selectivity and
sensitivity needed to properly detect and identify drugs of interest as they
emerge from the column. Popular detectors are the electron capture
detector (ECD), the flame ionization detector (FID), and the nitrogen-
phosphorous detector (NPD). Each of these detectors has i ts  own
characterist ics of sensit ivity and specificity.  The NPD detector is
particularly suitable for nitrogen containing compounds such as phencyclidine
or cocaine. The FID is of more general applicability, but is less sensitive
than the NPD or the ECD detector.
Gas-Liquid chromatography is a sensitive technique, and small amounts of
drugs can easily be detected and identified by determining their respective
retention times as compared with known drug standards under optimum
instrument conditions. Some of the limiting factors are (1) the slowness of
analysis, since only a single sample can be processed at one time, (2) the
expertise required in conducting the tests, and (3) the sample preparation
time, since many drugs or their metabolites must be derivatized before they
can become sufficiently volatile to move through the column. Additionally,
GLC as well as all other chromatographic methods suffers from the
deficiency that the retention time, which provides only a single parameter,
cannot be used as an unequivocal identification in many cases. Certain drugs
or conditions may require that other methods be used to provide rigorous
proof of identity.
High-Performance Liquid Chromatography (HPLC)
This method is sometimes used in urine and blood analysis (ElSohly et al.
1983; Law et al. 1984a; Dye et al. 1984). It employs a column through which
the drug passes while undergoing equilibration between two liquid phases,
rather than a gas and liquid phase as in the case of GLC. Again, the
characteristic of the drug molecule that is measured is the time it takes for
the drug to traverse the column at a given solvent flow rate. Detectors are
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ultraviolet, fluorescent, or electrochemical in nature. HPLC has the
advantage that polar drugs requiring derivatization on GLC systems can be
assayed directly on HPLC. Its disadvantages are similar to those of GLC,
although specimen preparation may be simpler. Some laboratories take
advantage of HPLC’s chromatographic capabilities and the superior
sensitivity of RIA methods by using RIA as the HPLC detector. In this case,
fractions from the HPLC column are sequentially analyzed by RIA to provide
a highly specific and sensitive system of analysis (Law et al. 1984a). This
technique is useful in many forensic applications but generally is too
cumbersome for routine urinalysis.
Gas Chromatography/Mass Spectrometry (GC/MS)
The analytical technique of gas chromatography/mass spectrometry (GC/MS)
combines the efficient separating power of gas chromatography with the high
sensitivity and specificity of mass spectrometric detection. GC/MS is
generally considered to be the moat conclusive method of confirming the
presence of a drug in urine. The major factors that have limited the use of
GC/MS have been its comparatively high cost and complexity. Fortunately,
GC/MS instrument manufacturers have recently introduced lower Priced
systems that are easier to operate and this should result in significantly lower
fees for GC/MS analyses.
In spite of the remarkable potential capabilities of GC/MS, it should not be
assumed that the results of all drug confirmations performed using GC/MS
are conclusive. There are many different modes of operating a GC/MS. It
can be operated in the “full scan” mode which provides a complete mass
spectrum for each component of the urine extract that passes through the gas
chromatograph. Since a complete mass spectrum represents a “fingerprint”
pattern that is unique for each drug, this mode of operation will give the
most conclusive identification if there is a sufficiently high concentration of
the drug to provide a good quality mass spectrum.
Alternatively, the GC/MS can be operated in the selected ion monitoring
mode in which the mass spectrometer monitors the ion currents at only a few
masses which are characteristic of a specific drug. This mode of operation
affords far higher sensitivity, but provides a less specific pattern for
identification. Other choices of modes of operation include the method by
which the drug molecules are ionized. Electron impact (EI) ionization is the
technique most widely used. Mass spectra obtained using EI ionization are
typically quite complex and therefore very suitable for obtaining a
“fingerprint” identification of a drug. The technique of chemical ionization
(CI) is an alternative method of ionizing molecules for mass spectral
analysis. CI mass spectra are typically less complex than EI mass spectra of
the same drug, and therefore are less unique. However, because CI is often
more sensitive than EI ionization, it can be used to detect and measure lower
concentrations of the drug. Also, some methods of chemical ionization are
relatively selective as to what compounds are ionized, as a result detection
of a drug by CI mass spectrometry is often less subject to potential
interferences from co-eluting components of the urine extract.
The choice of which modes of operation are to be used (full scan or selected
ion monitoring, CI or EI ionization, etc.) depends on what drugs are to be
detected, the minimum concentration of the drug that constitutes a positive
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identification, and whether or not the concentration of the drug is to be
quantitatively determined. The reliabitity of a GC/MS assay is also
dependent on the skill and experience of the operator, as well as on the
method used for extraction of the drug(s) from the urine and for preparation
of the extract for injection into the GC/MS. An extensive knowledge of
GC/MS technology is often needed to adequately evaluate the reliability of a
specific assay, but if appropriate methods are used by well-trained analysts,
a GC/MS analysis will ensure that a suspected drug is identified properly, and
conversely, that no one will be falsely accused of drug use.
SCREENING PROCEDURES
The principle of screening by immunoassay, a highly sensitive technique, is to
minimize the possibility of false negatives. By selecting highly sensitive
techniques for broad classes of drugs, however, absolute specificity is
lessened such that some false-positive results may be produced from
cross-reacting substances having a similar chemical structure present in the
specimen. For this reason, positive results from the screening procedure
should be considered only presumptive; they must be confirmed by a second
and distinctly different analytical technique.
Alternatively, thin-layer chromatography is often used as an initial screen
when the ability to screen inexpensively for a large number of drugs is more
important than the degree of sensitivity. Due to the level of subjectivity
involved in the interpretation of TLC assays, however, it is important to
confirm any presumptive positives with a highly specific method such as
GC/MS.
SENSITIVITY AND ASSAY “CUTOFF”
The ability of any assay to detect low levels of drugs has an inherent limit.
The concentration of drug in the urine sample below which the assay can no
longer be considered reliable is the “sensitivity” limit. It is sometimes called
the “detection limit” and is expressed as a concentration of the analyte in the
specimen. The “cutoff” point is the concentration limit that will actually be
used to assay samples. It is a value serving as an administrative breakpoint
for labeling a urine result positive or negative. Manufacturers of commercial
urine screening systems set cutoff limits to their assays well above the
sensitivity limits of the assay to minimize the possibility of a sample that is
truly negative giving a (fake) positive result. For example, although most
immunoassays for detection of marijuana are sufficiently sensitive to detect
drug metabolites at levels below 20 ng/ml, the assays are usually set for
cutoff levels of 20 to 100 ng/ml. This decreases the possibility of a false
positive that could result from operating the assay too close to its level of
sensitivity.
The cutoff levels selected should be reasonable concentrations reflecting
realistic urinary elimination of drugs. In immunoassay screening procedures,
a cutoff standard is selected along with control standards at other
concentrations.  Any sample that contains the drug of interest  at
concentration levels equal to or greater than the designated cutoff is
reported positive, and any sample that is less than the cutoff level is reported
negative. Setting screening cutoffs too low would allow for longer detection
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time after drug administration, but the results might be difficult to confirm
reliably. If the confirmatory procedures are not sensitive enough, the
screened positive may not be confirmed and the result would appear as a
false positive.
The distinction between an unconfirmed positive and a “true” false positive is
sometimes confusing. A sample determined positive by one method and
negative by a confirmation (different) method could be a situation where a
false result occurred in the first analysis and the drug was not in fact
present, or, alternatively, the drug might in fact be present but was not
detected in the second assay due to differences in the sensitivity of the two
assays. On the other hand, setting high cutoff levels for the screening
procedures will generate false negatives because drugs may be present in
significant concentration but below the designated cutoff and would
therefore be reported negative. Each urine sample must undergo a separate
immunoassay for each of the selected drug groups. Depending on the
laboratory and the technique employed, cutoff levels may differ. Therefore,
negative screening reports should contain a statement with reference to
established cutoff levels only, without providing the specific numbers leading
to the negative evaluation. Urine specimens testing negative do not require a
confirmatory test.
ASSAY SPECIFICITY
Specificity or selectivity of an assay method refers to the ability of the assay
to identify a single chemical component in a mixture of chemicals and
biological materials. This characteristic is a function of one or all of the
processes of isolation, separation, and detection of a particular product in a
biological matrix. A highly selective detector on an HPLC or GC can
compensate for a complex mixture, while the same compensation may be
achieved by an unusually efficient separation technique such as capillary
column chromatography.
The most specific types of assay methods optimize all these factors. GC/MS,
for instance, with a capillary column permits highly efficient separation of
components on the column, followed by extremely selective detection in the
mass spectrometer. It therefore achieves the most specific results of all
assay methods.
CONFIRMATION PROCEDURE
The principle of confirmation procedures is to use a highly specific and
alternate chemical technique to ensure that false-positive results do not
occur at the selected or established cutoff levels. For most assays, the
sensitivities for the confirmation procedures should be lower than the cutoff
of the screening procedures used, so that the number of false negatives or
positives due to concentration differences is minimized. In some cases (e.g.,
cannabinoids), the confirmation cutoff is generally set at a much lower level
than the screening cutoff, because the immunoassay reacts additively with
several metabolites from THC and the more specific confirmation methods
are directed at only one. A selective liquid-liquid or liquid-solid extraction
procedure prior to the confirmatory test is used to isolate the drug and/or
metabolite from the urine. The purified extraction product may require
further treatment (e.g., derivatization) before it is analyzed.
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Prior to extraction, a known amount of an internal standard is added to each
standard control and to each sample to ensure extraction integrity and to
serve as a basis for quantifying the drug in question. The internal standard is
a chemical compound having chemical and physical properties similar to the
drug being tested. A distinct advantage for GC/MS is the ability to use a
deuterium-labeled internal standard. In this case, the internal standard is
virtually identical to the drug being tested, but it can be measured separately
due to the different mass. A calibration standard containing the drug at the
cutoff level is included in each analysis, as are blanks and positive and
negative controls. (The quantitative analytical data are compared with
calibration curves for the analyte with a known quantity of the internal
standard.) AU quality control materials being run should give results within
acceptable deviations from the true mean (generally ±2 standard deviations).
RECOMMENDED ANALYTICAL APPROACH TO DRUG TESTING
Because of the potential impact of the results of a urinalysis on an individual,
only the most rigorous and conclusive procedures should be used. It is
essential to incorporate both a screening and a confirmation step in any urine
drug detection program where the consequences of such an analysis will he
the basis of actions taken against the individual who supplied the sample. ln
this regard, the confirmation techniques chosen by the laboratory should
provide the most accurate and unequivocal results possible. While
confirmation techniques other than GC/MS may be adequate for some drugs
of abuse, GC/MS is generally accepted as a rigorous confirmation technique
for all drugs, since it provides the best level of confidence in the result. Put
another way, the appropriate use of GC/MS as a confirmation technique is
least likely to become a topic of debate between expert witnesses at a legal
proceeding. Major Federal drug screening programs, such as the one used by
the Department of Defense, mandate GC/MS as the confirmatory method for
all drugs.
Thus, an effective analytical system for the detection of drugs of abuse in
urine should consist of (1) a sensitive, drug-class-selective technique such as
EMIT or RIA, employed as the initial screening process to identify negative
specimens and to select presumptive positive specimens, and (2) a highly
specific technique such as GC/MS, used for confirmation of the presumptive
positive results.
NEW DIRECTIONS IN URINE DRUG SCREENING
Because of the tremendous interest in drug screening today, efforts are being
made in many areas to develop new techniques that would be applicable to
this question. Some of these efforts are directed at developing new
analytical systems that will be simpler and perhaps less expensive than
conventional systems for drug screening or confirmation. In some cases, the
goal is portability, such as in efforts to produce dipstick-type assays.
Different biological media are being explored as alternatives to urine.
Efforts are also being directed at developing noninvasive means of diagnosis,
such as equipment to determine drug effects in the individual based on
certain electrical outputs from the brain. Other attempts are aimed at
developing methods or devices to better analyze impaired performance as an
indicator of a drug effect, a phenomenon not measured by urinalysis.
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Developments in screening systems are underway in the area of
immunoassays. Because fluorescent systems have very high sensitivity and do
not require the use of radiolabeled material as does RIA, fluorescent labels
have become an attractive idea. Problems with background fluorescence
have prevented fluorescence spectrometry from becoming highly useful in
drug analysis in spite of the high sensitivity, but in recent years, systems
have been developed that combine highly specific separation systems, based
on antibodies with fluorescent detectors, to produce highly sensitive and
specific fluorescent immunoassays. One example is the widely used TDx
System manufactured by Abbott Laboratories. Abbott has recently marketed
a new system called the TDx Abuse Drug Assay, which is designed to detect
classes of drugs of abuse. It is to be expected that other systems based on
immunoassay and fluorescent labels will be forthcoming in the near future.
Other research groups are investigating various ways to incorporate
immunoassay specificity into systems that would give rapid readouts of
presumptive drug presence based on a dipstick analysis of a urine, blood, or
saliva specimen.
Work continues in the area of mass spectrometry to make this highly specific
method more economical. The specificity and sensitivity of GC/MS are
already sufficient for most applications of drug screening. A disadvantage in
GC/MS analyses is  the t ime required for the drug to traverse the
chromatography column and for the analyst to prepare the sample for
injection into the instrument, although ways to reduce this time element are
being explored with an eye to using GC/MS as a screening as well as
confirmation tool.
A liquid chromatograph can be connected to a mass spectrometer (LC/MS) in
much the same way as the gas chromatograph is connected in GC/MS. As
discussed in the previous section on HPLC, derivatization is usually not
necessary and sample workup time is greatly decreased. While this type of
instrumentation is not generally in use now in urine drug assays, it may have
applicability in situations where confirmation analyses without derivatization
are desirable.
Another type of new MS technique that may have application to urinalysis is
called tandem mass spectrometry (MS/MS); this is particularly attractive
because it can often eliminate the need for a chromatography column. It also
offers the possibility of increased sensitivity and specificity over that of
conventional GC/MS. An extremely sensitive assay for THC in rabbit plasma
using this technique has been reported (Harvey et al. 1982). MS/MS is a
technique that couples two mass spectrometers together, so that one acts as
the sample cleanup system and the second as the ultimate analyzer. This
approach theoretically would allow a relatively crude extract to be
introduced directly into the first MS, eliminating the time-consuming
chromatography step, while at the same time providing increased sensitivity,
which may be necessary when drugs such as LSD and some fentanyl
derivatives which are extensively metabolized and appear in extremely low
concentrations in urine become the subject of urine screens.
OTHER BIOLOGICAL SAMPLES
Other types of biological samples, including blood, hair, and saliva, have been
proposed as alternatives to urine for drug screening. Although studies on
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analysis of blood for drugs have been extensive and such tests potentially
provide a more specific indication of drug impairment, blood analysis
generally requires more sophisticated techniques of analysis than urine. It
also is considered a more invasive sample to obtain, and requires trained
personnel to do so. Saliva is perhaps the most easily obtained sample. It has
been established that many drugs can be detected in saliva (Caddy 1984).
THC, for instance, is sequestered in the mucous membranes and can be
detected (Norton and Garriott 1983; Gross et al. 1985; Cook 1986) for several
hours after marijuana is smoked. Saliva testing is not generally used, because
the methods of analysis are frequently more difficult than for urine. Further,
the time period during which drugs can be detected in saliva after use is
usually only a few hours, often paralleling plasma levels.
The analysis of hair has also been proposed as a way of detecting past drug
use (Baumgartner et al. 1981, 1982). It has been shown that certain drugs can
be detected in hair samples by means of sensitive RIA or GC/MS techniques,
but the methods have not yet been sufficiently validated in clinical studies in
comparison with urinalysis to adequately assess their suitability for general
drug screening (Puschel et al. 1983). This type of screen also suffers from
the fact that the extremely small sample (20-30 hairs) is frequently
consumed in the screening assay, leaving insufficient material for
confirmation by any but the most sensitive GC/MS techniques.
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Accuracy in Urinalysis
Robert V. Blanke, Ph.D.
Accuracy is the absolutely essential ingredient of laboratory analysis. The
public perception of scientific measurements is that they are indisputable. If
a laboratory reports the presence of a quantity of drug in a specimen, this
ruling is judged to be correct, regardless of protestations to the contrary by
the subject. Users of laboratory tests assume the results are reliably
accurate; otherwise, the cost of these tests is wasted. But what is
“accuracy,” and how can it be estimated?
Accuracy can be viewed as the closeness with which test results agree with
the “true” quantity of a drug in urine. In an unknown urine specimen, the
“true” result, the center of the proverbial bull’s eye, obviously is not known.
Judging whether a specific test result is accurate can be done only by
evaluating a laboratory’s quality assurance program (Annino 1978).
Quality assurance (QA) is a term used, to represent those practices carried
out to assure that specified quality goals are achieved (Eilers 1975). Once
the quality goals have been defined, quality control (QC) procedures can be
designed to monitor performance parameters. Thus, it is important that the
testing laboratory and the user of the test results clearly understand the goal
of the testing program.
Urine drug testing programs can demonstrate the presence of certain drugs or
drug metabolites in urine. These results alone cannot be used to determine
dosage or the time of drug administration or the extent of any drug effects in
the subject, but urine drug testing programs can indicate drug use. They may
also provide presumptive evidence that certain behavioral changes or
decrements in performance observed in the subject may be associated with
drug use. Thus, the goal of urine drug testing may be stated as the reliable
demonstration of the presence, or absence, of specified drugs or metabolites
in the specimen--that is, the production of a valid positive or negative result.
FACTORS CONTRIBUTING TO ACCURACY
Generally, when large numbers of specimens are processed by a laboratory,
screening tests are used to separate the greater number of negative
specimens from those producing positive results. Since screening tests are
subject to interferences, all specimens that test positive must be confirmed
by an independent,  more specific procedure.  If  a relatively high
concentration of drug is present in the specimen, screening and confirmatory
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tests are more reliable. As the drug concentration approaches the limit of
the test to detect a drug, more uncertainty is associated with the test result.
This involves another aspect of lesting procedures known as “sensitivity.”
Sensitivity is the lowest concentration of a drug that can he reliably detected
by a particular test procedure. The key word here is “reliable.” A test may
be considered very sensitive when measuring a pure drug, but the test’s
reliability may be poor when the drug is in a complex matrix such as urine.
Most laboratory instruments are devices that measure drug concentrations by
means  of  a  de tec tor .  The  de tec tor  may  be  a  gamma counte r  in
radioimmunoassay, an optical device in fluorescence or enzyme immunoassay
techniques, or more complex in nature for some chromatographic methods.
The detector, in turn, generates an electronic signal, which drives a printer
or recorder to permit the analyst to visualize the intensity of the detector
response and thereby estimate the amount of drug present. All detectors
produce a certain amount of background “noise.” When tests are run near the
limit of sensitivity to a drug, it is increasingly difficult to discriminate
between the noise and a true signal in response to a small amount of drug.
In order to compensate for sensitivity problems, and possibly minimize the
incidence of positive results from passive drug exposure, frequently a cutoff
concentration is selected. Above this level, a test is considered positive, and
below it is considered negative. A disadvantage of establishing cutoff
concentrations is that some individuals with actual drug present in the urine,
albeit at low concentrations, will be deemed negative. These false-negative
tests are generally tolerable in order to avoid false-positive results due to
sensitivity variability.
Cutoff levels, when adopted, require consideration of another parameter of
drug testing methods known as precision. Precision is the degree of
agreement between repeated measurements. Good precision of a testing
method increases confidence that the test can discriminate between drug
concentrations above or below the cutoff level. Precision can be measured
by the standard deviation (s) or coefficient of variation (c.v.) of a method.
These are indicators of random error.
Consider the example in table 1. A cutoff level of 100 ng/ml has been set for
a test for a metabolite of THC. That is, a test showing greater than 100
ng/ml of this metabolite will be called positive; below 100 ng/ml the test is
negative. In order to determine the precision of this test, a specimen is
divided into 10 portions and each portion is assayed.
One result, test number 6, appears to be unusually different from the rest.
This result can be examined statistically to estimate the probability that it is
an extreme value and can be rejected. When this is done, it is found that the
probability that result number 6 is an “outlier” is greater than 995 times in
1,000. An outlier is a test result far removed from most of the other test
results on the same specimen. Thus, it can be rejected.
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Note that the “true” value is not known, but repetitive testing can result in a
valid estimate of the true value. When the outlier is included, the mean is
102.1 ng/ml (interpreted as positive), but when the outlier is excluded, the
mean is 99 ng/ml (interpreted as negative).
Table I
Test No. Result (ng/ml) Result (ng/ml)
1-
2-
3-
4-
5-
6-
7-
8-
9-
10-
98
101
95
99
103
(130)
100
97
96
102
98
101
95
99
103
100
97
96
102
Mean (x)
Standard deviation (s)
Coefficient of variation (c.v.)
102.1 99.0
±10.14 ±2.74
9.93 % 2.77 %
This example is chosen to illustrate two aspects of analytical testing:
1. The necessity for excellent precision to discriminate between
positive and negative when the concentration of the analyte is near
the cutoff (or limits of sensitivity) of the test
2. The troublesome problem of outliers
At times, a careful review of procedures used can explain why the unusual
result occurred, but frequently no obvious explanation can be found. When
repetitive analyses are done, outliers can he recognized and tested
statistically. Unfortunately, if a single test is done on an unknown specimen,
it is not possible to know whether the result obtained is an outlier or an
estimate of the true value within the standard deviation of the test. It has
been reported that, in intralaboratory testing, 5 percent to 15 percent of the
results may be statistical outliers (Horwitz 1982). Only repetitive analyses of
the same specimen can identify these discrepant results.
Tests for urinalysis should be precise and accurate and generally accepted by
the scientific eommunity. Such tests are of two types, screening and
confirmatory. Screening tests must reliably identify negative specimens,
although it is recognized that some weakly positive specimens will be
interpreted as negative due to sensitivity or precision limitations of screening
procedures or due to negative outliers. Since negative results by screening
tests are generally of little concern, confirmation of these is not necessary.
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Positive results of screening, on the other hand, should be repeated. If still
positive, the test must be confirmed by independent procedures of greater
specificity and precision. This is to better characterize the drug, confirm its
presence at concentrations above any cutoff level, and identify outliers. It is
also important to carefully document and follow specific criteria that defii
a posit ive versus a negative sample with any particular analytical
methodology.
Implementing these procedures, monitoring their performance, and
identifying and correcting defects in the testing procedure require continuous
attention to a quality assurance program.
QUALITY ASSURANCE
A quality assurance program includes all of the practices carried out by the
testing laboratory to assure that the goal of reliably identifying urine
specimens containing defiied quantities of specified drugs or drug
metabolites is achieved (Tietz 1986). All of the parameters of drug testing
(such as accuracy, precision, detection of outliers, etc.) are monitored by
quality control procedures.  QA involves all  aspects of the testing
laboratory. Specimen acquisition, processing, testing, and reporting of test
results must all be as error free as possible in order to achieve the goals of
urine drug testing.
Dedication to quality testing must be of paramount importance to the
laboratory management. Not only must laboratory directors and supervisors
be committed to these goals, but administrative support is essential to
provide a budgetary basis for space, equipment, staff, and all other resources
necessary for quality testing. The cost involved in maintaining QA must be
recognized at the outset.
PERSONNEL
The qualifications of personnel are important in achieving quality results in
urine drug testing. Different tasks require different degrees of training and
experience; all require attention to details and a disciplined approach to
carrying out procedures. Graduation from an accredited school of medical
technology with certification in clinical chemistry qualifies most individuals
to operate automated instruments, carry out laboratory recordkeeping
procedures, and implement quality control, all under supervision. Analysts
operating chromatographic instruments require additional training and
experience in these techniques. An individual holding a baccalaureate degree
in chemistry from an accredited university should understand the necessary
basic theory of instrumental analysis to permit the recognition of aberrant
results and the ability to “troubleshoot” an instrument that does not meet
specifications.
Supervisors and laboratory directors must possess these qualifications as a
minimum. In addition, experience and advanced training in analytical
methods and pharmacology or toxicology are required to understand the
strengths and weaknesses of the methods used to identify drugs, discriminate
between real knowledge of drugs and their effects as opposed to conjecture,
and interpret the test results reported by the laboratory.
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Certification in clinical chemistry (by the American Board of Clinical
Chemistry) or forensic toxicology (by the American Board of Forensic
Toxicology) is highly desirable. These individuals must be sufficiently skilled
and knowledgeable to defend and interpret the laboratory results in court, if
necessary (Forney 1978).
SPECIMEN ACQUISlTION
Drug testing laboratories are involved only rarely in actually obtaining the
specimen being examined. Obviously, collecting a valid, uncontaminated
specimen uniquely identified as from a specific individual is a key issue in
urine drug testing. Details relating to the specifics of specimen acquisition
are discussed in a previous chapter.
Once the specimen is collected, it is marked in a unique way traceable to the
individual giving the specimen. A name is normally not sufficient. Rather, a
unique number such as a social security number, employee number, etc., is
preferred. A record of the name, unique identifying number, time and date
of collection, and the identity of the individual receiving the specimen is
made. The specimens are packaged in a secure manner, marked “Urine Drug
Screen” (or flagged in a less obvious manner), and sent promptly to the
laboratory by courier, U.S. mail, or other secure means.
Upon receipt by the laboratory, the title “Urine Drug Screen” alerts the
receiving clerk to forward the unopened package to the individual assigned to
receive this type of specimen. A log is kept, listing name of the subject,
unique identifying number, laboratory accession number, time and date
received, condition of the specimen, and name of the individual carrying out
the task of logging in the specimen. The laboratory accession number is
firmly affixed to the specimen container, and it is stored securely at 4°C
until analyzed.
This process, termed “chain of custody,” must be followed in handling
specimens of legal significance. Records of all individuals, both in and
outside the laboratory, having access to the specimen must be kept, and these
records documented and preserved for future reference.
Errors can occur in this phase of specimen processing. Transcription errors,
misspelling, and even confusion of specimens can occur. Quality control can
be exercised by proper training and motivation of personnel involved and by
computer tracking of the specimen, together with computer printing of labels
and accession numbers. Further, artificially prepared specimens with known
errors can he introduced into the system. Technicians receiving the
specimens are made aware of this check but are not informed as to the
frequency of the checks. In a similar fashion, other steps in specimen
processing can be monitored.
CONTROL OF ANALYTICAL VARIABLES
A number of factors relating to the environment, water quality, power
sources, and other general aspects of a laboratory may affect analytical
testing and must he monitored. Measuring devices of all types--balances,
pipets, thermometers--must be monitored frequently to determine if they
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meet prescribed tolerances and reliably indicate true values. lnstruments of
all types must be checked routinely to maintain calibration and confirm that
they are performing according to specifications. All of these monitoring
procedures must be documented and reviewed regularly. When properly
implemented, review processes not only ensure that monitoring procedures
are conducted but identify emerging problems before they become critical
(Blanke 1978).
Analytical Methodology
The choice of a valid analytical procedure is an obvious and important factor
in achieving results of high quality. The specificity, sensitivity, and
reproducibility of the method must be known in order to achieve the quality
goats selected previously. Facility in the application of the method to real
samples by routine personnel must be demonstrated. The method must be
described in detail in a procedure manual. Any deviations from the method
must he approved by an authorized supervisor and documented. Improvement
in methodology is a continuous process and should be encouraged, provided all
improvements are validated. New and novel procedures should not be used in
routine testing until accepted by the scientific community.
Standards
The standards by which a method is calibrated must be selected with care.
Generally, drug standards can be obtained from Supelco Inc., Bellefonte, PA;
Alltech-Applied Science, State College, PA; Sigma Chemical Co., St. Louis,
MO, or the United States Pharmacopeia, Rockville, MD. Other sources such
as pharmaceutical companies or chemical suppliers may be used. In all cases,
efforts to assess the purity of the standard by chromatography or by
measuring a physical constant should be carried out frequently, since some
drugs degrade with time. Accounting for the degree of hydration of
crystalline substances can be particularly troublesome. Obviously, any
contaminant, whether water or another substance, is weighed out as the drug
when a standard solution is prepared. Unless the magnitude of the
contamination is known and corrected for, an error is easily introduced
(Blanke 1978).
Controls
An important aspect of any quality control procedure is the control material
or control specimen. This is a urine specimen containing a known quantity of
the drug(s) being tested that is run along with the subject’s specimen.
Controls can be purchased commercially or prepared by the laboratory.
Ideally, they are specimens containing the drug(s) in a physiological state,
i.e., present in the same matrix and environment as it would be in a patient.
Metabolites, conjugated forms of drugs or metabolites, interferences,
endogenous substances, all are present in the control. In practice, control
material can be collected by pooling excess specimens. The well-mixed
material is aliquoted into small volumes and frozen until used. By repetitive
assays, a mean concentration of the analyte is measured with a calculated
standard deviation. Thereafter, for an assay procedure to be “in control,” the
control result must agree with the known mean value within ±2 standard
deviations. A result outside of this range is deemed “out of control,” and no
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results are reported until the cause of the discrepancy is identified and the
assay again meets acceptable criteria.
Control material for screening procedures should contain analytes at or near
the cutoff or sensitivity limit of the test. A negative control with the
analyte below the cutoff and a positive control with the analyte slightly
elevated above the cutoff will permit the analyst to determine when the teat
is performing properly.
Control results are documented and recorded on a chart or in a computer
program such that trends in control results may be visualized to enable a
trained analyst to discover problems in an assay before they become critical
In addition, users of laboratory results should inspect these control charts
regularly and make sure that this documentation is retained if required in
cases that may be challenged in court.
EXTERNAL QUALITY CONTROL PROCEDURES
The QC procedures described earlier are designed to detect changes in
performance during routine operations, as compared with the careful setup
procedures used when the method was initiated. However, if the method was
not set up accurately (e.g., impure standard, miscalibration of a key
measuring device, etc.), or if other methods perform more acceptably,
internal QA procedures do not suffice.
Extemal QC procedures permit a laboratory to be compared with other
laboratories. External QC may be of two types: open proficiency testing
(PT) or blind proficiency testing. These two types of QC procedures have
been reviewed in a series of papers that appeared in the May/June 1977 issue
of the Journal of Analytical Toxicology.
In open PT, a sponsoring group prepares a large quantity of control material
and sends a portion to each participating laboratory. The laboratories are
aware of this program, test the material when it arrives, and send their
reports to the sponsoring group. When all the results are received, the
sponsoring group calculates the mean result reported by all participating
laboratories and reports back to the participants their performance by means
of a standard deviation index (SDI). This is an indication of the participating
Laboratory’s performance in terms of standard deviations from the mean
result of all laboratories. An SDI greater than ±2 indicates that the
Laboratory does not agree well with most of the others testing the same
specimen.
As its name suggests, a blind proficiency test is identical to the open test,
except that the participating laboratory is unaware of the test. The
proficiency specimen arrives at the laboratory exactly like other subject
specimens and is processed, tested, and results reported in a routine fashion.
The surrogate subject then reports results back to the sponsoring group,
which compares and scores results as before. Unfortunately, laboratories
that do well in open proficiency testing sometimes perform poorly in blind
testing (Hansen et al. 1985). Laboratory users should be aware of this
difference in proficiency testing programs and attempt to identify
laboratories willing to share their performance on blind PT programs before
contracting for their services.
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In order for. QA programs to work for the purpose for which they are
designed, a continuous review process must be carried out. This keeps the
laboratory director and supervisors constantly alert to the many variables
that influence the results of chemical testing. In addition, it enables
appropriate action to be carried out before errors are reported.
Excellent QA is costly, since personnel time, equipment, and supplies must be
committed to it. It is essential, however, when test results may be used in
decisions affecting employment, reputation, or even imprisonment of the
subjects being tested.
SOURCES OF ERRORS
Scientists recognize that errors may occur during any type of scientific
measurement. It is for this very reason that sound quality assurance
programs must be implemented and carried out. In this way, random errors
can be identified and corrected before reporting an analytical result.
Responsible critics have identified those aspects of urine drug testing that
are vulnerable (McBay 1966; Hanson 1986). This discussion centers on human
errors, errors in methodology, and alternate interpretations.
Human Errors
Errors of omission as well as commission occur in all human activities.
Fatigue, poor health, and boredom arising from the tedium of routine tasks
all contribute to high error rates. Providing good working conditions,
effective rest periods, and rotation of workers through different tasks can
help to alleviate these problems. Automation can minimize human error,
provided automated steps arc monitored by an effective QC program, which
is more easily accomplished in a laboratory with a high workload than in a
small laboratory.
Inappropriate training or experience for the task being carried out can also
lead to errors. It is for this reason that personnel qualifications, discussed
earlier, must become part of the total QA program.
The most difficult errors to control are administrative ones. Labeling errors,
spelling errors, transposition of numbers, all can lead to a correct test result
being assigned to the wrong subject. In fact, most laboratories have learned
by participating in external PT programs that these occur more frequently
than errors in testing procedures. For this reason, the steps involved in
specimen acquisition, transport, and processing (chain of custody) must be
part of the complete QA program. Drug testing laboratories must practice
good personnel policies like any other well-run enterprise.
Errors of Methodology
These types of errors have been discussed earlier relative to QC procedures.
Instrument malfunction, outdated reageuts, measurement errors, and many
other factors must be controlled by an effective QA program.
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It is important to emphasize that testing procedures cannot be forced to yield
results for which they are not designed. In particular, screening tests must
be confirmed.
Chromatographic procedures may not resolve substances sufficiently for
clear identification, while immunoassay procedures may use antihodies that
cross-react with a variety of substances. Recently, it was reported that an
immunoassay procedure, EMIT-d.a.u., erroneously gave a false-positive result
for amphetamine in the presence of the antihypertensive agent lahetalol.
Similarly, a commercial TLC screening procedure, TOXI-LAB A, confused
the same antihypertensive agent with amphetamines or trimethoprim (Apple
et al. 1985). Although the TONI-LAB manufacturer has indicated that
resolution of these substances can be made (Martel et al. 1986), the incident
illustrates the necessity for confirming all screening tests.
Other examples of false-posit ive results  due to cross-reaction of
immunoassays have been reported. The popular antihistamine diphen-
hydramine can react with the EMIT-d.a.u. antibody for methadone (Kelner
1984). Recently, Syva notified users of the EMIT kits for marijuana that the
analgesic ibuprofen (available over the counter), as well as some other
nonsteroidal anti-inflammatory agents, can interfere with the EMlT test for
marijuana (at the 20 ng/ml cutoff level), although the company has reportedly
taken steps to eliminate the problem by alteration of the enzyme reagent in
the system. Other interferences have been reported by Allen and Stiles (1981).
These types of false-positive testing results are not due to deficiencies in
methodology. Rather, they are the result of using screening tests without
adequate confirmation. In each case cited, effective confirmation
procedures will prevent the erroneous reporting of false-positive results.
RETENTION OF POSITIVE SPECIMENS
Since the possibility of error exists, although this is unlikely when appropriate
confirmation is done, excess urine from all positive specimens should be
retained until the case has been resolved. The remaining specimen in its
properly labeled, original container should be stored by freezing (-20°C or
lower). This will permit reanalysis by the original laboratory or a different
laboratory in the event the positive results are challenged by the subject.
The time between the original testing and ultimate resolution of the matter
can be quite variable, depending on the circumstances. For this reason,
clients should inform the laboratory as to when ultimate disposal of the
specimen can occur.
DIFFERENCES IN INTERPRETATION
Finally, the testing procedure may produce results that accurately indicate
the presence of drugs or their metabolites in a urine specimen, but
explanations other than drug abuse may be invoked. These are not truly
errors but rather alternate interpretations of the accurate test results.
Frequently, these interpretations are invoked in the event that a charge is
brought against a subject whose urine test has been reported as positive.
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Many examples can be mentioned, most of which are related to marijuana.
Accidental or inadvertent ingestion of marijuana as salad greens or
components of food has been offered as an explanation. While experimental
evidence is not available to support this claim for marijuana in uncooked
foods, studies have demonstrated the possibility of this occurrence in baked
goods (Cone and Johnson 1986). Passive inhalation of marijuana smoke is
more frequently raised as a defense. The latter phenomenon has been
investigated. Although passive inhalation can give rise to metabolites of
THC being excreted and measured in urine, it would be extremely unlikely
that high concentrations can occur by this means of dosage (Perez-Reyes et
al. 1983).
Recently, cocaine has been identified in certain herbal teas (Siegel et al.
1986). It is possible, therefore, that a positive test for cocaine may be
obtained in urine from a subject who ingests large amounts of this material.
Note, however, that such teas are technically illegal and have recently been
removed from the market by Federal authorities.
Other alternative explanations of positive drug findings are based on claims
of errors arising from screening tests. These have already been discussed.
Effective testing procedures in which positive screening results are
confirmed by valid tests will refute these claims. The presence of a specific
drug or metabolite will be documented, although how or why the substance
was absorbed by the subject may not be answered.
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Interpretation of Urinalysis
Results
Joseph E. Manno, Ph.D
Urine drug testing has been used for several decades to monitor human drug
use. This type of urinalysis procedure was first used for patients who had
been using drugs on a regular basis, and positive results were an indication of
continued drug abuse. The methodology most commonly used for performing
the tests, thin-layer chromatography, was satisfactory for detecting a wide
variety of drugs in common use at that time.
Over the years, both the population being tested and the laboratory
methodology have changed dramatically. Today, the use of urine drug tests
has been extended outside the substance abuse treatment facility and is
currently used as part of preemployment physicals and for monitoring drug
use in employees in a variety of industries and government agencies.
From an analytical standpoint, the development of immunoassay procedures
has provided inexpensive and very sensitive procedures for analyzing for
classes of drugs in urine. The analytically powerful technique of gas
chromatography-mass spectrometry has become more commonly available
and is currently the method of choice for the analysis of drugs in a sensitive
and specific manner and for confirming the presence of drugs found in an
initial screen. Other methodologies such as gas-liquid chromatography and
high-performance liquid chromatography also play a role in the analysis of
drugs in urine. The variety of methodology available permits inexpensive
mass screening and also allows the specificity needed to provide accurate and
sensitive confirmation of drugs found in the initial screening test. The wide
variety of methodology now in use, as well as the variety of drug use
patterns, makes the interpretation of urine drug assays more complex.
Although the vast majority of all drug tests will be negative, the user must
understand that both negative and positive test results have meaning. In
order to understand how to properly interpret the results of a drug assay, one
must first determine what information is desired. In addition to finding a
reputable laboratory with adequate professional staff to assist them,
consumers must define their individual goals for starting the program. In
particular, they must determine the consequences that will befall individuals
who test positive. Since no uniform required standards exist for urine drug
testing, the use of expert consultants to assist in the development of a
program will be beneficial.
Before embarking on any urine drug testing program, the consumer must first
determine the program goals.
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Some questions that might be asked about the meaning of a drug screen
follow. If an analysis is positive, does it mean that:
the subject is using the drug chronically?
the subject is using the drug intermittently?
the subject is addicted to the drug?
the subject is taking the drug under a physician’s order?
the subject was under the influence of the drug when the urine was
collected?
If, on the other hand, the analysis was negative, does it mean that:
the subject has never used the drug?
the subject may use the drug intermittently but has not used the drug
recently?
the subject knew that the urine would be screened, and stopped
taking the drug long enough for the urine specimen to be negative?
the subject diluted the urine at the time of collection, or prior to
collection, by drinking large amounts of fluids prior to sample
collection and thereby rendered it negative?
the subject adulterated the urine by adding water or another
substance or switched it with urine from another individual during
the confusion inevitable when large numbers of persons are involved
in a process like urine collection?
All these possibilities must be considered as part of the process of deciding
the relevance of urine drug test results.
The end user of the results of a urine drug analysis must also be familiar with
proper specimen collection and handling procedures, have a general
understanding of laboratory methodology used to perform the analysis, and
have some understanding of drug kinetics. This information will permit
correct interpretation of laboratory results and allow for reconciliation of
these data with the subject history.
The purpose of this chapter is to provide the reader with information that
will help in such interpretation.
DRUG FACTORS THAT DETERMINE WHETHER A TEST
IS POSITIVE OR NEGATIVE
Dose
The higher the dose of drug taken, the more likely that the drug will be
detected in urine. As an example, a dose of 30 mg codeine might be
detected for 1 to 6 hours after use by a particular method; a 60 mg dose by
the same method might be detected for 1-10 hours.
Frequency of Use
Drugs remain in the body for varying lengths of time. Drugs like cocaine are
eliminated from the body relatively rapidly. Depending on the assay
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procedure, a single dose of cocaine, for example, may only be detectable in
urine for 1 day or less. Continued use on a daily basis may cause the drug to
be detectable for 2 or 3 days after cessation of use. Smoking a single
marijuana cigarette may result in a positive urine test for cannabinoids for 1
or 2 days with some methods and for 3 to 5 days with more sensitive
methods. Continued use of marijuana on a daily basis however, may result in
a positive urine for 3 or more weeks after drug use has stopped. As a general
rule, most drugs tend to accumulate in the body if they are taken on a regular
basis. The more frequently a drug is ingested, the more likely that it will be
detected on a urine drug test.
Time From Drug Use to Urine Collection
Different drugs leave the body over various time intervals depending on the
drug, the dose administered, and the frequency of drug use. For drugs like
cocaine that leave the body very rapidly, it is necessary to collect the urine
very close to the time of drug use to get a positive sample. With drugs like
marijuana that are eliminated more slowly, the urine collection could occur
up to several days after use and still be positive.
Sensitivity of the Urinalysis Test Used
Laboratory tests used to detect drugs in urine have different sensitivities for
various drugs. Immunoassays, for example, generally can detect smaller
quantities of drug in urine than can thin-layer chromatography, If the assay
is not sensitive, drugs will not readily be detected in the urine specimen. If
tbe assay is extremely sensitive, it may detect drugs in urine for days or
weeks after their use. By understanding the sensitivity of the assay, the
client will be able to relate the assay result to a “drug use window” and
thereby determine approximately when the drug could have been used.
The sensitivity of the first urine drug test, often referred to as a preliminary
screen, is important for determining whether a urine is positive or negative.
The most commonly used laboratory procedures for the initial screen are
thin-layer chromatography (TLC), radioimmunoassay (RIA), the EMIT test,
and the newly introduced TDx Abused Drug Detection Assays (TDx).
Although the RIA, EMIT, and TDx tests use methodologies that are
significantly different from each other, they have in common several
features. Each of the tests assays for a specific drug or for drugs in a single
class (e.g., methadone, barbiturate class, amphetamine class, cannabinoids,
etc.). The tests are very sensitive and will generally detect drug use for 1 or
more days after a single use. The TLC system has the advantage that it can
detect a wide variety of drugs, but it has less sensitivity than the
immunoassay tests. Ideally, a combination of the TLC and immunoassay tests
could be used for optimum sensitivity and versatility. If costs are a
significant factor, then the number and variety of different tests will be
limited.
As an example, initial screening could include a TLC assay and immunoassays
for drugs that are not detected well (or at all) by the TLC screen, but are
known to be commonly abused. A typical test battery might, include the
combination of a TLC screen, a cannabinoid immunoassay test, and a cocaine
immunoassay test.
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In addition to TLC and the immunoassay procedures, other laboratory tests
that can be utilized include gas-liquid chromatography, high-performance
liquid chromatography, and gas chromatography-mass spectrometry. These
tests are rarely used as initial screens. They have the advantage that they
can detect a wide variety of drugs and are generally more sensitive than
TLC. Their primary disadvantages include relatively high cost and long assay
times. For these reasons, they are used primarily for specific drug analyses
and for confirmation (particularly GC/MS) of presumed positives from initial
screens.
If the results of the preliminary screen are negative, no further chemical
testing of the urine specimen is usually performed. If the preliminary screen
is positive for one or more drugs, however, a second laboratory test is then
necessary to verify the presence of the detected drugs. This “confirmatory”
test must use different technology, must be as sensitive as or preferably
more sensitive than the preliminary screen, and must be specific for the drug
or drugs detected in the initial screen. The confirmatory test is usually
performed by gas-liquid chromatography, high-performance liquid
chromatography, or ideally by gas chromatography-mass spectrometry.
RELATING DRUG FACTORS TO INTERPRETATION OF
THE URINALYSIS TEST
Negative Test Result
Several interpretations are possible:
The subject is not using a drug that can be detected by the test.
The subject may be taking one of the drugs detected by the test but
-is not taking a large enough dose to be detected
-is not taking it frequently enough to be detected
-the urine is being collected too long after the drug was ingested
-the urine sample was diluted or otherwise tampered with or
switched with another sample by the subject.
The subject may be taking the drug but the assay used was not
sufficiently sensitive to detect the drug in urine.
Positive Test Result
If the test was properly performed and the results from the laboratory are
valid, the result means that the drug indicated was present in the urine. A
positive result does not mean that the individual tested was under the
influence of the drug at the time the specimen was collected. An expert
would be able to provide some general information regarding the timeframe of
the drug use. Even experts will vary in their opinions, however. The
significance of a single positive urine drug test can be increased by repeat
testing at regular intervals. Multiple positives over a period of time reinforce
that an individual may be a regular user of the detected substance. Although
multiple negatives do not completely negate drug use, they do provide
evidence that the individual may not be using on a regular basis.
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Prolonged Monitoring
In some cases, such as treatment situations or probationary periods for an
employee, it may be advisable to collect sequential specimens over time to
assess continued drug abstinence.
Collection of multiple urine specimens over a prolonged period of time
requires that special attention be given to subjects who have ingested drugs
such as marijuana and certain benzodiazepine antianxiety agents that are
excreted in urine for long periods of time. If the subject had used one of
these drugs chronically prior to the start of urine drug testing, it is possible
that the test could be positive for several weeks or months after he or she
stopped using the drug.
Since the results of urine drug tests are normally reported as either positive
or negative, it is not possible to determine if a positive result is due to
continued use of the drug or continued excretion of the drug from previous
use. In order to differentiate between recent drug use and continuing urine
drug excretion from previous use, it is necessary to request that the labora-
tory perform a semiquantitative analysis for the drug in the urine. If the
subject has stopped using the drug, the concentration of drug in urine would
be expected to decrease each time the urine is assayed. If the concentration
of drug increases, continued use of the drug should be considered.
Monitoring this decreasing drug level is complicated by variations in urine
water content. Greater than normal intake of water can dilute the amount of
drug in the urine, and, conversely, a limited intake particularly in conjunction
with dehydrating exercise can lead to an abnormally concentrated urine
specimen.
Figure 1 illustrates a series of samples taken every 2 days from one subject.
The solid line is urine concentration for cannabinoids. The concentrations are
seen to decrease over the 3-week period with the exception of an increase on
day 6, which might imply a smoking incident.
When using the semiquantitative analysis procedure, it is imperative that the
concentration of drug found in the urine be adjusted for the changes in the
urine water content that occur throughout the day. The adjustment can be
made by performing a urine creatinine analysis and dividing the drug
concentration (ng/ml of urine) by the creatinine concentration (mg creati-
nine/ml of urine). This allows the drug concentration to be expressed as ng
drug/mg creatinine. After drug use has stopped, measurement of ng/mg
creatinine will show a continuous decrease on sequential sample analysis,
while sequential concentration measures (ng/ml urine) may show significant
fluctuation. Because creatinine is excreted at a relatively constant rate, the
use of the creatinine analysis compensates for (or corrects) the hour-to-hour
concentration or dilution of urine that normally occurs.
The need for this adjustment can be seen in the example in figure 1. The
dashed line shows the excretion levels in terms of ng/mg creatinine. As can
be seen, the apparent increase in excreted cannabinoids at day 6 is, in fact, a
more concentrated urine specimen and not an indication of further marijuana
use. On the other hand, the creatinine-corrected levels show a clear increase
in excreted cannabinoid at day 10, indicating that the subject probably used
marijuana again. This was not apparent in the ng/ml analysis. Apparently at
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day 10, the urine was relatively dilute (perhaps in an attempt by the subject
to mask the drug use), but the creatinine analysis provided the compensation
for an appropriate interpret at ion.
Figure 1. Urinary cannabinoid levels of specimens taken on alternate
days after last marijuana use. concentration of THC metabolite in
ng/ml urine. THC metabolite concentration divided by the
creatinine concentration expressed in ng metabolite/mg creatinine.
In this hypothetical example, several benefits were obtained by performing
semiquantitative analyses and adjusting by the use of creatinine levels. The
semiquantitative results allowed more careful monitoring than the positive
or negative (concentration analysis) results. In the example shown, adjusting
the cannabinoid concentration by means of the creatinine analysis protected
the subject on day 6 by substantiating his story about sweating (which could
have led to dehydration and subsequent concentration of the urine). On day
10, it allowed the detection of smoking and the subject’s attempted coverup
by sample dilution.
When used attentively, semiquantitative urine drug analysis and adjustment
with creatinine can provide a valuable adjunct to the interpretation of
multiple urine drug screens taken from healthy individuals who have abused
drugs that are excreted slowly from the body.
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METHODS OF URINALYSIS
It is important to remember that no single laboratory test is capable of
detecting all drugs in urine. The commonly used term “drug screen” is
somewhat inaccurate in that it implies that all drugs are detected. Quite
frequently, laboratories will provide lists of drugs that can be detected by
their particular drug screen. Even with such a list, the consumer must still
be cautious unless the list specifically details which drugs are detected in
urine. For purposes of this discussion, the term “comprehensive drug screen”
will be used to describe tests that can detect a variety of drugs in urine.
Other laboratory tests that can detect individual or classes of drugs will be
referred to as special or specific tests.
Comprehensive Drug Screen
The comprehensive drug screen can be performed by a variety of laboratory
techniques. While gas-liquid chromatography, gas chromatography-mass
spectrometry, and high-performance liquid chromatography are sometimes
used for this purpose, thin-layer chromatography remains the most
commonly utilized technique for the detection of a large number of drugs at
low cost. The other chromatographic techniques are used to a much more
limited extent because of higher cost per assay. They are generally
employed for specific drug assays and for confirmation purposes.
It must be understood that considerable variation does exist between
laboratories in the performance of this test, a factor that will influence both
the types of drugs detectable and the time interval during which they can be
detected. Detection times are also affected by the dose of the drug, the
frequency of use, the time from drug use to urine collection, and the specific
laboratory procedure used for performing the test.
The following drugs can be detected by comprehensive drug screens based on
TLC procedures for periods of 24 hours or longer after use:
Amphetamines such as amphetamine, methamphetamine,
pseudoephedrine, phenylpropanolamine, and ephedrine
Benzodiazepines such as chlordiazepoxide (Librium), diazepam
(Valium), and flurazepam (Dalmane)
Barbiturates such as phenobarbital, secobarbital, and amobarbital
Methadone
Propoxyphene (Darvon)
Tricyclic antidepressants such as imipramine, desipramine, etc.
Nicotine
Drugs that can be detected for shorter periods of time after use, usually 3 to
12 hours, include:
Opiates such as morphine, codeine, etc.
Pentazocine (Talwin)
Cocaine
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Drugs that cannot normally be detected in urine by a TLC comprehensive
drug screen are:
Cannabinoids (marijuana)
Phencyclidine (PCP)
LSD and other hallucinogens
Specific Tests
Specific tests include EMIT, RIA, TDx, GC, HPLC, and GC/MS. The specific
urine tests that are available are usually more sensitive than thin-layer
chromatography, but they can generally be used to test for only one drug or
class of drugs in a single assay experiment. Generally, a subject will be
positive with one of the specific urine tests for 1 to 3 days after drug use.
These tests are most commonly performed using immunoassay procedures.
Because they are restricted to individual drugs or classes of drugs, desired
tests must be specifically ordered. The option includes tests for:
Alcohol (ethanol)
Amphetamine
Barbiturate
Benzodiazepines [detects various benzodiazepines, including
chlordiazepoxide (Librium), diazepam (Valium), and flurazepam
(Dalmane)]
Cocaine
Methaqualone (Quaalude)
Opiates (detects several of the opiate drugs, including morphine,
codeine, and hydrocodone [Dilaudid] for a day or more after use)
Methadone
Phencyclidine (PCP)
Propoxyphene (Darvon)
Cannabinoids (THC metabolite--detects marijuana use)
DRUG TESTING STRATEGY
It can be seen that a urinalysis can include a single test or a battery of
different tests. In order to develop a drug testing program that serves the
needs of the client at a reasonable cost, individualized test batteries must be
carefully selected. In some cases, a general or comprehensive screen with
followup confirmation testing may be appropriate where the client or
employer is willing to sacrifice some sensitivity in order to screen for a wide
variety of drugs. In other cases, an analysis program aimed at three or four
drugs that are known to be problematic in a given work situation may be
indicated. Increased sensitivity for a smaller number of drugs increases the
likelihood of detecting these substances and decreases the chance of false
negatives.
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Implications of Drug Levels in
Body Fluids: Basic Concepts
C. Nora Chiang, Ph.D., and Richard L. Hawks, Ph.D.
Urine drug analysis aimed at the detection of drug users generally is focused
on the detection of illicit drugs such as marijuana, cocaine, amphetamines,
etc., or their metabolites To effectively use the results that can be provided
by current technology for the analysis of biological fluids, a basic
understanding of drug pharmacokinetics and pharmacodynamics is important
(Rowland and Tozer 1980; Holford and Sheiner 1981; Gibaldi and Perrier 1982;
Goodman and Gilman 1985). Such an understanding provides the basis for
attempts to estimate the time and extent of drug use and possibly the extent
to which the drug level is predictive of impairment or pharmacologic effect.
Such knowledge is equally important in understanding the limits of
interpretation of drug levels in specific instances.
Pharmacodynamics describes the relationship between the concentration and
the effect of a drug. Drug effects result from the presence of appropriate
drug concentrations at the site of drug action To reach the site of drug
action, except for a few drugs that act topically, a drug must enter the blood
circulation from the site of administration. Through blood circulation, the
drug distributes to the site of drug action and simultaneously to other tissues
where it is stored, metabolized, and excreted. The fate of a drug in the body
is schematically represented in figure 1. The concentration of most drugs at
the site of action is therefore a function of the drug concentration in the
blood. The concentration or amount of a drug in other body fluids such as
saliva and urine can, in some cases, be related to drug concentration in the
blood. Pharmacokinetics is a science that quantitatively describes these
processes--absorption, distribution, metabolism, and excretion--that a drug
undergoes in the body.
This chapter describes basic principles of pharmacokinetics and pharmaco-
dynamics and the application of this information to the understanding of the
significance of drug concentrations in terms of prediction of time of drug
exposure or degree of drug effects. Marijuana and cocaine will be used as
specific examples to illustrate these principles.
PHARMACODYNAMICS
The effects of most drugs result from interactions with their receptors at the
site of drug action. The time course of most responses, determined by the
effective concentrations of the drug at these receptor sites, depends on the
processes that a drug undergoes in the body. As plasma concentrations
generally reflect drug concentrations at the site of drug action, the intensity
of the effects for most drugs can be related to plasma concentrations,
although this relationship is usually not a simple linear one.
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Figure 1. Schematic representation of the fate of a drug in the body.
A poor correlation is often found between effects and plasma drug concen-
trations. Factors that may contribute to the poor correlation are the
presence of active metabolites, time delays in the drug response, or the
development of tolerance. The relationship of specific drug concentrations
to effects for a general population is further complicated by individual
differences in the pharmacological response and the pharmacokinetics of the
drug.
Most abused drugs act on the central nervous system and produce effects on
mood, perception, behavior, and performance (Goodman and Gilman 1985).
The relationship of a perceived subjective “high” and performance decre-
ments with plasma concentrations has been a subject of many studies.
Psychological "High" Effects and Drug Concentrations
Pleasurable effects have been associated with the self-administration of
psychoactive drugs such as cocaine and marijuana. The time course of the
effects produced by cocaine and plasma levels after administration of
cocaine by the intravenous (20 mg), intranasal (95 mg), and smoking (50 mg)
routes are shown in figure 2 (Cook et al. 1985). In spite of the twofold
difference in the dose for intravenous and smoking routes of administration,
the plasma profiles of cocaine are very similar, as are the profiles for the
self-reported “high” effects. Following the intranasal route of administra-
tion, the plasma cocaine levels peaked more slowly and were prolonged longer
as compared with those following the intravenous and smoking routes. The
high effects reported by the subjects were also perceived at a later time
point for the intranasal dose. This result indicates that the high effect is
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Figure 2. Comparison of cocaine plasma concentrations (upper panel)
and psychological self-reported “high” (lower panel) after administra-
tion of cocaine by intravenous, intranasal, and smoking routes (From
Cook et al. 1985. Copyright 1985, PSG Publishing Company, Inc.).
better  related to plasma cocaine concentrations than to the dose
administered. The decline of the high effect is more rapid than the decline
of plasma cocaine levels. Tolerance to the subjective high effects has been
suggested (Fischman et al. 1985).
In the case of the psychoactive component in marijuana, delta-9-tetrahydro-
cannabinol (THC), the pattern of the high effect showed a slower rise and a
slower decline than the plasma level of THC (figure 3) (Hollister et al., 1981;
Chiang and Barnett 1984; Ohlsson et al. 1985). This delay of the high effect
suggests that the site of action of THC is not easily accessible to the blood.
When this was taken into consideration in a pharmacokinetic and pharmaco-
dynamic compartmental model analysis, the effects were able to be well
correlated with plasma THC levels (Chiang and Barnett 1984). However, the
estimation of the degree of intoxication from a single value of THC plasma
level is very difficult (Hollister et al. 1981), due not only to this time delay
but also to large individual variations in both effects and plasma levels.
Performance Decrement and Plasma THC Concentrations
Marijuana use has been associated with decrements in behavior and cognitive
performance. The incidence of detectable levels of THC in fatally injured
drivers ranges from 3.7 percent to 37 percent (Mason and McBay 1984;
Williams et al. 1985). While a direct causal effect of marijuana is difficult to
establish from such studies because of the generally high incidence of alcohol
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Figure 3. Plasma THC concentration-time and subjective high-time
after smoking one 2.5 percent THC cigarette (mean ± SE; n=6)
Solid curves are computer fits to the data (From Chiang and Barnett
1984. Copyright 1984, The C.V. Mosby Co.)
in the subjects as well as lack of control groups, the indication is clear that a
performance-impairing drug (THC) is present and is therefore likely to
contribute to the factors leading to the accident.
In laboratory investigations, it has been reported that THC may affect
complex performance skills up to 24 hours after drug ingestion. One study
reports a “hangover” effect on the morning following a dose of marijuana (9
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hours after smoking a marijuana cigarette of 3 percent THC) (Chait et al.
1985). The mean performance of pilots in a flight simulator showed a trend
toward impairment at 24 hours after smoking a cigarette of 2 percent THC
(Yesavage et al. 1985). These results have implications for THC effects on
the performance of complex tasks the day after smoking when blood
concentrations are very low.
A recent study demonstrated that a mathematical correlation could be
established between certain laboratory tasks and THC plasma concentrations
(Barnett et al. 1985). This correlation was shown for the “critical tracking
breakpoint” task for up to 7 hours after smoking and for plasma THC
concentrations as low as 2 ng/ml. This and similar tasks are widely used to
evaluate factors related to driving; however, the precise predictive validity is
unknown. Although impairment on a laboratory task can be related to plasma
THC levels, the extent to which it predicts driving impairment from smoking
marijuana is unclear.
Presumptive impairment levels for THC are difficult to establish, although
the impairment for alcohol has been reasonably correlated with blood alcohol
levels. Data currently available indicate that wide ranges of drug concen-
trations for different individuals may be present at equal levels of
impairment (Reeve et al. 1983). Conversely, evidence of impairment is often
lacking in some subjects at drug concentrations that are associated with
impairment in others. A general consensus of forensic toxicologists stated
that the blood concentrations associated with impairment after smoking
marijuana and after use of many other drugs has not been sufficiently
established to provide a basis for legal testimony in cases concerning driving
under the influence (Consensus Report 1985).
PHARMACOKINETICS
Pharmacokinetics, which characterizes the relationship of drug concentra-
tions with time, is important for the understanding of drug actions. It is a
quantitative description of the complex processes that a drug undergoes in
the body, as shown in figure 1. From the site of administration, a drug is
absorbed into the systemic circulation. Through circulation, the drug is
distributed into various tissues. At the site of action, it exerts its pharma-
cological effects. It may also accumulate in tissues. It is eliminated from
the body through metabolism or excretion by the eliminating organs. (The
liver is the primary organ for metabolism and the kidney the most important
organ for excretion for most psychoactive drugs.) The concentration of a
drug in the body (pharmacokinetic profile) is a function of these processes--
absorption, distribution, metabolism, and excretion (Rowland and Tozer 1980;
Gibaldi and Perrier 1982; Goodman and Gilman 1985).
Absorption
Absorption describes the transfer of a drug from the site of administration
into the systemic circulation (figure 1). Drugs can be administered by various
routes, which are classified as intravascular and extravascular.
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Intravascular administration refers to a direct and instant input of a drug into
the systemic circulation and is usually accomplished by intravenous
administration of a bolus dose or by an infusion. The intravenous route of
administration is commonly used for heroin, methamphetamine, and cocaine.
For a given dose, the shorter the time of infusion, the earlier and higher is
the maximum concentration in the blood. The onset of the pharmacological
response is also more rapid, and the intensity is greater. This increases the
risk of toxic effects of the drug.
By extravascular routes of administration such as smoking, intranasal
administration, or oral ingestion, the drug gets into the systemic circulation
through absorption processes. The rate and extent of the absorption of the
drug from different routes may be quite different, depending on the
physicochemical properties of the drug as well as the physiological and
anatomical factors involved in absorption.
From the smoking route, the drug is inhaled and absorbed from the lung or
the respiratory tract into the circulation. The amount absorbed may be quite
variable, as part of the dose is lost from pyrolysis and from side-stream
smoke. The amount absorbed is affected by the burning characteristics of
the cigarette, the depth of inhalation, and the puff duration. However, the
rate of absorption from this route is in general very rapid. Peak plasma
concentrations are rapidly reached, and the plasma profile is very similar to
that of an intravenous dose. This route of administration is generally used
for marijuana, phencyclidine (PCP), cocaine, and occasionally for heroin and
methamphetamine.
The intranasal route of administration, in which the drug is absorbed from the
nasal mucous membrane, is commonly used for cocaine and occasionally for
heroin. A plasma concentration time curve for cocaine is shown in figure 2.
As shown here, the intranasal route also provides a relatively quick and
sustained level of drug in the plasma.
Oral administration, the most commonly used route for therapeutic drugs, is
a relatively less popular route for abused drugs except for the hallucinogens,
such as lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphet-
amine (MDMA or “Ecstasy”), and mescaline. The drug so taken is absorbed
from the gastrointestinal (GI) tract. The absorption rate depends on the
physicochemical properties of the drug, and it may not be completely
absorbed. The drug may be degraded by gastric juice or the digestive
enzymes, or it may also be metabolized by intestinal flora in the GI tract or
the enzymes in the liver, which result in less drug entering the systemic
circulation. Absorption may be affected by the presence of food or other
drugs.
Figure 4 illustrates the plasma profiles of THC after administration by
intravenous (IV), oral, and smoking (marijuana) routes. Plasma THC profiles
for IV and smoking are similar, with peak levels reached rapidly and declining
rapidly. After oral administration, plasma levels for THC increase slowly and
the peak level is lower. This indicates that smoking provides an efficient
method of delivering drug into the systemic circulation. However, the
amount absorbed from smoking is quite varied, ranging from 2 percent to 56
percent of the amount of THC in the cigarette, depending on the efficiency
of the smoker (Lindgren et al. 1981). Experienced smokers may inhale more
efficiently than naive ones. The fraction of dose absorbed after the oral
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Figure 4. Plasma concentrations (means and standard deviations) of THC after
intravenous, smoking, and oral routes of administration (From Ohlsson et al. 1980.
Copyright 1980, The C.V. Mosby Co.).
route ranged from 6 percent to 20 percent (Ohlsson et al. 1980; Wall et al.
1983). Because THC is extensively metabolized by the liver, part of the drug
may be degraded to metabolites before reaching the systemic circulation.
Distribution
Once the drug is absorbed into the systemic circulation, it is distributed into
different tissues, into the site of action to elicit pharmacological effects,
into organs where metabolism or excretion occurs, and into tissue reservoirs
in which it may accumulate and serve as a storage depot of the drug. The
rate and extent of distribution in tissue are determined by the blood flow to
the tissue, the ability of the drug to pass through the tissue membrane, and
the relative binding affinity of the drug for the tissue and plasma proteins.
Storage of drugs in the tissue by tissue binding or dissolution in the adipose
tissue may prolong the time in which drugs are detected in the plasma. Drugs
such as THC are very lipophilic and distribute into tissues, including the
adipose (fatty) tissue, leaving a small amount in the blood. The slow release
of THC from the sequestered tissue including adipose tissue into the plasma
is suggested for the reason for the slow elimination of the drug from the body
and therefore the long detection times of previous marijuana use in urinalysis.
Metabolism
Drugs are eliminated from the body through metabolism and excretion. Liver
is the primary metabolizing organ, although lung, kidney, and other tissues
also have metabolic activities. The drug is metabolized by oxidation,
reduction, hydrolysis, and conjugation reactions to more polar forms
(metabolites) to facilitate the excretion process. Metabolism also provides a
mechanism to terminate drug effects, as most metabolites are devoid of
pharmacological activit ies.  Some metabolites,  however,  rnay have
pharmacological activities that are similar to or different from those of the
parent drug.
Most psychoactive drugs are extensively metabolized. Over twenty
metabolites of THC have been identified in urine and feces, including various
carboxylated (acidic) and hydroxytated metabolites as well as glucuronic acid
conjugates (Wall et al. 1981, Widman et al. 1985). Still, a significant portion
of the dose in both urine and feces has not been identified. Metabolites in
the urine are primarily the carboxylated products. The major metabotite is
11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (9-carboxy-THC), a
non-psychoactive metabolite. The metabolites, 11-hydroxy-delta-9-
tetrahydrocannabinol (11-OH-THC) and 8-beta-hydroxy-delta-9-tetrahydro-
cannabinol are reportedly psychoactive (Lemberger et al. 1972; Perez-Reyes
et al. 1972). However, they are found only in very low (frequently
undetectable) concentrations in plasma after smoking or intravenous
administration and are unlikely to make a significant contribution to the
effects of THC. Their concentrations in urine as well as that of THC itself
are frequently undetectable.
Cocaine undergoes primarily metabolic hydrolysis by the esterases present in
liver and in plasma (Cook et al. 1985). The major metabolites identified in
urine are benzoylecgonine, ecgonine methyl ester, and ecgonine. These
metabolites are not psychoactive.
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Excretion
Drugs are eliminated from the body as unchanged drug or as metabolites
through urine, bile, sweat, saliva, and expired air. Renal excretion is a
common and important route for drug elimination, making kidney the most
important organ for drug excretion. For many drugs, biliary excretion also
plays an important role. Through bile, drugs enter into the gastrointestinal
tract, where they may be either excreted in feces or reabsorbed and excreted
through urine or feces. Other routes such as saliva or sweat do not in general
contribute significantly to the excretion of most drugs. They may be of
forensic importance for the detection of drugs, however.
For THC, about 80 percent to 90 percent of the dose is excreted during the
first 5 days following a dose. Approximately 65 percent of the dose is
excreted in the feces and 20 percent excreted in urine (Hunt and Jones 1980;
Wall et al. 1983). Cocaine is excreted almost exclusively in the urine. Only 4
percent to 6 percent is excreted in the feces (Cook et al. 1985). Both THC
and cocaine, as well as most other drugs, are extensively metabolized. The
urinary as well as fecally excreted compounds are primarily metabolites with
only a minor fraction of unchanged drugs. Phencyclidine, on the other hand,
is excreted unchanged to the extent of 10 percent (Cook et al. 1982).
Salivary excretion-- The excretion of a drug into saliva depends on the ability
of the drug to pass through the epithelial cells of the salivary glands into the
saliva. The concentration of a drug in saliva could be higher, such as
amphetamine (Wan et al. 1978), or lower, such as methaqualone (Sharp et al.
1983), than that in plasma. THC or its metabolites are not detectable in
saliva following an intravenous dose (Perez-Reyes, personal communica-
tions). THC is detectable after smoking marijuana, however, due to the
absorption of THC by the oral mucosa during smoking. This illustrates the
need for caution in the interpretation of saliva concentrations of drugs
shortly after an oral or inhalation dose. Nevertheless, the THC in saliva
after smoking is reported to be indirectly correlated with recent use of
marijuana (Gross et al. 1985).
Saliva is perhaps the most easily obtained sample, and it has been established
that some drugs can be easily detected in saliva (Danhof and Breimer 1978).
It has not come to be generally used, however, because salivary concentra-
tions for many drugs are so low that they cannot be detected. In addition,
the methods of analysis for saliva samples are frequently more difficult than
for urine samples. Furthermore, the time period during which drugs can be
detected after use is usually shorter than that in the urine.
Renal excretion-- Most drugs are extensively metabolized in the body and
excreted in the urine as metabolites. The processes involved with the
excretion of a drug via the kidney are filtration, secretion, and reabsorption.
In the kidney, drugs that are in the “plasma water” (not bound to plasma
proteins) pass through the glomerulus, which functions to filter the water as
welt as small molecules and leave the protein material of the blood behind
(along with any drug bound to it). This water filtrate then passes through the
tubules of the kidney, where water is reabsorbed and thereby the filtrate
become more concentrated. This “concentrated” filtrate leaves the kidney to
the bladder as urine. In the kidney, acidic or basic drugs (or metabolites) can
be added to the filtrate (urine) by the process of secretion through the
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tubular membrane. Drugs or metabolites in the filtrate (urine) may diffuse
back into the blood by reabsorption through the tubular membrane.
The filtration process occurs with all drugs and metabolites, but secretion
and reabsorption do not occur with all drugs or metabolites. Since only
unbound drugs and metabolites are filtered in the kidney, the extent to which
a drug is protein-bound influences directly the rate at which it will be
excreted in the renal system. The reabsorption process is affected by urinary
pH as well as urinary flow, as are the excretion rates of some drugs and
metabolites. For most drugs that are not actively secreted or whose
concentration is far below the saturation concentration for secretion, urinary
excretion rates are directly proportional to drug plasma concentrations.
Plots of the urinary excretion rate and the plasma concentration of cocaine
and benzoylecgonine are shown in figure 5 (Ambre 1985). The excretion rates
of cocaine and benzoylecgonine are parallel to the respective plasma
concentrations.
As the urinary flow rate and pH may change from time to time, urinary
excretion rates could also be affected by these changes and may fluctuate.
In some cases, a plot of excretion rates may not parallel that of plasma
concentrations.
Urine drug analysis--Urinalysis quantitates the concentration of a drug in the
urine. A change in the urinary flow rate may change the concentration of a
drug in the urine, even if the renal excretion rate remains the same. ln
general, drug in the urine is more concentrated than that in the plasma. For
example, if a drug is neither secreted nor reabsorbed by the kidney, the
concentration of the drug in the urine will be about 100 times that of the
unbound drug in plasma. This is due to the fact that about 99 percent of the
plasma water filtered into the tubular lumen is reabsorbed, and only 1-2
ml/min of water leaves the kidney as urine. Ingesting a large volume of
liquid or using diuretics may increase the urine volume, and drug in that urine
is therefore diluted. Creatinine is an endogenous substance that is neither
secreted nor reabsorbed and can therefore be used as a “marker” to correct
the fluctuation of urine flow. In some laboratories engaged in urinalysis, drug
urine levels are reported as nanograms or micrograms of drug per milligram
of creatinine (see the previous chapter).
PHARMACOKINETIC PARAMETERS
Pharmacokinetics is a mathematical description of the time course of a drug
in the body. The important parameters are bioavailability, clearance, volume
of distribution, and half-life. Bioavailability refers to the fraction of a dose
that enters into the systemic (blood) circulation. Clearance indicates the
ability of an organ to clear drug from the systemic circulation. The volume
of distribution indicates the amount of drug in the body in relation to the
drug concentration in the plasma or blood after equilibrium has been
achieved. Half-life is the time required to reduce the plasma concentration
by 50 percent.
Generally, the half-life is determined from plasma concentration measure-
ments during the terminal or elimination phase (after distribution processes
have equilibrated). As the clearance of a drug by an eliminating organ in
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Cocaine and Benzoyl Ecgonine
Figure 5. A similar plot of plasma levels and urinary excretion rates of
cocaine and benzoylecgonine (From Ambre 1985. Copyright 1985,
Preston Publications, Inc.).
general is constant, the rate of elimination of a drug is a function of the
concentration of a drug in plasma. Plasma drug concentrations decline
following a first-order rate constant--a constant fraction of the drug is
eliminated per unit time. A half-life is the time unit for removing 50
percent of the drug from the body by either metabolism or excretion. A five
half-life period is required to eliminate approximately 97 percent of the drug
in the body.
Examples of pharmacokinetic analysis for cocaine (one-compartment model)
and THC (multiple-compartment model) follow.
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One-Compartment Model
Cocaine exemplifies a one-compartment pharmacokinetic model (figure 6).
This model considers the body as a single homogeneous compartment and
assumes that the drug which is introduced into the plasma is instantaneously
in equilibrium with other tissues. Although the drug concentration in other
tissues may not necessarily be the same as that in the plasma, any changes in
the tissue are reflected by changes in plasma--the central compartment.
The elimination of the drug in the body follows first-order kinetics (the rate
constant k), and the elimination rate of the drug is proportional to plasma
drug concentration.
Figure 6. Plasma levels of cocaine (o) following an intravenous dose of
20 mg cocaine. Solid curve is a computer fit of the data to a
one-compartment model (data from Cook et al. 1985). The inset is a
schematic representation of a one-compartment model.
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The plasma concentration (C) at a certain time (t) after an intravenous bolus
dose is described by the following equations.
C = Coexp(-kt) (Eq. 1)
V = Dose/Co (Eq. 2)
t1/2 = 0.693/k (Eq. 3)
Where Co is the plasma concentration extrapolated to time zero, k is the
elimination rate constant, V is volume of distribution, and t1/2 is
half-life.
A plasma concentration-time curve for an intravenous dose of 20 mg cocaine
in a subject is illustrated in figure 6 (data from Cook et al. 1985). The solid
line is the least square fitted curve of the data using equation 1. Co is
estimated to be 102 ng/ml, and the elimination rate constant (k) is 0.46/hour.
The volume of distribution (V) estimated by Eq (2) is 196 liters, which indicates
that the majority of cocaine in the body is distributed in the tissue. The
half-life from Eq (3) is 1.5 hour.
The half-life is a very important parameter for estimating the time required
to eliminate the drug in the body. It takes one half-life for plasma levels to
fall to half of their original level. In the case of cocaine (fig. 6), it takes 1.5
hour for cocaine plasma levels to fall from 102 ng/ml to 51 ng/ml. This is the
same time that it takes for concentrations to fall from 51 ng/ml to 25.5
ng/ml. By five half-lives (7.5 hours) the plasma concentration of cocaine
decreased from 102 ng/ml to 3.1 ng/ml, which is 3 percent of the original drug
in the body. Almost all the drug (97 percent) will be eliminated by five
half-lives. For reaching a certain drug level, an additional half-life will be
required if the dose is doubled. For example, if cocaine is given at a dose of
40 mg, it will take two half-lives to reach the level of 51 ng/ml and six
half-lives to reach the level of 3.1 ng/ml.
Mu1ticompartment Model
The disposition of most drugs, including THC, is described by a multicompart-
ment model. Here, the body consists of a central compartment interacting
with several  peripheral  compartments Drugs entering the systemic
circulation require some time to distribute fully throughout the body. In the
“postdistributive” phase, where a pseudoequilibrium has been reached between
the central compartment (plasma) and the peripheral compartments (other
tissues), any changes in the central compartment reflect changes in the
peripheral compartments. In this phase, the loss of drug in the central
compartment (plasma) or peripheral compartments (other tissues) can be
described by a monoexponential process as for the one-compartment model.
The half-life for this terminal or postdistributive phase, as for that in the
one-compartment, is the time required to eliminate half of the drug from the
body.
In the multicompartment model for THC, concentrations in plasma (see figure
7) decrease rapidly, due to distribution of the drug to different tissues. The
plasma concentration follows a multiexponential decay, where each disposition
phase has a characteristic half-life. As four exponentials are required for the
description of the plasma levels of THC, a four-compartment model best
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describes the pharmacokinetics of THC (Hunt and Jones 1980). This is
indicative of a minimum of four composites of the body compartment into
which the drug has variable rates of permeation. The volume of distribution
of 600-750 liters, after equilibrium is reached between blood and tissues, is
about 200 times that of the plasma volume, indicating that the majority of
the drug is accumulated in other tissues. The slow return of THC from
sequestered tissues (including adipose or fatty tissue) to plasma is suggested
as the reason for the long terminal half-life of THC--about 18 hours. It
takes at least 3-4 days to eliminate about 90 percent of THC remaining in
the body.
Metabolite Kinetics
The concentrations of metabolites in the body depend on the rate of genera-
tion of metabolites from the parent compound and the rate of elimination of
the metabolites. After the drug administration, the metabolite concentration
will increase until the formation rate of the metabolite is equal to its
elimination rate, and then the metabolite level will decrease. When the
elimination of the metabolite is very fast, whatever metabolite formed is
almost immediately eliminated, and the decline of the metabolite concentra-
tion is therefore at the same rate as that of the parent drug. If the elimina-
tion rate for metabolite is not significantly faster than the formation rate of
the metabolite, the metabolite might build up in the body and decline at a
rate slower than that for the parent drug. Tbe elimination half-life in this
case is consequently longer than that for the parent drug. The urinary
excretion of the metabolite is subsequently a function of how fast the
metabolites are formed and excreted.
This latter case is illustrated by a graphic presentation of cocaine and
metabolite (benzoylecgonine) levels after the intravenous injection of
cocaine, as shown in figure 5. The urinary excretion rates of cocaine and
benzoylecgonine are also shown. The terminal half-lives in both plasma and
urine for benzoylecgonine are longer than those of cocaine, and consequently
the detection of benzoylecgonine after a dose of cocaine is easier than for
the parent drug.
Dose-Dependent Kinetics
“Dose-dependent kinetics” refers to a situation where the kinetics of a drug
change with the dose administered, an increase in dose resulting in a dispro-
portional increase in plasma concentration. This may be caused by changes in
the absorption, distribution, or elimination of a drug with changes in dose.
Cocaine, for example, has been reported to be dose-dependent in the dose
range of 1 mg/kg to 3 mg/kg (Barnett et al. 1981). The half-life increased
from about 40 minutes to 80 minutes, and the clearance decreased from 1.95
liters/hour/kg to 0.6 liters/hour/kg. This means that increasing the admin-
istered dose of cocaine 2-3 times may in fact increase the blood concentra-
tion (and associated adverse effects) significantly more than 2-3 times.
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Figure 7. A semilogarithmic plot of average THC plasma concentrations vs. time
following a 2-min infusion of 2 mg THC in six subjects. Each point is the group average
and each bar represents one standard deviation. The inset is a continuation of the data on
a large time scale. (From Hunt and Jones 1980, copyright 1980, American Society for
Pharmacology and Experimental Therapeutics). The far right-hand figure is a compart-
ment model consistent with THC plasma kinetics. C is the concentration of THC in the
central or plasma compartment; T2, T3, and T4 are the hypothetical tissue compartments.
FACTORS TO BE CONSIDERED IN THE INTERPRETATION OF DRUG
CONCENTRATIONS
The interpretation of a drug concentration in biological fluids (blood or urine)
to estimate the time of drug administration requires knowledge about the
disposition kinetics of the drug. In addition, it requires some knowledge of
the route of drug administration, the dose given, and the pattern or frequency
of the drug use. This information is very rarely available in a forensic or
urine screening case. It is sometimes available in treatment situations when
a series of samples over time gives an indication of use patterns along with
self-reports (see the preceding chapter).
Disposition Kinetics
The decline of plasma concentrations of a drug depends on the disposition
(distribution, metabolism, and elimination) of the drug in the body. The
disposition kinetics of a drug for each individual may be different, as each
individual may handle the drug differently.
The drug concentration in urine is more variable than that in blood or plasma,
as the urine volume and the urinary pH (which affects drug elimination) may
change considerably. All the factors that may affect the urine concentration
discussed in the previous section on renal excretion have to be considered in
the use of urine data. For single samples, the variables involved create a
sufficiently great range of possible interpretations to render any specific
interpretation questionable other than that drug was probably used in the
immediate past (days) by the individual.
Doses
Drug levels in the body depend on the dose given; a higher dose in general
produces higher drug concentrations in plasma and urine, etc. Figure 8 shows
simulated plasma concentration-time curves of THC when marijuana
cigarettes of two different potencies (the high-potency one containing 4
times the THC of the low-potency one) were given to a subject. For the
purpose of the illustration, it is assumed that similar kinetics were followed
for these two doses, although it has been suggested that a subject may titrate
THC intake during smoking (Perez-Reyes 1985). It is seen that the plasma
concentration of 2 ng/ml is reached about 1 hour after smoking a
low-potency cigarette, while this concentration is not reached until 9 hours
after the high-potency cigarette.
It would therefore be very difficult to predict a time of administration from
the plasma concentration, even in this idealized situation, if the exact dose
were not known. It would be more difficult, if not equal, for the estimation
of the time of drug administration without the knowledge of the exact dose.
Route of Administration
As explained in the section on absorption, plasma profiles may be quite
different with different routes of administration (see figures 2 and 4).
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Figure 8. A simulated plasma THC concentrations vs. time curve following smoking
marijuana cigarettes of two different potencies of THC content, the high-potency one
(broken line) containing 4 times the THC of the low-potency one (solid line), using the
pharmacokinetic parameters of THC reported by Hunt and Jones (1980).
Figure 9. A simulated plasma THC concentration vs. time curve following smoking
marijuana at four times a day (at 12, 6, 7, and 8 pm) for 4 days, using the pharmacokinetic
parameters reported by Hunt and Jones (1980).
Consequently, the urinary excretion patterns may also be different, although
it is difficult to characterize urine excretion patterns as predictive of route
of administration.
Chronic Dose vs. Single Dose
When a drug is taken over a period of time, accumulation of the drug or its
metabolites may occur if elimination of the drug or metabolites is not
complete in the interval between doses. This is illustrated by the simulated
curves in figure 9, which compares plasma levels of THC following a single
marijuana cigarette (single dose) and four cigarettes a day for 5 days (chronic
dose). The THC plasma levels at 24 hours after the last cigarette for the
chronic dose is 3 ng/ml, which is about 4 times the level at 24 hours after a
single marijuana cigarette. It will take more than 2 days for THC plasma
levels to decline to 1 ng/ml after the chronic user (the subject who has taken
four cigarettes for 5 days) stops smoking, while it takes about 15 hours for
the subject who takes only a single cigarette.
For chronic and heavy marijuana users (cannabis use daily or more often for
periods of several months), it has been reported that the marijuana
metabolites were detectable in the urine with EMIT-d.a.u. at 20 ng/ml for an
average of 31 days with a range of 4-77 days of abstinence (Ellis et al. 1985),
while for light users (cannabis use weekly or less often), it is detectable for
an average of 13 days with a range of 3-29 days. Due to the individual
variations, substantial overlap occurs in the ranges observed. As explained in
the multicompartment model for THC, THC is sequestered in tissues (deep
compartment), and the rate of elimination of THC from the body is limited
by the slow release of THC from this “tissue compartment.” As substantial
amounts of THC can be accumulated in tissues for chronic users, considerably
long times are required to eliminate it. Consequently, a positive analysis for
THC metabolite in urine at these concentration levels may indicate last time
marijuana use of a few hours to as much as a few weeks previously.
SUMMARY
Drug concentrations in biological fluids are affected by the dose, route of
administration, pattern of drug use,  and the disposit ional kinetics
(distribution, metabolism, and excretion) of the drug. As most drugs are
distributed to the site of action by blood, drug concentration measurement in
this body fluid provides the best information as to the potential effect on
behavior such as driving impairment or on psychological high. Due to wide
individual variations in the pharmacokinetics and pharmacodynamics of drugs,
however, the use of plasma drug concentrations for the estimation of
impairment has not been established for most drugs.
As for urinalysis, drug concentrations in the urine are further complicated by
other factors such as urine flow and pH. Even if a specific method is used for
the quantitation of a specific drug (the active species, not the inactive
metabolite), interpretation in forensic samples to predict time of drug use or
impairment is not possible, except within broad time periods, because of the
variations in urine drug concentration as well as the limited knowledge
available about the dose or the route of administration.
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Examples of
Specific Drug Assays
Richard L. Hawks, Ph.D., and C. Nora Chiang, Ph.D.
The following protocols and summary information will illustrate typical
combined screening and confirmation techniques for a selected group of
abused drugs. Reference to a particular assay or technique does not
necessarily indicate a preference for that system. More detailed descriptions
of the specific analytical methods mentioned in this chapter can be found in
the previous chapter on analytical methodology. For more details about
pharmacology, toxicology, and metabolism of drugs, several textbooks on
these subjects are available (Baselt 1982, 1984; Goodman and Gilman 1985;
Clarke 1986).
The chapter sections are arranged by drug. Each section concludes with a list
of references for further information. Drugs discussed are:
Marijuana/Cannabinoids
Cocaine
Amphetamine and Methamphetamine
Opiates (narcotics)
Phencyclidine (PCP)
Alcohol
Lysergic Acid Diethylamide (LSD)
Methaqualone
Barbiturates
Benzodiazepines
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MARIJUANA/CANNABINOIDS
Delta-9-tetrahydrocannabinol (THC) is the primary psychoactive ingredient
present in the leaves and flowering tops of cannabis plants, sold on the street
as marijuana. Confiscated marijuana analyzed over the past 10 years shows a
steadily increasing potency as defined as the percentage THC by weight
found in the plant material. In the mid seventies, this potency averaged
about 1 percent. Now it averages 4 percent; a special preparation called
sinsemilla averages almost 7 percent. Marijuana is commonly abused by
smoking and occasionally by oral ingestion of the plant material.
How Cannabinoids Are Handled by the Body
THC enters the bloodstream rapidly by the smoking route (in minutes) and
more slowly by the oral route (1.5-3 hours) and is rapidly transformed by liver
enzymes to several metabolites, the primary one being 11-nor-delta-9-tetra-
hydrocannabinol-9-carboxylic acid (9-carboxy-THC). THC itself is detect-
able for a few hours in blood, but because it is so rapidly metabolized and
distributed into body tissues, practically no THC is excreted in the urine.
THC tends to be stored in fatty tissue and can therefore accumulate faster
than it can be eliminated in chronic (repetitive) smokers. This accumulation
leads to much longer detection times in urinalysis for the chronic marijuana
smoker than for the occasional smoker.
The concentrations of THC metabolites found in urine are influenced by the
amount of THC (the dose) absorbed into the bloodstream, by frequency of
prior use, by the timing of collection of the urine specimen with respect to
the last exposure to marijuana, and by the rate of release of stored
cannabinoids from adipose tissue. In addition, the quantity of liquids ingested
prior to the time of sampling also affects cannabinoid concentrations in urine
(see previous chapters on implications of drug levels and on interpretations of
urinalysis results).
Methods of Analysis for Cannabinoids in Urine
Marijuana components and their metabolites have been the subject of many
analytical methods. A useful review of recent methods has been published by
Cook (in press). Cannabinoids present particularly difficult analytical
problems because of their high lipid solubility and low concentrations in body
fluids. Lipid solubility increases the difficulty of separating cannabinoids
from the biological matrix for analysis.
The immunoassays (EMIT, RIA, and FIA) detect the major metabolite of THC
(9-carboxy-THC) in urine, along with probable cross-reactivity to many of
the other metabolites of THC and their glucuronide conjugates known to be
excreted in urine. These are generally the methods of choice for the initial
screening assay. TLC is sometimes used as a screening method, although it is
a more labor-intensive approach.
The chromatography methods in current use (GLC, HPLC, TLC, GC/MS) can
separate and detect more specifically 9-carboxy-THC itself.
GLC, HPLC, and TLC have all been reported as confirmation methods for 9-
carboxy-THC, although they all are subject to interference from co-eluting
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substances. Some published methods do not appear to have adequate
specificity for use as confirmation methods, while others seem to be
adequately validated (see Irving et al. 1984).
Gas chromatography-mass spectrometry (GC/MS) is clearly the most reliable
confirmatory method. Both the electron impact (EI) and the chemical
ionization (CI) modes have been applied to the quantitation of 9-carboxy-
THC. The El spectrum provides generally three ions in a particular ratio
characteristic of 9-carboxy-THC, and the CI modes (positive ion CI and
negative ion CI) provide a single ion. While the EI spectrum provides more
information (three ions), it can be argued that the CI modes are less prone to
producing interfering ion fragments and are therefore inherently more
specific. The point to be made here is that, regardless of the type of mass
spectrometry used, it provides much more specific information and therefore
certainty of analysis than other chromatography methods. While other
confirmation methods can be adequately validated in some situations, GC/MS
will provide the best assurance against legal challenge.
Special Assay Considerations
Acute or occasional (less than twice a week) smoking. Assuming that
screening assays of 50 to 100 ng/ml cutoff and confirmation assays for
9-carboxy-THC of about 10-15 ng/ml are used, urine samples will generally
be positive for 1 to 3 days.
Chronic (daily) smoking. An individual who smokes regularly even as few as
two or three times a week will generally have marijuana-positive urines most
of the time. A heavy (daily for months at least), chronic smoker who stops
smoking may continue to produce positive samples for longer than a month
(depending on the assay cutoff) because of the amount of THC accumulated
in the body. It becomes difficult, therefore, to distinguish between the
chronic smoker who may in fact have stopped smoking weeks before from the
smoker who has not.
Oral administration (ingestion) of marijuana. For the first few hours after a
dose, the metabolic profile (relative concentrations of THC and its
metabolites) of THC in blood samples, is quite different following a dose
taken orally versus the one taken from smoking. However, metabolic profiles
in urine samples cannot generally differentiate between a dose taken orally
and one taken by smoking.
Passive inhalation of marijuana. Marijuana smoke can be inhaled passively
and can result in detectable body fluid levels of THC and 9-carboxy-THC.
However, the studies cited generally involve several smokers in a small room
or car and one or more nonsmokers in the room for at least an hour with no
ventilation. Other studies have used smoking machines to generate the
smoke. The probability of this type of exposure leading to a positive urine is,
of course, dependent on the sensitivity of the analytical method used, but the
screening methods in use today generally incorporate assay cutoffs high
enough to make such a possibility highly improbable.
What the Results Mean
A positive urine analysis for THC metabolite(s) indicates that the individual
has consumed marijuana or marijuana derivatives within 1 hour to as much as
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several weeks before the specimen was collected. While some disagreement
exists about what concentration is indicative of “recent” use, it is generally
accepted that total cannabinoid concentrations of less than 50 ng/ml by
immunoassay in urine may be consistent with usage beyond 36 hours, or from
long-term excretion in the chronic user. Without other knowledge of the
individual’s habits, more specific interpretatiou than this is not usually
feasible.
Multiple sampling of urine can frequently help make interpretations more
specific. For instance, if several weekly samples are taken from an
individual whose fit sample was positive, there should be a different pattern
of positives depending on the circumstances of use. If the individual is an
occasional or “one time” user, the second or third sample should be negative,
along with any subsequent ones. If the individual is a previously heavy
chronic smoker who has in fact stopped, samples may be positive for 3 or
more weeks, but the concentrations should show a generally decreasing trend,
eventually becoming negative for an extended period (2 weeks). If, however,
the individual continues to smoke, the samples will continue to be positive for
several weeks with no particular indication of a decreasing concentration
trend. There has been a recent report by McBurney of a “non-acid”
metabolite of THC (8-beta-11-hydroxy-delta-9-THC) which is only
detectable in urine for a few hours after the dose. This metabolite may be
useful as an indicator of recent use.
A single positive urine test does not mean that the person was under the
influence of marijuana at the time the urine specimen was collected. A
true-positive urine test means only that the person providing the specimen
used marijuana in the recent past, which could be hours, days, or weeks
depending on the specific use pattern.
References--Marijuana/Cannabinoids
Reviews
Cook, C.E. Analytical methodology for delta-9-tetrahydrocannabinol and its
metabolites. In: Alcohol, Drugs and Driving: Abstr Rev, in press.
Hawks, R.L., ed. The Analysis of Cannabinoids in Biological Fluids. NIDA
Research Monograph No. 42. DHHS Pub. No. (ADM) 82-1212. Washington,
DC: Supt. of Docs., U.S. Govt. Print. Off., 1982.
Hawks, R.L. Developments in cannabinoid analyses of body fluids:
Implications for forensic applications. In: Agurell, S.; Dewey, W.L.; and
WiIlette, R.E., eds. The Cannabinoids: Chemical, Pharmacologic, and
Therapeutic Aspects. Orlando, FL: Academic Press, 1984. pp. 123-134.
Harvey, D.L. Advances in methods for detection and measurement of the
cannabinoids. In: Harvey, D.J., ed. Marihuana ‘84, Proceedings of the
Oxford Symposium on Cannabis. Oxford, England: IRL Press Ltd., 1984. pp.
121-136.
Lindgren, J.-E. Quantification of delta-1-tetrahydrocannabinol in tissues and
body fluids. Arch Toxicol [Suppl] 6:74-80, 1983.
-87-
Thin-layer chromatography (TLC)
Kaistha., K.K., and Tadrus, R. Semi-quantitative thin-layer mass-screening
detection of 11-nor-delta-9-THC-9-carboxylic acid in human urine. J
Chromatogr 235:528-533, 1982.
Kanter, S.L.; Hollister, L.E.; and Zamora, J.U. Marijuana metabolites in
man. XI. Detection of unconjugated and conjugated delta-9-THC-11-oic acid
by thin layer chromatography. J Chromatogr 235:507-512, 1982.
Kogan, M.J.; Newman, E.; and Wilson, N.J. Detection of the marijuana
metabolite 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid in human
urine by bonded-phase absorption and thin-layer chromatography. J
Chromatogr 303:441-443, 1984.
Sutheimer, C.A.; Yarborough, R.; Hepler, B.R.; and Sunshine, I. Detection
and confirmation of urinary cannabinoids. J Anal Toxicol 9:156-160, 1985.
Verebey, K.; Jukofsky, D.; and Mule, S.J. Evaluation of a new TLC
confirmation technique for positive EMIT cannabinoid urine samples. Res
Commun in Substances Abuse 6:1-9, 1985.
Vinson, J.A., and Lopatofsky, D.J. A semi-automated extraction and
spotting system for drug analysis by TLC. I. Procedure for analysis of the
major metabolite of delta-9-tetrahydrocannabinol in urine. J Anal Toxicol
9:156-160, 1985.
Vinson ,  J .A. ,  and  Pa te l ,  A .H.  Detec t ion  and  quan t i f i ca t ion  o f
tetrahydrocannabinol in serum using thin layer chromatography and
fluorometry. J Chromatogr 307:493-499, 1984.
High-performance liquid chromatography (HPLC)
Borys, H.K., and Karler, R. Post-column derivatization procedure for the
colorimetric analysis of tissue cannabinoids separated by high-performance
liquid chromatography. J Chromatogr 205:303-323, 1981.
ElSohly, M.A.; ElSohly, H.N.; Jones, A.B.; Dimson, P.A.; and Wells, K.E.
Analysis of the major metabolite of delta-9-tetrahydrocannabinol in urine.
II: A HPLC procedure. J Anal Toxicol 7:262-264, 1983.
Law, B.; Mason, P.A.; Moffat, A.C.; and King, L.J. Confirmation of cannabis
use by the analysis of delta-9-tetrahydrocannabinol metabolites in blood and
urine by combined HPLC and RIA. J Anal Toxicol 8:19-21, 1984.
Posey, B.L., and Kimble, S.N. Quantitative determination of 11-nor-
delta-9-tetrahydrocannabinol-9-carhoxylic acid in urine by HPLC. J Anal
Toxicol 8:234-238, 1984.
Gas-liquid chromatography (GC or GLC)
ElSohly, M.A.; Arafatt, E.S.; and Jones, A.B. Analysis of the major
metabolite of delta-9-tetrahydrocannabinol in urine. III. A GC/ECD
procedure. J Anal Toxicol 8:7-9, 1984.
-88-
Fenimore, D.C.;  Freeman, R.R.;  and Loy, P.R. Determination of
delta-9-THC in blood by electron capture GLC. Anal Chem 45:2331-2335,
1973.
Garrett, E.R., and Hunt, C.A. Picogram analysis of THC and application to
biological fluids. J Pharm Sci 62:1211-1214, 1973.
Karlsson, L., and Roos, C. Combination of liquid chromatography with
ultraviolet detection and gas chromatography with electron-capture
detection for the determination of delta-9-tetrahydrocannabinol-11-oic acid
in urine. J Chromatogr 306: 183-189, 1984.
McCallum, N.K.; Cairns, E.R.; Ferry, D.G.; and Wong, R.J. A simple gas
chromatographic method for routine delta-1-tetrahydrocannabinol analysis of
blood and brain. J Anal Toxicol 2:89-93, 1978.
Gas chromatomphy-mass spectrometry (GC/MS)
Baker, T.S.; Harry, J.V.; Russell, J.W.; and Myers, R.L. Rapid method for the
GC/MS confirmation of 11-nor-9-carboxy-delta-9-tetrahydrocannabinol in
urine. J Anal Toxicol 8:255-259, 1984.
Foltz, R.L.; McGinnis, K.M.; and Chinn, D.M. Quantitative measurement of
delta-9-tetrahydrocannabinol and two major metabolites in physiological
specimens using capillary column gas chromatography in negative chemical
ionization mass spectrometry. Biomed Mass Spectrom 10:316-323, 1983.
Foltz, R.L. Analysis of cannabinoids in physiological specimens by gas
chromatography/mass spectrometry. In: Baselt, R., ed. Advances in
Analytical Toxicology. Vol. 1. Foster City, CA: Biomedical Publications,
1984. pp. 125-157.
Karlsson, L.; Jonsson, H.; Aberg, K.; and Roos, C. Determination of
delta-9-tetrahydrocannabinol-11-oic acid in urine as its pentafluoropropyl-
pentafluoropropionyl derivative by GC/MS utilizing negative ion chemical
ionization. J Anal Toxicol 7:198-202, 1983.
Rosenfeld, J.M.; McLeod, R.A.; and Foltz, R.L. Solid-supported reagents in
the determination of cannabinoids in plasma. Anal Chem 58:716-721, 1986.
Wall, M.E.; Brine, D.R.; Bursey, J.T.; and Rosenthal, D. Detection and
quantitation of tetrahydrocannabinol in physiological fluids. In: Vinson, J.A.,
ed. ACS Symposium Series 98, Cannabinoid Analysis in Physiological Fluids.
Washington, DC: American Chemical Society, 1979. pp. 39-57.
Immunoassays--RIA
Cook, C.E. Radioimmunoassay of cannabinoid compounds. In: Vinson, J.A.,
ed. ACS Symposium Series 98, Cannabinoid Analysis in Physiological Fluids.
Washington, DC: American Chemical Society, 1979. pp. 137-154.
Jones, A.B.; ElSohly, H.N.; and ElSohly, M.A. Analysis of the major
metaholite of delta-9-tetrahydrocannabinol in urine. V. Cross-reactivity of
selected compounds in a radioimmunoassay. J Anal Toxicol 8:252-254, 1984.
-89-
Yeager, E.P.; Goebelsmann, U.; Soares, J.R.; Grant, J.D.; and Gross, S.J.
Delta-9-tetrahydrocannabinol by GLC-MS validated radioimmunoassays of
hemolyzed blood or serum. J Anal Toxicol 5:81-84, 1981.
Cook, C.E.; Seltzman, H.H.; Schindler, F.H.; Tallent, C.R.; Chin, K.M.; and
Pitt, C.G. Radioimmunoassays for cannabinoids. In: Hawks, R.L., ed. The
Analysis of Cannabinoids in Biological Fluids. NIDA Research Monograph No.
42. DHHS Pub. No. (ADM) 82-1212. Washington, DC: Supt. of Docs., U.S.
Govt. Print. Off., 1982. pp. 19-32.
Jones, A.B.; ElSohly, H.N.; and ElSohly, M.A. Analysis of the major
metabolite of delta-9-tetrahydrocannabinol in urine: V. Cross-reactivity of
selected compounds in a radioimmunoassay. J Anal Toxicol 8:252-254, 1984.
Law, B.; Mason, P.A.; Moffat, A.C.; and King, L.J. A novel 125radio-
immunoassay for the analysis of delta-9-tetrahydrocannabinol and its
metabolites in human body fluids. J Anal Toxicol 8:14-18, 1984.
Owens, S.M.; McBay, A.J.; Reisner, H.M.; and Perez-Reyes, M. 125I
Radioimmunoassay of delta-9-tetrahydrocannabinol in blood and plasma with
a solid-phase second-antibody separation method. Clin Chem 27:619-624,
1981.
Peat, M. The analysis of delta-9-tetrahydrocannabinol and its metabolites by
immunoassay. in: Baselt, R., ed. Advances in Analytical Toxicology.
Volume 1. Foster City, CA: Biomedical Publications, 1984. pp. 59-80.
Soares, J.R.; Grant, J.D.; and Gross S.J. Significant developments in
radioimmune methods applied to delta-9-THC and its 9-substituted
metabolites. In: Hawks, R.L., ed. The Analysis of Cannabinoids in Biological
Fluids. NIDA Research Monograph No. 42. DHHS Pub. No. (ADM)82-1212.
Washington, DC: Supt. of Docs., U.S. Govt. Print. Off., 1982. pp. 44-55.
Immunoassays--EIA
DeLaurentis, M.J.; McNeil, K.; Mann, A.J.; Clark, S.; and Greenwood, H.M.
An EMIT assay for cannabiioid metabolites in urine. In: Hawks, R.L.. ed.
The Analysis of Cannabinoids in Biological Fluids. NIDA Research Monograph
No. 42. DHHS Pub. No. (ADM)82-1212. Washington, DC: Supt. of Docs., U.S.
Govt. Print. Off., 1982. pp. 69-84.
Deutsch, A.; LeGrand, C.; and Spinner, H. Generation of monoclonal
antibodies to cannabinoids and their use in an EIA. Clin Chem 32:1052
(abstr.), 1986.
Law, B.; Pocok, K.; and Moffat, A.C. An evaluation of homogeneous enzyme
immunoassay (EMIT) for cannabinoid detection in biological fluids. J
Forensic Sci Soc 22:275-281, 1982.
Rogers, R.; Crowl, C.P.; Eimstad, W.M.; et al. Homogeneous enzyme
immunoassay for cannabinoids in urine. Clin Chem 24:95-100, 1978.
-90-
Comparisons of methods
Frederick, D.L.; Green, J.; and Fowler, M.W. Comparison of six cannabinoid
metabolite assays. J Anal Toxicol 9:116-120, 1985.
Hanson, V.W.; Buonarati, M.H.; Baselt, R.C.; Wade, N.A.; Yap, C.; Biasotti,
A.A.; Reeve, V.C.; Wong, A.S.; and Orbanowsky, M.W. Comparison of 3H- and
125I-Radioimmunoassay and gas chromatography-mass spectrometry for the
determination of delta-9-tetrahydrocannabinol and cannabinoids in blood and
serum. J Anal Toxicol 7:96-102, 1983.
Irving, J.; Leeb, B.; Foltz, R.L.; Cook, C.E.; Bursey, J.T.; and Willette, R.E.
Evaluation of immunoassays for cannabinoids in urine. J Anal Toxicol
8:192-196. 1984.
Jones, A.B.; ElSohly, H.N.; Aragat, E.S.; and ElSobly, M.A. Analysis of the
major metabolite of delta-9-tetrahydrocannabinol in urine.  IV. A
comparison of five methods. J Anal Toxicol 8:249-251, 1984.
O’Connor, J.E., and Rejent, T.A. EMIT cannabinoid assay for urinary
metabolites and confirmation by alternate techniques. Clin Chem 27:1104,
1981.
O’Connor, J.E., and Rejent, T.A. EMIT cannabinoid assay: Confirmation by
RlA and GC/MS. J Anal Toxicol 5:168-173, 1981.
Rosenthal, D.; Harvey, T.M.; Bursey, J.T.; Brine, D.R.; and Wall, M.E.
Comparison of gas chromatography mass spectrometry methods for the
determination of delta-9-tetrahydrocannabinol in plasma. Biomed Mass
Spectrom 5:312-316, 1978.
Metabolism and kinetics
Agurell, S.; Gillespie, H.; Halldin, M.; Holliiter, L.E.; Johansson, E.; Lindgren,
J.E.; Ohlsson, A.; Szirmai, M.; and Widman, M. A review of recent studies on
the pharmacokinetics and metabolism of delta-1-tetrahydrocannabinol,
cannabidiol and cannabinol in man. In: Harvey, D.J., ed. Marihuana. ‘84,
Proceedings of the Oxford Symposium on Cannabis. Oxford, England: IRL
Press Ltd., 1984. pp. 49-62.
Halldin, M.M.; Carlsson, S.; Kanter, S.L.; Widman, M.; and Agurell, S.
U r i n a r y  m e t a b o l i t e s  o f  d e l t a - 1 - t e t r a h y d r o c a n n a b i n o l  i n  m a n .
Arzneim-Forsch/Drug Res 32:764-768, 1982.
Halldin, M.M.; Andersson, L.K.R.; Widman, M.; and Holliiter, L.E. Further
urinary metabolites of delta-1-tetrahydrocannabinol in man. Arzneim -
Forsch/Drug Res 329:1135-1138, 1982.
Hunt, C. A., and Jones, R.T. Tolerance and disposition of tetrahydro-
cannabinol in man. J Pharmacol Exp Ther 215:35-44, 1980.
McBurney, L.J.; Bobble, B.A.; and Sepp, L.A. GC/MS and EMIT analyses for
delta-9-tetrahydrocannabinol metabolites in plasma and urine of human
subjects. J Anal Toxicol 10:56-64, 1986.
-9 l -
Peat, M.A.; Deyman, M.E.; and Johnson, J.R. High performance liquid
chromatography-immunoassay of delta-9-tetrahydrocannabinol and its
metabolites in urine. J Forensic Sci 29: 110-119, 1984.
Wall, M.E., and Perez-Rcyes, M. The metabolism of delta-9-tetrahydrocan-
nabinol and related compounds in man. J Clin Pharmacol 21:1785-1795, 1980.
Wall, M.E.; Sadler, B.M.; Brine, D.; Taylor, H.; and Perez-Reyes, M.
Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men
and women. Clin Pharmacol Ther 34:352-363, 1983.
Wall, M.E.; Brine, D. R.; and Perez-Reycs, M. Metabolism of cannabinoids in
man. In: Braude, M.C., and Szara, S., eds. The Pharmacology of Marijuana.
Vol. 1. New York: Raven Press, 1976. pp. 93-116.
Passive inhalation
Cone, E.J., and Johnson, R.E. Contact highs and urinary cannabinoid
excretion after passive exposure to marijuana smoke. Clin Pharmacol Ther
40:247-256, 1986.
Ferslew, K.E.; Manno, J.E.; and Manno, B.R. Determination of urinary
cannabinoid metabolites following incidental exposure to marijuana smoke.
Res Commun in Substance Abuse 4:287-300, 1983.
Law, B.; Mason, P.A.; Moffat, C.A.; King, L.J.; and Marks, V. Passive
inhalation of cannabis smoke. J Pharm Pharmacol 36:578-581, 1984.
Mason, A.P.; Perez-Reyes, M.; McBay, A.J.; and Foltz, R.L. Cannabinoids in
plasma after passive inhalation of marijuana smoke. J Anal Toxicol
7:172-174, 1983.
Morland, J.; Bugge, A.; Skuterud, B.; Steen, A.; Wethe, G.H.; and Kjeldsen,
T. Cannabinoids in blood and urine after passive inhalation of cannabis
smoke. J Forensic Sci 30:997-1002, 1985.
Perez-Reyes, M.; Giuseppi, S.D.; Mason, A.P.; and Davis, K.H. Passive
inhalation of marijuana smoke and urinary excretion of cannabinoids. Clin
Pharmacol Ther 34:36-41, 1983.
Waterhouse, G.A.W.; Pence, P.J.C.; and Forney, R.B. Positive urine
cannabinoid levels produced in individuals passively exposed to marijuana
smoke. Abstracts of the 35th Annual Meeting of the American Academy of
Forensic Sciences 1983. p. 90.
Urinary excretion
Ellis, M.G.; Mann, M.A.; Judson, B.A.; Schramm, N.T.; and Taschian, A.
Excretion patterns of cannabinoid metabolites after last use in a group of
chronic users. Clin Pharmacol Ther 38:572-598, 1985.
Dackis, C.A.; Pottash, A.L.C.; Annitto, W.; and Gold, M. Persistence of
urinary marijuana levels after supervised abstinence. Am J Psychiatry
139:1196-1198, 1982.
-92-
COCAINE
Cocaine, a central nervous system stimulant prepared from an extract of the
coca plant, is self-administered in a variety of ways: snorting, smoking
(“freebasing”), and intravenous injection. It is considered one of the most
highly reinforcing drugs abused today. Its smoked form (freebase or “crack”)
appears to be extremely addicting because of the rapid onset and
disappearance of its sought-after effect.
How Cocaine Is Handled by the Body
Cocaine is rapidly absorbed (the maximum plasma concentration occurring at
about 5 minutes) after smoking. Plasma profiles after smoking are almost
equivalent to those following an intravenous dose. There are significant
temporal differences in plasma cocaine profiles between the intranasal route
and the intravenous or smoking routes. Maximum cocaine concentrations are
reached at around 30-40 minutes and persist longer after intranasal
inhalation than via intravenous or smoke. The terminal half-life (1.5 hours)
of cocaine is the same for all the routes of administration. The fraction of a
cocaine dose that enters the circulatory system after the intranasal and
smoked routes is estimated at 80 percent and 46 percent, respectively,
although large variations occur among individuals.
Cocaine is extensively metabolized, primarily by liver and plasma esterases,
and only 1 percent of the dose is excreted in the urine unchanged.
Approximately 70 percent of the dose can be recovered in the urine over a
period of 3 days. Benzoylecgonine (25-40 percent of the dose) is the major
metabolite found in the urine. About 18-22 percent of the dose is excreted as
ecgonine methyl ester and 2-3 percent as ecgonine.
Examples of Analytical Methods
lmmunochemical techniques such as EMIT and RIA designed to detect
benzoylecgonine are widely used. Unchanged cocaine can sometimes be
detected by chromatographic methods for up to 24 hours after a given dose,
while benzoylecgonine can generally be detected by immunoassays for 24-48
hours.
Gas-liquid chromatography (GLC), HPLC, and GC/MS are probably the most
generally useful techniques for confirmation of cocaine and its metabolite(s)
in urine. GC/MS provides the most specific and unchallengeable confirmation.
Special Assay Considerations
Benzoylecgonine can generally be detected in urine up to 2 days after cocaine
use. A positive cocaine metabolite assay therefore indicates use within thii
period. Depending on the frequency of urine testing, a negative assay may
not be a clear indication of lack of chronic use. With this and other drugs
that clear the body relatively rapidly, short detection times in urinalysis
procedures mean that individuals using such drugs will be less likely to be
detected than those using drugs like marijuana or PCP, which have longer
detection times.
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AMPHETAMINE AND METHAMPHETAMINE
Amphetamine and methamphetamine (the N-methyl derivative of
amphetamine) are central nervous system stimulants usually taken orally,
intravenously, or by snorting. Recent reports cite increased use of smoking
as  a  p re fe r red  rou te  fo r  methamphetamine  by  some ind iv idua l s .
Amphetamines increase the heart rate and blood pressure and curb the
appetite. In large doses, they cause irritability and anxiety. Tolerance has
been observed in amphetamine abusers, and the possibility of developing
psychological dependence on the drug is quite significant. Studies have also
suggested that chronic abuse may lead to permanent neuronal damage to
certain essential nerve structures in the brain.
How Amphetamines Are Handled by the Body
When methamphetamine is administered, some of the drug is metabolized
into amphetamine, its major active metaholite, and both of these drugs will
appear in the urine. Amphetamine is metabolized to deaminated (hippuric
and benzoic acids) and hydroxylated metabolites.
The fraction of a dose of amphetamine excreted unchanged varies with the
pH of the urine, with a range of 2 percent (alkaline pH) to 68 percent (acidic
pH). In 24 hours, about 79 percent of the dose is excreted in acidic urine and
about 45 percent in alkaline urine. Typically, 20-30 percent is excreted as
unchanged amphetamine and 25 percent as benzoic acid and its conjugate
(hippuric acid).
Methamphetamine is excreted primarily unchanged (44 percent) with a small
fraction as amphetamine (6 percent). Its urinary excretion also fluctuates
with urinary pH. Under acidic urine conditions, the excretion of unchanged
methamphetamine is increased.
Methods of Analysis for Amphetamines in Urine
RIA assays such as the Roche Abuscreen will detect only amphetamine, while
Syva’s EMIT is able to detect both amphetamine and methamphetamine.
Although RIA does not react significantly with methamphetamine, sufficient
amphetamine is often produced by metabolism to cause a positive response.
A more specific Abuscreen amphetamine assay is also available and is
sometimes used as a second screen. The new Abbott TDx Drug Detection
System is reported to detect both methamphetamine and amphetamine with
little or no cross-reactivity to ephedrine and phenylpropanolamine.
Special Assay Considerations
Unchanged amphetamine has been detected in the urine up to 29 hours after a
single oral dose of 5 mg amphetamine. Unchanged methamphetamine also
has been identified up to 23 hours following a single oral dose.
After chronic intravenous administration, methamphetamine abusers have
shown methamphetamine concentrations of 25-300 ug/ml and amphetamine
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concentrations of 1-90 ug/ml in urine. Several over-the-counter prepara-
tions used as decongestants and diet aids contain ephedrine and phenylpropa-
nolamine, which are capable of producing positive EMIT and RIA tests if
present in the urine in significant concentrations. Several prescription drugs,
such as benzphetamine, fenfluramine, mephentermine, phenmetrazine, and
phenter- mine, can also produce positive immunoassay results.
A positive amphetamine analysis indicates previous use of amphetamine or
methamphetamine, generally within the previous 24-48 hours.
Because of the high prevalence of phenylpropanolamine and ephedrine in use
for dietary aid and cold remedies and the high probability of their cross-
reactivity in immunoassays, it is important to perform careful confirmatory
tests for samples screened presumptively positive by immunoassay tests.
Gas-liquid chromatography with a nitrogen-phosphorus detector (GLC/NPD)
and with appropriate columns for resolving derivatized and underivatized
phenylethylamines, and GC/MS with capillary column capability, provide
excellent sensitivity and specificity for resolution of presumptive positives by
immunoassay tests.
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OPIATES
Morphine, codeine, and semisynthetic derivatives of morphine belong to the
class of drugs called opiates. Both morphine and codeine (methylmorphine)
are naturally occurring alkaloids from opium, the dried milk juice of the
unripe seed pod of the opium poppy Papaver somniferum. An opiate exerts
its effects on the central nervous system. Heroin, a semisynthetic derivative
(diacetylmorphine) of morphine, is more potent than morphine and is strictly
a drug of abuse. Codeine, commonly used in analgesics and cough medicine,
and morphine, used in analgesics, are prescription drugs.
Heroin users may take the drug by insufflation (snorting), by subcutaneous
injection (“skin-popping”), by intravenous injection (“mainlining”), or by
smoking.
How Opiates Are Handled by the Body
Morphine is rapidly absorbed from an oral dose (peak plasma levels at 15-60
minutes) and from intramuscular and subcutaneous injection (peaks at 15
minutes). It is metabolized extensively, with only 2-12 percent excreted as
unchanged morphine in the urine. Large amounts (60-80 percent) of the
conjugated metabolites (glucuronides) are excreted in the urine, with small
amounts (5-14 percent) being excreted in the feces. The quantitatively most
important metabolite is morphine-3-glucuronide, which is excreted in the
urine to an extent of 67-70 percent of the given dose in 48 hours. The
half-life for morphine has been reported in the range of 1.7-4.5 hours.
Heroin is rapidly broken down first to monoacetylmorphine, which is then
metabolized to morphine in the body. Both heroin and monoacetylmorphine
disappear rapidly from the blood (half-life for heroin is 3 minutes, and that
for monoacetylmorphine is somewhat longer), while morphine levels rise
slowly, persist longer, and decline slowly. The pattern of urinary excretion of
heroin is similar to that of morphine: unchanged morphine (7 percent) and
conjugated morphine (glucuronides, 50-60 percent). However, additional
trace amounts of 6-acetylmorphine are detectable in the urine.
Codeine is rapidly absorbed from an oral dose; maximum concentrations
occur at 1 hour after ingestion. It is extensively metabolized, primarily to
conjugated 6-codeine-glucuronide, while 10-15 percent of the dose is
demethylated to form morphine and norcodeine, principally in the form of
conjugates. Therefore, codeine, norcodeine, and morphine in free and
conjugated form appear in the urine after codeine ingestion.
Methods of Analysis for Opiates in Urine
Both EMIT and the Abuscreen RIA detect codeine and morphine in free and
conjugated forms but do not distinguish between them. Morphine from heroin
use may be detected 2-4 days after the last dose by the immunoassays when
these are used at cutoffs of 300 ng/ml. Other narcotics detected by the
immunoassays for morphine include dihydrocodeine, dihydromorphine, and
hydromorphone. Acid or enzyme hydrolysis of the urine sample is necessary
when testing techniques such as TLC, HPLC, and GLC are employed, since
approximately 90 percent of codeine and morphine are found in urine in the
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conjugated form (glucuronide). Because morphine can come from either
heroin or codeine administration, it is important that (1) a confirmatory
procedure such as GC/MS, HPLC, or GLC be selected, and (2) the sample be
hydrolyzed prior to analysis.
Special Assay Considerations
A screening assay that is positive for opiates could be the result of several
different circumstances of drug administration. Since immunoassays do not
distinguish between codeine, morphine, or their glucuronide conjugates, a
confirmation test that is specific for morphine and/or codeine is necessary.
The presence of morphine alone or its conjugate can indicate either clinical
morphine use or illicit morphine or heroin use (within the previous 1-2 days).
The presence of both morphine and codeine in urine is consistent with
ingestion of codeine alone, when the codeine concentration is high and
greater than that of morphine, which can be produced as a metabolite in
urine. Prescribed use of codeine must be ascertained in this case. Generally,
ingestion of a therapeutic dose of codeine (30 mg) will lead to detectable
levels of the free morphine or codeine for only a few hours, although other
metabolites may be detectable for 2-3 days by immunoassay.
Street heroin also contains acetylcodeine, which metabolizes to codeine.
Therefore, in cases of low morphine and codeine concentrations in urine, it is
not possible to determine whether the subject has taken heroin, codeine, or
morphine. Although codeine presence in urine may indicate illicit drug use,
its presence in many antitussive or analgesic prescription preparations makes
such a conclusion questionable.
The ingestion of a large quantity of poppy seeds can result in positive opiate
findings in urine samples by immunoassay methods up to 60 hours after
ingestion. This is  apparently due to trace amounts of morphine in
commercial poppy seeds. A recent report by Fehn and Megges suggests that
an analysis by GC/MS for 6-O-acetylmorphine, a metabolite of heroin can be
used to distinguish between an opiate positive urine resulting from poppy seed
ingestion versus heroin use (1985).
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PHENCYCLIDINE
Phencyclidine (PCP, or angel dust) is commonly taken orally, by inhalation
(smoked), by insufflation, or intravenously. The drug can be added to parsley,
mint, oregano, or other leaves and smoked in the form of a cigarette. In
liquified form, it can be swallowed, injected, or applied to smoking material.
Several PCP derivatives produce similar pharmacological effects.
How PCP Is Handled by the Body
Phencyclidine is well absorbed following all routes of administration.
Maximum plasma PCP concentrations are observed 5-15 minutes after
smoking. In one study, approximately 40 percent of PCP spiked on a
cigarette entered into smoker’s bloodstream as PCP and 30 percent as
phencyclohexene, a decomposition product of PCP. Oral absorption of PCP is
slower; the maximum plasma concentration is observed at 2 hours after the
dose. About 72 percent of the oral dose is absorbed. The terminal half-life
for PCP varies considerably, with a range of 8-55 hours and average of 18
hours.
PCP undergoes oxidation and conjugation in the body. Unchanged PCP is
excreted in the urine in moderate amounts (10 percent of the dose).
Metabolites identified are primarily conjugates of hydroxylated PCP. About
40 percent of the material in the urine has not been identified. Excretion of
PCP is increased in acidic urine, but excretion of polar metabolites is
unaffected by urinary pH. PCP may be detectable in urine for several days to
several weeks. Some PCP is secreted in the saliva.
Examples of Analytical Methods
Immunochemical methods are relatively specific for PCP, its metabolites,
and some of the closely related analogs. Methods for confirmation include
gas-liquid chromatography with nitrogen-phosphorus detection (GLC/NPD),
with differential columns to rule out interference from other drugs, or gas
chromatography-mass spectrometry (GC/MS), which will provide the most
specific and unchallengeable assay for PCP and its analogs.
Special Assay Considerations
A positive urine assay for PCP generally indicates drug use within the
previous week. There have been reports that sufficient PCP can be absorbed
through skin to lead to a positive urinalysis. The use of saliva has been
reported to correlate well with blood as a means of detection of recent PCP
use. Hair analysis for the detection of PCP has also been reported.
False positives in immunochemical assays for PCP have been reported with
the administration of thioridazine (Mellaril), dextromethorphan, and
chlorpromazine (Thorazine). This supports the need for specific confirmation
of the screening analysis.
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ALCOHOL
With the possible exception of caffeine, ethyl alcohol is the most widely used
drug in our society. The determination of alcohol in bodily fluids is perhaps
the most commonly performed drug analysis.
How Alcohol Is Handled by the Body
Alcohol is used orally, and its concentration in the blood at any given time is
influenced by such factors as a person’s weight, the rate at which the
individual drinks, whether food is taken with the “dose,” and tolerance. Blood
alcohol concentrations (BACs) are usually expressed as “percent” (g/deciliter)
or as “mg percent” (mg/dl). Drinking 1.5 oz of 86 proof alcohol in a short
period of time will result in a BAC of approximately 0.03 percent (or 30 mg
percent) in a 160-pound individual.
The liver metabolizes 95 percent of the ingested alcohol at a relatively
constant rate. A normal liver will metabolize alcohol at approximately .015
g/dl per hour. This means it takes the body about 2 hours to metabolize 3/4
oz of pure alcohol. This is equivalent to a 5-oz glass of wine, a 12-oz can of
beer, or a 1.5 oz glass of 88 proof liquor. If a person drinks at a rate faster
than 1.5 oz per hour, the blood concentration (and the effects) will
accumulate.
If a 160-pound individual took four drinks each containing 1.5 oz of 100 proof
liquor within 4 hours, a BAC of about 0.08 percent (80 mg percent) would be
reached. The same number of drinks or a six-pack of beer imbibed over a
l-hour lunch period might render the individual above the legal limit for the
rest of the workday.
Examples of Analytical Methods
Methods for analysis are classified as chemical, biochemical, and gas
chromatographic. Chemical methods utilizing acid potassium dichromate
solutions are not specific for ethyl alcohol but can be used to provide rapid
screening for volatile substances. If negative, no further testing is required.
If positive, a confirmation test is necessary to ensure the presence of ethyl
alcohol.
Biochemical methods for alcohol analysis employ an enzyme. The enzyme
alcohol dehydrogenase (ADH) is combined with other reagents in a kit form
and is available from several manufacturers. The enzyme method is reliable
and accurate when used by experienced analysts. The enzyme is fairly
specific in that it does not react with methanol or acetone, but it does react
to some degree with isopropyl and long chain alcohols. Although these higher
molecular weight alcohols are rarely encountered, positive identification for
ethyl alcohol is required in legal situations.
Gas chromatographic methods offer excellent proof for the identification of
ethyl alcohol and are the most widely used. These methods can
simultaneously detect other alcohols, ketones (acetone from diabetics), and
other  vo la t i l e  subs tances .  Of  the  th ree  types  o f  methods ,  gas
chromatographic procedures are the methods of choice.
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A variety of techniques involve extraction, distillation, or direct injection.
All are reliable when an internal standard is incorporated into the procedure
for quantitation purposes. More recently, automated head space analyses are
being used; they offer excellent precision and accuracy, in addition to
providing rapid turnaround time.
What the Results Mean
Unlike most of the other drugs discussed in this monograph, alcohol is a legal
drug and its presence in urine does not indicate illicit activity. An alcohol
analysis is always aimed at determining the BAC in order to relate this to a
particular level of impairment or at least to a legally defined definition of
impairment. In practice, evidence or suspicion of alcohol abuse is best
confirmed by breath or blood analyses to determine the concentration
present. If this concentration is more than (or close to) the legally accepted
presumptive concentration for impairment (100 mg/dl or 0.1 percent in most
States), grounds exist for an assumption of impairment.
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LYSERGIC ACID DIETHYLAMIDE
Lysergic acid diethylamide (LSD) is an extremely potent drug capable of
producing altered mental states at doses as low as 25 micrograms
(approximately one-millionth of an ounce). The drug is relatively easily
prepared from natural products. Although LSD was most widely used during
the 1960s. it continues to be available through illicit channels, and there is
evidence that its use is again increasing. The drug is not physically addictive,
and there are no known. examples of deaths directly attributable to the
pharmacological effects of LSD. While under the influence of the drug,
however, a person’s ability to perform complex mental and physical tasks is
severely affected. Furthermore, use of the drug is known to sometimes cause
bizarre behavior, which can lead to fatal accidents and suicides.
How LSD Is Handled by the Body
Following oral ingestion of LSD, the effects are perceived within a few
minutes and usually last for about 12 hours. Recurrence of the drug’s effects
long after its use (“flashbacks”) has been reported, but the actual cause of
this phenomenon is not understood. Studies with laboratory animals have
shown that LSD is rapidly metabolized and only a small proportion of the dose
is excreted in the urine as the parent drug. Few reports have been published
regarding the concentrations of LSD and its metabolites in urine following
ingestion of the drug by man. However, because only small amounts of LSD
are ingested and because it is likely that the drug is rapidly metabolized in
man just as it is in laboratory animals, concentrations of the drug in the urine
of a user are unlikely to exceed a few nanograms per milliliter. In a recent
study, after administration of LSD to two volunteers at a dose of 1 microgram
of drug per kilogram of body weight, the concentration of the parent drug in
the urine reached a maximum of 1 to 2 ng/ml between 2 and 8 hours, and then
decreased to less than 0.1 ng/ml within 20 hours. A radioimmunoassay (RIA)
with a cutoff of 0.5 ng/ml for LSD-reactive substances gave a positive test
for the urine collected from the same subjects for up to 30 hours after
administration. Two metabolites of LSD could be detected by a highly
sensitive GC/MS assay in the urine specimens collected for up to 72 hours
after administration.
Methods for Analysis of LSD in Urine
Most published assays for LSD are intended for identification of the drug in
illicit preparations and do not offer the sensitivity and specificity required
for detection of LSD in urine specimens from users. A radioimmunoassay for
LSD was recently introduced commercially by Roche Diagnostic Systems,
Nutley, NJ, and appears to offer an effective means of detecting very recent
use of the drug. However, confirmation of the presence of LSD or its
metabol i t es  remains  a  d i f f i cu l t  t a sk .  High-per formance  l iqu id
chromatography combined with fluorescence detection has been used to
detect LSD at urinary concentrations as low as 0.5 ng/ml. A method
employing the combination of capillary column gas chromatography and
electron ionization mass spectrometry has been developed and is also capable
of measuring LSD concentrations as low as 0.5 ng/ml. However, neither of
these assays is useful for detection of LSD in urine for more than about 12
hours after ingestion. A GC/MS assay for the N-demethyl and 13-hydroxy
metabolites of LSD in urine has been developed and shown to permit
-105-
detection of LSD use for more than 2 days after ingestion. Other analytical
techniques that have been evaluated for detection of LSD in urine include the
combination of liquid chromatography and mass spectrometry (LC/MS)
(Kidwell, personal communication) and tandem analyzer mass spectrometry
(MS/MS).
Special Assay Considerations
The task of developing an assay with sufficient sensitivity to detect LSD or
its metabolites in urine from users is made more difficult by the drug’s
sensitivity to both light and heat. However, two studies have shown that LSD
is stable in urine for more than a month when stored at or below room
temperature and protected from direct sunlight or other sources of
ultraviolet radiation. LSD analyses based upon gas chromatography require a
well-deactivated capillary column in order to avoid severe adsorptive loss of
the drug. Conversion of LSD to its N-trimethylsilyl or N-trifluoroacetyl
derivative results in improved gas chromatographic behavior and permits
higher sensitivities to be achieved.
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METHAQUALONE
Methaqualone (Quaalude) is a sedative-hypnotic drug taken orally in doses of
75-300 mg. Far higher doses may be taken in nontherapeutic abuse
situations. Chronic use in tolerant individuals of over 3 g per day has been
reported.
How Methaqualone Is Handled by the Body
The absorption of methaqualone is rapid, with peak plasma concentration
reached in 1.5-2 hours. The drug is extensively metabolized in man; less than
1 percent of the dose is excreted as unchanged methaqualone in the urine.
Approximately 30 percent of the dose is excreted in the urine in 24 hours, 25
percent as hydroxylated metabolites (12 have been identified).
After the ingestion of a therapeutic dose (300 mg) of methaqualone,
methaqualone is negligible (usually less than 1 ng/ml) in the urine, while
metabolites may still be detectable for more than a week by sensitive GC/MS
methods.
Examples of Analytical Methods
EMlT and RIA not only detect unchanged drug but can significantly detect
various metabolites of the drug, thus providing longer detection periods after
last ingestion. Confirmatory methods for the detection of unchanged
methaqualone and conjugated (bound) metabolites after hydrolysis of the
sample include GLC and GC/MS.
References--Methaqualone
Alvan, C.; Lindgren, J.-E.; Bogentoft, C.; and Ericsson, O. Plasma kinetics
of methaqualone in man after single oral doses. Eur J Clin Pharmacol
6:187-190, 1973.
Bonnichsen, R.; Marde, Y.; and Ryahge, R. Identification of free and
conjugated metabolites of methaqualone by gas chromatography-mass
spectrometry. Clin Chem 20:230-235, 1974.
Evenson, M.A., and Lensmeyer, G.L. Qualitative and quantitative
determination of methaqualone in serum by gas chromatography. Clin Chem
20:249-254, 1974.
Peat, M.A., and Finkle, B.S. Determination of methaqualone and its major
metabolite in plasma and saliva after single oral doses. J Anal Toxicol
4:114-118, 1980.
Permisohn, R.C.; Hillpert, L.R.; and Kazyak, L. Determination of meth-
aqualone in urine by metabolite detection via gas chromatography. J
Forensic Sci 21:98-107, 1976.
Sleeman, H.K.; Cella., J.A.; Harvey, J.L.; and Beach, D.J. Thin-layer
chromatographic detection and identification of methaqualone metabolites in
urine. Clin Chem 21:76-80, 1975.
-108-
BARBITURATES
Barbiturates are central  nervous system depressants and used as
hypnot ics / seda t ives .  They  a re  c lass i f i ed  as  u l t r a - shor t ,  shor t - ,
intermediate-, and long-acting. The duration of action of barbiturates is
quite variable, ranging from 15 minutes for ultra-short-acting drugs to a day
or more for long-acting drugs. The most commonly abused barbiturates are
short- and intermediate-acting agents such as pentobarbital (Nembutal),
secobarbital (Seconal), and amobarbital (Amytal). Long-acting agents such as
phenobarbital are rarely subject to abuse.
How Barbiturates Are Handled by the Body
Barbiturate derivatives are excreted into the urine in varying amounts of
unchanged drug and metabolites. Long-acting barbiturates like phenobarbital
are excreted with a higher percentage of unchanged drug in the urine, while
short-acting barbiturates, secobarbital and amobarbital, are extensively
metabolized and excreted in the urine with a smaller percentage of
unchanged drugs.
Examples of Analytical Methods
EMIT and RIA are designed to detect unchanged secobarbital in the urine;
however, both assays will detect other commonly encountered barbiturates,
depending on the concentration of drug present in the sample. Phenobarbital
positives have been noted in chronic users up to several weeks after cessation
of use. With standard single doses of secobarbital, pentobarbital, or
amobarbital, RIA and GLC identified drug presenee for up to 52 hours and 76
hours, respectively, utilizing a 100 ng/ml cutoff. TLC, less sensitive than
RIA, demonstrated the presence of barbiturate for approximately 30 hours
under the same conditions. With high dosages and/or chronic daily doses,
EMIT and RIA can be used effectively for screening. Gas-liquid
chromatography/flame ionization (GLC/FID) after derivatization, GLC/NPD
and GC/MS are reliable methods used for confirmation of the various
barbiturates.
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BENZODlAZEPlNES
The benzodiazepines are considered by many as the most prescribed drugs in
the United States. They are primarily used as antianxiety and sedative-
hypnotic drugs and also have broad therapeutic use as anticonvulsants and
muscle relaxants. The benzodiazepines have a low order of acute and chronic
toxicity when used in a medically supervised manner. Chronic use does result
in some moderate dependence and tolerance to the drug. More than a dozen
benzodiazepines are in clinical use today. The best known benzodiazepine
drugs are Valium (diazepam) and Librium (chlordiazepoxide).
How Benzodiazepines Are Handled by the Body
These drugs are well absorbed when administered orally, the most common
route of administration. Most benzodiazepines are extensively metabolized
in the liver and excreted in the urine as metabolites. Nonconjugated
metabolites may possess pharmacological activity that may account for the
“next  day”  e f fec ts  for  some benzodiazepines .  Many of  the  new
benzodiazepines are metabolites and derivatives of the old drugs. For
example, oxazepam is a common urinary metabolite of many benzodiazepines
and is also a marketed drug (Serax).
The duration of action and elimination half-lives of the different
benzodiazepines vary widely. The half-lives for major benzodiazepines are:
chlordiazepoxide, 5-10 hours; diazepam, 30-60 hours; oxazepam (Setax), 5-10
hours; flurazepam (Dalmane), 2-3 hours for the parent drug and 50-100 hours
for active metabolites.
Because of the long elimination time for the benzodiazepines, an individual
who has been using a drug for months or years may maintain detectable
urinary concentrations of the drug for weeks to months after discontinuation
of its use.
Examples of Analytical Methods
A broad spectrum of analytical methods, GC, HPLC, TLC, GLC/MS, RIA, and
EMIT, has been reported for the analysis of the benzodiazepines, or their
metabolites, or of their acid hydrolysis products, e.g., benzophenones.
Because many benzodiazepines have common metabolites, it is not always
possible to determine the drug taken through the use of urine testing. The
EMIT screening procedure is rapid and specific for benzodiazepiues, as it
detects thii class of drugs by recognizing oxazepam, a common metabolite of
many benzodiazepines, and also many cross-reacting benzodiazepine drugs or
metabolites. Other screening procedures used to detect benzodiazepines
alone or in combination with major drugs of abuse in urine screening
programs can be achieved by TLC and HPLC. Radioimmunoassay methods
possess the necessary sensitivity for the determination of diazepam directly
in microsamples of blood/plasma (10 ul) and saliva (100 ul) for up to 16 hours
following oral administration of a single 5 mg dose of the drug.
Confirmation of positive results from tests performed with immunoassay or
thin-layer chromatography, which detect many of the metabolites, may be
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difficult using more specific techniques such as GLC and GC/MS. Care must
be taken to ensure that the metabolites detected with TLC or immunoassay
will chromatograph when using GLC and GUMS techniques.
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Glossary
Accuracy--Ability to get the correct (or true) result.
Analyte--Substance to be measured.
Blank--Biological specimen with no detectable drugs added, routinely
analyzed to ensure that no false-positive results are obtained.
Blind sample--Control material submitted to the analyst (unknown to him or
her) as a routine specimen.
Chain of custody--Handling samples in a way that supports legal testimony to
prove that the sample integrity and identification of the sample have not
been violated, as well as the documentation describing these procedures.
Concentration--Amount of a drug in a unit volume of biological fluid,
expressed as weight/volume. Urine concentrations are usually expressed
either as nanograms per milliliter (ng/ml), as micrograms per milliliter
(ug/ml), or milligrams per liter (mg/l). (There are 28,000,000 micrograms in
an ounce, and 1,000 nanograms in a microgram.)
Confirmation--A second test by an alternate chemical method to positively
identify a drug or metabolite. Confirmations are carried out on presumptive
positives from initial screens.
Creatinine--An endogenous substance appearing in the urine.
Cross-reacting substances--In immunoassays, refers to substances that react
with antiserum produced specifically for other substances.
Cutoff level (threshold)--Value serving as an administrative breakpoint (or
cutoff point) for labeling a urine result positive or negative.
Detection limit--Lowest concentration of a drug that can reliably be
detected.
False negative--An erroneous result in an assay that indicates the absence of
a drug that is actually present.
False positive--An erroneous result in an assay that indicates the presence of
a drug that is actually not present.
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Interfering substances--Substances other than the analyte that give a similar
analytical response or alter the analytical result.
Metabolite--A compound produced from chemical changes of a drug in the
body.
Pharmacokinetics--The study of the time course of the processes (absorption,
distribution, metabolism, and excretion) a drug undergoes in the body.
Pharmacodynamics--The study of the relationship of drug concentration to
drug effects.
Precision--Ability to get the same result between repeated measurements.
Presumptive positive--Sample which has been flagged as positive by
screening but which has not been confirmed by an equally sensitive
alternative chemical method.
Proficiency-testing specimen--A specimen whose expected results are
unknown to anyone in the laboratory, known only by an external agency, and
later revealed to the laboratory as an aid to laboratory improvement and/or a
condition of licensure.
Quality Assurance (QA)--Practices that assure accurate laboratory results.
Quality Control (QC)--Those techniques used to monitor errors which can
cause a deterioration in the quality of laboratory results. Control material
most often refers to a specimen, the expected results of which are known to
the analyst, that is routinely analyzed to ensure that the expected results are
obtained.
Qualitative test--Chemical analysis to identify the components of a mixture.
Quantitative test--Chemical analysis to determine the amounts or
proportions of a mixture.
Screen--A series of initial tests designed to separate samples with drugs at
the particular minimum concentration from those below that minimum
concentration (positive versus negative).
Sensitivity--The detection limit, expressed as a concentration of the analyte
in the specimen.
Specificity--Quality of an analytical technique that tends to exclude all
substances but the analyte from affecting the result.
Split specimen--Laboratory specimen that is divided and submitted to the
analyst, unknown to him or her, as two different specimens with different
identifications.
Standard--Authentic sample of the analyte of known purity, or a solution of
the analyte of a known concentration.
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Not available from GPO NTIS PB #82-190760 $42.95
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42 THE ANALYSIS OF CANNABINOIOS IN BIOLOGICAL FLUIDS. Richard L.
Hawks, Ph.D., ed.
GPO Stock #017-024-01151-7 $5 NTIS PB #83-136044 $18.95
43 PROBLEMS OF DRUG DEPENDENCE, 1982: PROCEEDINGS OF THE 44TH
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
DEPENDENCE, INC. Louis S. Harris, Ph.D., ed. NCDAI out of stock
GPO out of stock NTIS PB #83-252-692/AS $42.95
44 MARIJUANA EFFECTS ON THE ENDOCRINE AND REPRODUCTIVE SYSTEMS.
Monique C. Braude. Ph.D., and Jacqueline P. Ludford, M.S., eds. A
RAUS Review Report. NCDAI out of stock
GPO Stock #017-024-01202-5 $4 NTIS PB #85-150563/AS $18.95
45 CONTEMPORARY RESEARCH IN PAIN AND ANALGESIA, 1983. Roger M.
Brown, Ph.D.; Theodore M. Pinkert, M.D., J.D.; and Jacqueline P.
Ludford, M.S., eds. A RAUS Review Report. NCDAI out of stock
GPO Stock #017-024-01191-6 $2.75 NTIS PB #84-184670/AS $13.95
46 BEHAVIORAL INTERVENTION TECHNIQUES IN DRUG ABUSE TREATMENT. John
Grabowski, Ph.D .; Maxine L. Stitzer. Ph.D.. and Jack E.
Henningfleld, Ph.D.. eds.
GPO Stock #0l7-024-01192-4 $4.25 NTIS PB #84-184688/AS $18.95
47 PREVENTING ADOLESCENT DRUG ABUSE: INTERVENTION STRATEGIES.
Thomas J. Glynn, Ph.D .; Carl G. Leukefeld, D.S.W.; and
Jacqueline P. Ludford, M.S.. eds. A RAUS Review Report.
GPO Stock #0l7-024-01180-l $5.50 NTIS PB #85-159663/AS $24.95
48 MEASUREMENT IN THE ANALYSIS AND TREATMENT OF SMOKING BEHAVIOR.
John Grabowski, Ph.D.. and Catherine S. Bell, M.S., eds.
GPO Stock #017-024-01181-9 $4.50 NCDAI out of stock
NTIS PB 84-145-184 $18.95
49 PROBLEMS OF DRUG DEPENDENCE, 1983: PROCEEDINGS OF THE 45TH
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
DEPENDENCE, INC. Louis S. Harris, Ph.D., ed. NCDAI out of stock
GPO Stock #017-024-01198-3 $12 NTIS PB 85-151553/AS $36.95
50 COCAINE: PHARMACOLOGY, EFFECTS, AND TREATMENT OF ABUSE. John
Grabowski. Ph.D., ed.
GPO Stock #0l7-024-01214-9 $4.50 NTIS PB 85-150381/AS $18.95
51 DRUG ABUSE TREATMENT EVALUATION: STRATEGIES, PROGRESS, AND
PROSPECTS. Frank M. Tims, Ph.D., ed.
GPO Stock #017-024-01218-1 $4.50 NTIS PB 85-150365/AS $18.95
52 TESTING DRUGS FOR PHYSICAL DEPENDENCE POTENTIAL AND ABUSE
LIABILITY. Joseph V. Brady, Ph.D., and Scott E. Lukas, Ph.D., eds.
GPO Stock #017-024-0204-1 $4.25 NTIS PB 85-150373/AS $18.95
53 PHARMACOLOGICAL ADJUNCTS IN SMOKING CESSATION. John Grabowski,
Ph.D., and Sharon M. Hall, Ph.D., eds.
GPO Stock #017-024-01266-1 $3.50 NCDAI out of stock
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54 MECHANISMS OF TOLERANCE AND DEPENDENCE. Charles Wm. Sharp,
Ph.D.. ed. NCDAI out of stock
GPO Stock #017-024-01213-1 $8.50
55 PROBLEMS OF DRUG DEPENDENCE, 1984. PROCEEDINGS OF THE 46TH
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
DEPENDENCE, INC. Louis S. Harris, Ph.D., ed. NCDAI out of stock
GPO Stock #017-024-01242-4 $9.50
56 ETIOLOGY OF DRUG ABUSE: IMPLICATIONS FOR PREVENTION. Coryl LaRue
Jones, Ph.D., and Robert J. Battjes, D.S.W., eds.
GPO Stock #0l7-024-01250-5 $6.50
57 SELF-REPORT METHODS OF ESTIMATING DRUG USE: MEETING CURRENT
CHALLENGES TO VALIDITY. Beatrice A. Rouse, Ph.D., Nicholas J.
Kozel. M.S.. and Louise G. Richards. Ph.D., eds.
GPO Stock #017-024-01246-7 $4.25  NCDAI out of stock
58 PROGRESS IN THE DEVELOPMENT OF COST-EFFECTIVE TREATMENT FOR DRUG
ABUSERS. Rebecca S. Ashery, D.S.W.. ed.
GPO Stock #017-024-01247-5 $4.25 NCDAI out of stock
59 CURRENT RESEARCH ON THE CONSEQUENCES OF MATERNAL DRUG ABUSE.
Theodore M. Pinkert, M.D., J.D., ed.
GPO Stock #017-024-01249-1 $2.50
60 PRENATAL DRUG EXPOSURE: KINETICS AND DYNAMICS. C. Nora Chiang.
Ph.D., and Charles C. Lee, Ph.D., eds.
GPO Stock #017-024-01257-2 $3.50
61 COCAINE USE IN AMERICA: EPIDEMIOLOGIC AND CLINICAL PERSPECTIVES.
Nicholas J. Kozel. M.S., and Edgar H. Adams, M.S., eds.
GPO Stock #017-024-01258-1 $5
62 NEUROSCIENCE METHODS IN DRUG ABUSE RESEARCH. Roger M. Brown,
Ph.D., and David P. Friedman, Ph.D., eds.
GPO Stock #017-024-01260-2 $3.50
63 PREVENTION RESEARCH: DETERRING DRUG ABUSE AMONG CHILDREN AND
ADOLESCENTS. Catherine S. Bell, M.S., and Robert Battjes.
D.S.W.. eds.
GPO Stock #017-024-01263-7 $5.50
64 PHENCYCLIDINE: AN UPDATE. Doris H. Clouet, Ph.D., ed.
GPO Stock #017-024-01281-5 $6.50
65 WOMEN AND DRUGS: A NEW ERA FOR RESEARCH. Barbara A. Ray, Ph.D.,
and Monique C. Braude, Ph.D., eds.
GPO Stock #017-024-01283-1 $3.25
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66 GENETIC AND BIOLOGICAL MARKERS IN DRUG ABUSE AND ALCOHOLISM.
Monique C. Braude, Ph.D., and Helen M. Chao, Ph.D. eds.
GPO Stock #017-024-01291-2 $3.50 NCDAI out of stock
67 PROBLEMS OF DRUG DEPENDENCE, 1985. PROCEEDINGS OF THE 47TH
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
DEPENDENCE, INC. Louis S. Harris, Ph.D., ed. NCDAI out of stock
GPO Stock #017-024-01292-1 $18
68 STRATEGIES FOR RESEARCH ON THE INTERACTIONS OF DRUGS OF ABUSE.
Monique C. Braude. Ph.D., and Harold M. Ginzburg. M.D., J.D., M.P.H.,
eds.
GPO Stock #0l7-024-01296-3 $6.50 NCDAI out of stock
69 OPIOID PEPTIDES: MEDICINAL CHEMISTRY. Rao S. Rapaka, Ph.D.;
Gene Barnett, Ph.D .; and Richard L. Hawks, Ph.D., eds.
GPO Stock #017-024-1297-1 $11
70 OPIOID PEPTIDES: MOLECULAR PHARMACOLOGY, BIOSYNTHESIS, AND
ANALYSIS. Rao S. Rapaka, Ph.D., and Richard L. Hawks, Ph.D., eds.
GPO Stock #017-024-1298-0 $12
71 OPIATE RECEPTOR SUBTYPES AND BRAIN FUNCTION. Roger M. Brown,
Ph.D.; Doris H. Clouet. Ph.D .; and David P. Friedman, Ph.D., eds.
GPO Stock #017-024-01303-0 $6
72 RELAPSE AND RECOVERY IN DRUG ABUSE. Frank M. Tims, Ph.D., and
Carl G. Leukefeld, D.S.W.. eds.
GPO Stock #017-024-01302-1 $6
73 URINE TESTING FOR DRUGS OF ABUSE. Richard L. Hawks, Ph.D., and
C. Nora Chiang. Ph.D., eds.
GPO Stock #017-024-1313-7 $3.75
74 NEUROBIOLOGY OF BEHAVIORAL CONTROL IN DRUG ABUSE. Stephen I.
Szara. M.D., D.Sc.. ed.
GPO Stock #017-024-1314-5 $3.75
75 PROGRESS IN OPIOID RESEARCH. PROCEEDINGS OF THE 1986 INTER-
NATIONAL NARCOTICS RESEARCH CONFERENCE. John W. Holaday, Ph.D.;
Ping-Yee Law, Ph.D.; and Albert Herz, M.D., eds.
GPO Stock #017-024-01315-3 $21
76 PROBLEMS OF DRUG DEPENDENCE, 1986. PROCEEDINGS OF THE 48TH
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
DEPENDENCE, INC. Louis S. Harris, Ph.D., ed.
GPO Stock #017-024-1316-1 $16
IN PRESS
77 ADOLESCENT DRUG ABUSE: ANALYSES OF TREATMENT RESEARCH.
Elizabeth R. Rahdert, Ph.D. and John Grabowski, Ph.D., eds.
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